ID EPHA2_HUMAN Reviewed; 976 AA. AC P29317; B5A968; Q8N3Z2; DT 01-DEC-1992, integrated into UniProtKB/Swiss-Prot. DT 05-MAY-2009, sequence version 2. DT 28-JAN-2026, entry version 259. DE RecName: Full=Ephrin type-A receptor 2; DE EC=2.7.10.1; DE AltName: Full=Epithelial cell kinase; DE AltName: Full=Tyrosine-protein kinase receptor ECK; DE Flags: Precursor; GN Name=EPHA2; Synonyms=ECK; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), CATALYTIC ACTIVITY, AND RP AUTOPHOSPHORYLATION. RC TISSUE=Epithelium; RX PubMed=2174105; DOI=10.1128/mcb.10.12.6316-6324.1990; RA Lindberg R.A., Hunter T.; RT "cDNA cloning and characterization of eck, an epithelial cell receptor RT protein-tyrosine kinase in the eph/elk family of protein kinases."; RL Mol. Cell. Biol. 10:6316-6324(1990). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), AND ALTERNATIVE SPLICING. RX PubMed=18593464; DOI=10.1186/ar2447; RA Jin P., Zhang J., Sumariwalla P.F., Ni I., Jorgensen B., Crawford D., RA Phillips S., Feldmann M., Shepard H.M., Paleolog E.M.; RT "Novel splice variants derived from the receptor tyrosine kinase RT superfamily are potential therapeutics for rheumatoid arthritis."; RL Arthritis Res. Ther. 10:R73-R73(2008). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16710414; DOI=10.1038/nature04727; RA Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A., RA Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C., RA Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K., RA Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C., RA Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W., RA Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J., RA Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., RA Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., RA Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., RA Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H., RA Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L., RA Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J., RA Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S., RA Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K., RA Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R., RA Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M., RA Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S., RA Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J., RA Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., RA McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N., RA Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V., RA Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J., RA Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E., RA Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S., RA Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M., RA White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H., RA Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E., RA Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G., RA Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.; RT "The DNA sequence and biological annotation of human chromosome 1."; RL Nature 441:315-321(2006). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Pancreas; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [6] RP NOMENCLATURE. RX PubMed=9267020; DOI=10.1016/s0092-8674(00)80500-0; RG Eph nomenclature committee; RT "Unified nomenclature for Eph family receptors and their ligands, the RT ephrins."; RL Cell 90:403-404(1997). RN [7] RP FUNCTION IN INTEGRIN-MEDIATED CELL ADHESION, FUNCTION IN CELL MIGRATION, RP PHOSPHORYLATION, INTERACTION WITH PTK2/FAK1 AND PTPN11, AND SUBCELLULAR RP LOCATION. RX PubMed=10655584; DOI=10.1038/35000008; RA Miao H., Burnett E., Kinch M., Simon E., Wang B.; RT "Activation of EphA2 kinase suppresses integrin function and causes focal- RT adhesion-kinase dephosphorylation."; RL Nat. Cell Biol. 2:62-69(2000). RN [8] RP ONCOGENICITY. RX PubMed=11280802; RA Zelinski D.P., Zantek N.D., Stewart J.C., Irizarry A.R., Kinch M.S.; RT "EphA2 overexpression causes tumorigenesis of mammary epithelial cells."; RL Cancer Res. 61:2301-2306(2001). RN [9] RP INTERACTION WITH ACP1, AND DEPHOSPHORYLATION BY ACP1. RX PubMed=12167657; DOI=10.1074/jbc.m207127200; RA Kikawa K.D., Vidale D.R., Van Etten R.L., Kinch M.S.; RT "Regulation of the EphA2 kinase by the low molecular weight tyrosine RT phosphatase induces transformation."; RL J. Biol. Chem. 277:39274-39279(2002). RN [10] RP FUNCTION IN CELL-CELL INTERACTION, INTERACTION WITH CLDN4, AND MUTAGENESIS RP OF LYS-646. RX PubMed=16236711; DOI=10.1074/jbc.m503786200; RA Tanaka M., Kamata R., Sakai R.; RT "EphA2 phosphorylates the cytoplasmic tail of Claudin-4 and mediates RT paracellular permeability."; RL J. Biol. Chem. 280:42375-42382(2005). RN [11] RP TISSUE SPECIFICITY. RX PubMed=17332925; RA Liu D.-P., Wang Y., Koeffler H.P., Xie D.; RT "Ephrin-A1 is a negative regulator in glioma through down-regulation of RT EphA2 and FAK."; RL Int. J. Oncol. 30:865-871(2007). RN [12] RP INTERACTION WITH INPPL1. RX PubMed=17135240; DOI=10.1074/jbc.m608509200; RA Zhuang G., Hunter S., Hwang Y., Chen J.; RT "Regulation of EphA2 receptor endocytosis by SHIP2 lipid phosphatase via RT phosphatidylinositol 3-Kinase-dependent Rac1 activation."; RL J. Biol. Chem. 282:2683-2694(2007). RN [13] RP FUNCTION IN APOPTOSIS, AND INDUCTION BY UV. RX PubMed=18339848; DOI=10.1158/0008-5472.can-07-2372; RA Zhang G., Njauw C.-N., Park J.M., Naruse C., Asano M., Tsao H.; RT "EphA2 is an essential mediator of UV radiation-induced apoptosis."; RL Cancer Res. 68:1691-1696(2008). RN [14] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-570; SER-579 AND THR-647, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [15] RP SUBCELLULAR LOCATION, AND PHOSPHORYLATION. RX PubMed=18794797; DOI=10.1038/onc.2008.328; RA Wykosky J., Palma E., Gibo D.M., Ringler S., Turner C.P., Debinski W.; RT "Soluble monomeric EphrinA1 is released from tumor cells and is a RT functional ligand for the EphA2 receptor."; RL Oncogene 27:7260-7273(2008). RN [16] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-570; SER-892 AND SER-901, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [17] RP DISEASE, FUNCTION IN CELL MIGRATION, SUBCELLULAR LOCATION, MUTAGENESIS OF RP ASP-739 AND SER-897, AND PHOSPHORYLATION AT SER-897 BY PKB. RX PubMed=19573808; DOI=10.1016/j.ccr.2009.04.009; RA Miao H., Li D.Q., Mukherjee A., Guo H., Petty A., Cutter J., Basilion J.P., RA Sedor J., Wu J., Danielpour D., Sloan A.E., Cohen M.L., Wang B.; RT "EphA2 mediates ligand-dependent inhibition and ligand-independent RT promotion of cell migration and invasion via a reciprocal regulatory loop RT with Akt."; RL Cancer Cell 16:9-20(2009). RN [18] RP GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-435. RC TISSUE=Liver; RX PubMed=19159218; DOI=10.1021/pr8008012; RA Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.; RT "Glycoproteomics analysis of human liver tissue by combination of multiple RT enzyme digestion and hydrazide chemistry."; RL J. Proteome Res. 8:651-661(2009). RN [19] RP UBIQUITINATION BY STUB1. RX PubMed=19567782; DOI=10.1158/1541-7786.mcr-08-0582; RA Annamalai B., Liu X., Gopal U., Isaacs J.S.; RT "Hsp90 is an essential regulator of EphA2 receptor stability and signaling: RT implications for cancer cell migration and metastasis."; RL Mol. Cancer Res. 7:1021-1032(2009). RN [20] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-570; TYR-628; THR-647 AND RP SER-869, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200; RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., RA Mann M., Daub H.; RT "Large-scale proteomics analysis of the human kinome."; RL Mol. Cell. Proteomics 8:1751-1764(2009). RN [21] RP FUNCTION IN CELL MIGRATION, AND INTERACTION WITH ARHGEF16; DOCK4 AND ELMO2. RX PubMed=20679435; DOI=10.1083/jcb.201005141; RA Hiramoto-Yamaki N., Takeuchi S., Ueda S., Harada K., Fujimoto S., RA Negishi M., Katoh H.; RT "Ephexin4 and EphA2 mediate cell migration through a RhoG-dependent RT mechanism."; RL J. Cell Biol. 190:461-477(2010). RN [22] RP FUNCTION IN KERATINOCYTE ADHESION AND DIFFERENTIATION, AND SUBCELLULAR RP LOCATION. RX PubMed=20861311; DOI=10.1091/mbc.e10-03-0242; RA Lin S., Gordon K., Kaplan N., Getsios S.; RT "Ligand targeting of EphA2 enhances keratinocyte adhesion and RT differentiation via desmoglein 1."; RL Mol. Biol. Cell 21:3902-3914(2010). RN [23] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [24] RP SUBCELLULAR LOCATION. RX PubMed=20223987; DOI=10.1126/science.1181729; RA Salaita K., Nair P.M., Petit R.S., Neve R.M., Das D., Gray J.W., RA Groves J.T.; RT "Restriction of receptor movement alters cellular response: physical force RT sensing by EphA2."; RL Science 327:1380-1385(2010). RN [25] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [26] RP FUNCTION (MICROBIAL INFECTION). RX PubMed=21516087; DOI=10.1038/nm.2341; RA Lupberger J., Zeisel M.B., Xiao F., Thumann C., Fofana I., Zona L., RA Davis C., Mee C.J., Turek M., Gorke S., Royer C., Fischer B., Zahid M.N., RA Lavillette D., Fresquet J., Cosset F.L., Rothenberg S.M., Pietschmann T., RA Patel A.H., Pessaux P., Doffoel M., Raffelsberger W., Poch O., RA McKeating J.A., Brino L., Baumert T.F.; RT "EGFR and EphA2 are host factors for hepatitis C virus entry and possible RT targets for antiviral therapy."; RL Nat. Med. 17:589-595(2011). RN [27] RP INTERACTION WITH ANKS1A. RX PubMed=22332920; DOI=10.1021/bi300141h; RA Mercurio F.A., Marasco D., Pirone L., Pedone E.M., Pellecchia M., Leone M.; RT "Solution structure of the first Sam domain of Odin and binding studies RT with the EphA2 receptor."; RL Biochemistry 51:2136-2145(2012). RN [28] RP INTERACTION WITH HHV-8 GLYCOPROTEIN L/GLYCOPROTEIN H (MICROBIAL INFECTION). RX PubMed=22635007; DOI=10.1038/nm.2805; RA Hahn A.S., Kaufmann J.K., Wies E., Naschberger E., Panteleev-Ivlev J., RA Schmidt K., Holzer A., Schmidt M., Chen J., Konig S., Ensser A., Myoung J., RA Brockmeyer N.H., Sturzl M., Fleckenstein B., Neipel F.; RT "The ephrin receptor tyrosine kinase A2 is a cellular receptor for Kaposi's RT sarcoma-associated herpesvirus."; RL Nat. Med. 18:961-966(2012). RN [29] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-575; SER-892; SER-897 AND RP SER-901, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [30] RP FUNCTION IN CELL MIGRATION, PHOSPHORYLATION AT TYR-930, DEPHOSPHORYLATION RP AT TYR-930 BY PTPRF, AND INTERACTION WITH NCK1. RX PubMed=23358419; DOI=10.1128/mcb.01708-12; RA Lee H., Bennett A.M.; RT "Receptor protein tyrosine phosphatase-receptor tyrosine kinase substrate RT screen identifies EphA2 as a target for LAR in cell migration."; RL Mol. Cell. Biol. 33:1430-1441(2013). RN [31] RP INTERACTION WITH CEMIP. RX PubMed=23936024; DOI=10.1371/journal.pone.0069473; RA Tiwari A., Schneider M., Fiorino A., Haider R., Okoniewski M.J., RA Roschitzki B., Uzozie A., Menigatti M., Jiricny J., Marra G.; RT "Early insights into the function of KIAA1199, a markedly overexpressed RT protein in human colorectal tumors."; RL PLoS ONE 8:E69473-E69473(2013). RN [32] RP PHOSPHORYLATION AT SER-897 BY RPS6KA1 AND RPS6KA3, AND FUNCTION IN CELL RP MIGRATION. RX PubMed=26158630; DOI=10.1038/ncomms8679; RA Zhou Y., Yamada N., Tanaka T., Hori T., Yokoyama S., Hayakawa Y., Yano S., RA Fukuoka J., Koizumi K., Saiki I., Sakurai H.; RT "Crucial roles of RSK in cell motility by catalysing serine phosphorylation RT of EphA2."; RL Nat. Commun. 6:7679-7679(2015). RN [33] RP PHOSPHORYLATION AT SER-897 BY PKA, PHOSPHORYLATION AT SER-901, AND RP FUNCTION. RX PubMed=27385333; DOI=10.1091/mbc.e16-01-0048; RA Barquilla A., Lamberto I., Noberini R., Heynen-Genel S., Brill L.M., RA Pasquale E.B.; RT "Protein kinase A can block EphA2 receptor-mediated cell repulsion by RT increasing EphA2 S897 phosphorylation."; RL Mol. Biol. Cell 27:2757-2770(2016). RN [34] RP INTERACTION WITH EPSTEIN-BARR VIRUS/HHV-4 GLYCOPROTEIN L/GLYCOPROTEIN H RP (MICROBIAL INFECTION). RX PubMed=29292383; DOI=10.1038/s41564-017-0080-8; RA Zhang H., Li Y., Wang H.B., Zhang A., Chen M.L., Fang Z.X., Dong X.D., RA Li S.B., Du Y., Xiong D., He J.Y., Li M.Z., Liu Y.M., Zhou A.J., Zhong Q., RA Zeng Y.X., Kieff E., Zhang Z., Gewurz B.E., Zhao B., Zeng M.S.; RT "Ephrin receptor A2 is an epithelial cell receptor for Epstein-Barr virus RT entry."; RL Nat. Microbiol. 3:1-8(2018). RN [35] RP INTERACTION WITH EPSTEIN-BARR VIRUS/HHV-4 GLYCOPROTEIN L/GLYCOPROTEIN H RP (MICROBIAL INFECTION). RX PubMed=29292384; DOI=10.1038/s41564-017-0081-7; RA Chen J., Sathiyamoorthy K., Zhang X., Schaller S., Perez White B.E., RA Jardetzky T.S., Longnecker R.; RT "Ephrin receptor A2 is a functional entry receptor for Epstein-Barr RT virus."; RL Nat. Microbiol. 3:172-180(2018). RN [36] RP INTERACTION WITH TIMD4, AND SUBCELLULAR LOCATION. RX PubMed=34067457; DOI=10.3390/cells10061290; RA Moon B., Yang S., Kim K., Lee J., Jeong D., Park D.; RT "EphA2 Interacts with Tim-4 through Association between Its FN3 Domain and RT the IgV Domain of Tim-4."; RL Cells 10:0-0(2021). RN [37] RP FUNCTION (MICROBIAL INFECTION), AND INTERACTION WITH HUMAN CYTOMEGALOVIRUS RP PROTEINS GH AND GL (MICROBIAL INFECTION). RX PubMed=37146061; DOI=10.1371/journal.ppat.1011304; RA Dong X.D., Li Y., Li Y., Sun C., Liu S.X., Duan H., Cui R., Zhong Q., RA Mou Y.G., Wen L., Yang B., Zeng M.S., Luo M.H., Zhang H.; RT "EphA2 is a functional entry receptor for HCMV infection of glioblastoma RT cells."; RL PLoS Pathog. 19:e1011304-e1011304(2023). RN [38] RP X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 596-900. RX PubMed=12467573; DOI=10.1016/s0969-2126(02)00907-3; RA Nowakowski J., Cronin C.N., McRee D.E., Knuth M.W., Nelson C.G., RA Pavletich N.P., Rogers J., Sang B.C., Scheibe D.N., Swanson R.V., RA Thompson D.A.; RT "Structures of the cancer-related Aurora-A, FAK, and EphA2 protein kinases RT from nanovolume crystallography."; RL Structure 10:1659-1667(2002). RN [39] RP STRUCTURE BY NMR OF 902-976. RG RIKEN structural genomics initiative (RSGI); RT "Solution structure of the C-terminal SAM-domain of EPHAA2: ephrin type-A RT receptor 2 precursor (EC 2.7.10.1)."; RL Submitted (JAN-2008) to the PDB data bank. RN [40] RP X-RAY CRYSTALLOGRAPHY (2.52 ANGSTROMS) OF 28-201, X-RAY CRYSTALLOGRAPHY RP (2.0 ANGSTROMS) OF 28-201 IN COMPLEX WITH EFNA1, SUBUNIT, DISULFIDE BOND, RP AND MUTAGENESIS OF ARG-103. RX PubMed=19525919; DOI=10.1038/embor.2009.91; RA Himanen J.P., Goldgur Y., Miao H., Myshkin E., Guo H., Buck M., Nguyen M., RA Rajashankar K.R., Wang B., Nikolov D.B.; RT "Ligand recognition by A-class Eph receptors: crystal structures of the RT EphA2 ligand-binding domain and the EphA2/ephrin-A1 complex."; RL EMBO Rep. 10:722-728(2009). RN [41] RP X-RAY CRYSTALLOGRAPHY (1.95 ANGSTROMS) OF 25-202, AND DISULFIDE BOND. RG Structural genomics consortium (SGC); RT "Ephrin A1 bound to the ligand binding domain of the human ephrin A2 RT (EPHA2) receptor protein kinase."; RL Submitted (FEB-2009) to the PDB data bank. RN [42] RP STRUCTURE BY NMR OF 523-563. RA Mayzel M.L., Bocharov E.V., Volynsky P.E., Arseniev A.S.; RT "Left-handed dimer of EPHA2 transmembrane domain helix packing diversity RT among receptor tyrosine kinases."; RL Submitted (AUG-2009) to the PDB data bank. RN [43] RP X-RAY CRYSTALLOGRAPHY (2.65 ANGSTROMS) OF 23-202 IN COMPLEX WITH EFNA1, AND RP SUBUNIT. RX PubMed=20505120; DOI=10.1073/pnas.1004148107; RA Himanen J.P., Yermekbayeva L., Janes P.W., Walker J.R., Xu K., Atapattu L., RA Rajashankar K.R., Mensinga A., Lackmann M., Nikolov D.B., Dhe-Paganon S.; RT "Architecture of Eph receptor clusters."; RL Proc. Natl. Acad. Sci. U.S.A. 107:10860-10865(2010). RN [44] RP VARIANTS [LARGE SCALE ANALYSIS] ARG-391; MET-511; HIS-568; SER-777 AND RP HIS-876. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [45] RP VARIANT CTRCT6 TRP-948. RX PubMed=19005574; RA Shiels A., Bennett T.M., Knopf H.L.S., Maraini G., Li A., Jiao X., RA Hejtmancik J.F.; RT "The EPHA2 gene is associated with cataracts linked to chromosome 1p."; RL Mol. Vis. 14:2042-2055(2008). RN [46] RP VARIANT CTRCT6 ILE-940. RX PubMed=19306328; DOI=10.1002/humu.20995; RA Zhang T., Hua R., Xiao W., Burdon K.P., Bhattacharya S.S., Craig J.E., RA Shang D., Zhao X., Mackey D.A., Moore A.T., Luo Y., Zhang J., Zhang X.; RT "Mutations of the EPHA2 receptor tyrosine kinase gene cause autosomal RT dominant congenital cataract."; RL Hum. Mutat. 30:E603-E611(2009). RN [47] RP VARIANT CTRCT6 GLN-721, AND CHARACTERIZATION OF VARIANT CTRCT6 GLN-721. RX PubMed=19649315; DOI=10.1371/journal.pgen.1000584; RA Jun G., Guo H., Klein B.E., Klein R., Wang J.J., Mitchell P., Miao H., RA Lee K.E., Joshi T., Buck M., Chugha P., Bardenstein D., Klein A.P., RA Bailey-Wilson J.E., Gong X., Spector T.D., Andrew T., Hammond C.J., RA Elston R.C., Iyengar S.K., Wang B.; RT "EPHA2 is associated with age-related cortical cataract in mice and RT humans."; RL PLoS Genet. 5:E1000584-E1000584(2009). RN [48] RP CHARACTERIZATION OF VARIANTS CTRCT6 ILE-940 AND CTRCT6 TRP-948. RX PubMed=22570727; DOI=10.1371/journal.pone.0036564; RA Park J.E., Son A.I., Hua R., Wang L., Zhang X., Zhou R.; RT "Human cataract mutations in EPHA2 SAM domain alter receptor stability and RT function."; RL PLoS ONE 7:E36564-E36564(2012). CC -!- FUNCTION: Receptor tyrosine kinase which binds promiscuously membrane- CC bound ephrin-A family ligands residing on adjacent cells, leading to CC contact-dependent bidirectional signaling into neighboring cells. The CC signaling pathway downstream of the receptor is referred to as forward CC signaling while the signaling pathway downstream of the ephrin ligand CC is referred to as reverse signaling. Activated by the ligand ephrin- CC A1/EFNA1 regulates migration, integrin-mediated adhesion, proliferation CC and differentiation of cells. Regulates cell adhesion and CC differentiation through DSG1/desmoglein-1 and inhibition of the CC ERK1/ERK2 (MAPK3/MAPK1, respectively) signaling pathway. May also CC participate in UV radiation-induced apoptosis and have a ligand- CC independent stimulatory effect on chemotactic cell migration. During CC development, may function in distinctive aspects of pattern formation CC and subsequently in development of several fetal tissues. Involved for CC instance in angiogenesis, in early hindbrain development and epithelial CC proliferation and branching morphogenesis during mammary gland CC development. Engaged by the ligand ephrin-A5/EFNA5 may regulate lens CC fiber cells shape and interactions and be important for lens CC transparency development and maintenance. With ephrin-A2/EFNA2 may play CC a role in bone remodeling through regulation of osteoclastogenesis and CC osteoblastogenesis. {ECO:0000269|PubMed:10655584, CC ECO:0000269|PubMed:16236711, ECO:0000269|PubMed:18339848, CC ECO:0000269|PubMed:19573808, ECO:0000269|PubMed:20679435, CC ECO:0000269|PubMed:20861311, ECO:0000269|PubMed:23358419, CC ECO:0000269|PubMed:26158630, ECO:0000269|PubMed:27385333}. CC -!- FUNCTION: (Microbial infection) Acts as a receptor for hepatitis C CC virus (HCV) in hepatocytes and facilitates its cell entry. Mediates HCV CC entry by promoting the formation of the CD81-CLDN1 receptor complexes CC that are essential for HCV entry and by enhancing membrane fusion of CC cells expressing HCV envelope glycoproteins. CC {ECO:0000269|PubMed:21516087}. CC -!- FUNCTION: Acts as a receptor for human cytomegalovirus (HCMV) to CC mediate viral entry and fusion in glioblastoma cells. CC {ECO:0000269|PubMed:37146061}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA- CC COMP:20101, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858, CC ChEBI:CHEBI:61978, ChEBI:CHEBI:456216; EC=2.7.10.1; CC Evidence={ECO:0000255|PROSITE-ProRule:PRU10028, CC ECO:0000269|PubMed:2174105}; CC -!- SUBUNIT: Homodimer. Interacts with SLA. Interacts (phosphorylated form) CC with VAV2, VAV3 and PI3-kinase p85 subunit (PIK3R1, PIK3R2 or PIK3R3); CC critical for the EFNA1-induced activation of RAC1 which stimulates cell CC migration (By similarity). Interacts with INPPL1; regulates activated CC EPHA2 endocytosis and degradation. Interacts (inactivated form) with CC PTK2/FAK1 and interacts (EFNA1 ligand-activated form) with PTPN11; CC regulates integrin-mediated adhesion. Interacts with ARHGEF16, DOCK4 CC and ELMO2; mediates ligand-independent activation of RAC1 which CC stimulates cell migration. Interacts with CLDN4; phosphorylates CLDN4 CC and may regulate tight junctions. Interacts with ACP1. Interacts (via CC SAM domain) with ANKS1A (via SAM domain). Interacts with CEMIP. CC Interacts with NCK1; may regulate EPHA2 activity in cell migration and CC adhesion. Interacts with TIMD4 (PubMed:34067457). CC {ECO:0000250|UniProtKB:Q03145, ECO:0000269|PubMed:10655584, CC ECO:0000269|PubMed:12167657, ECO:0000269|PubMed:16236711, CC ECO:0000269|PubMed:17135240, ECO:0000269|PubMed:19525919, CC ECO:0000269|PubMed:20505120, ECO:0000269|PubMed:20679435, CC ECO:0000269|PubMed:22332920, ECO:0000269|PubMed:23358419, CC ECO:0000269|PubMed:23936024, ECO:0000269|PubMed:34067457}. CC -!- SUBUNIT: (Microbial infection) Interacts with human herpes virus 8/HHV- CC 8 glycoprotein L/gL and glycoprotein H/gH heterodimer; this interaction CC triggers EPHA2 phosphorylation and endocytosis, allowing virus entry. CC {ECO:0000269|PubMed:22635007}. CC -!- SUBUNIT: (Microbial infection) Interacts with human cytomegalovirus CC (HCMV) glycoprotein L/gL and glycoprotein H/gH heterodimer. CC {ECO:0000269|PubMed:37146061}. CC -!- SUBUNIT: (Microbial infection) Interacts with Epstein-Barr virus/HHV-4 CC glycoprotein L/gL and glycoprotein H/gH heterodimer; this interaction CC facilitates virus internalization and fusion. CC {ECO:0000269|PubMed:29292383, ECO:0000269|PubMed:29292384}. CC -!- INTERACTION: CC P29317; P30530: AXL; NbExp=2; IntAct=EBI-702104, EBI-2850927; CC P29317; P35222: CTNNB1; NbExp=2; IntAct=EBI-702104, EBI-491549; CC P29317; P20827: EFNA1; NbExp=9; IntAct=EBI-702104, EBI-715194; CC P29317; P52803: EFNA5; NbExp=8; IntAct=EBI-702104, EBI-1753674; CC P29317; P98172: EFNB1; NbExp=3; IntAct=EBI-702104, EBI-538287; CC P29317; P29320: EPHA3; NbExp=3; IntAct=EBI-702104, EBI-1641575; CC P29317; P54756: EPHA5; NbExp=3; IntAct=EBI-702104, EBI-1383718; CC P29317; Q9UF33: EPHA6; NbExp=4; IntAct=EBI-702104, EBI-3950019; CC P29317; Q15375: EPHA7; NbExp=7; IntAct=EBI-702104, EBI-1383428; CC P29317; P08238: HSP90AB1; NbExp=2; IntAct=EBI-702104, EBI-352572; CC P29317; O15357-1: INPPL1; NbExp=3; IntAct=EBI-702104, EBI-15963021; CC P29317; P29376: LTK; NbExp=3; IntAct=EBI-702104, EBI-6596163; CC P29317; Q05397: PTK2; NbExp=3; IntAct=EBI-702104, EBI-702142; CC P29317; Q06124: PTPN11; NbExp=3; IntAct=EBI-702104, EBI-297779; CC -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:18794797, CC ECO:0000269|PubMed:19573808, ECO:0000269|PubMed:20223987, CC ECO:0000269|PubMed:20861311, ECO:0000269|PubMed:34067457}; Single-pass CC type I membrane protein {ECO:0000255}. Cell projection, ruffle membrane CC {ECO:0000269|PubMed:19573808}; Single-pass type I membrane protein CC {ECO:0000255}. Cell projection, lamellipodium membrane CC {ECO:0000269|PubMed:19573808}; Single-pass type I membrane protein CC {ECO:0000255}. Cell junction, focal adhesion CC {ECO:0000269|PubMed:10655584}. Note=Present at regions of cell-cell CC contacts but also at the leading edge of migrating cells CC (PubMed:19573808, PubMed:20861311). Relocates from the plasma membrane CC to the cytoplasmic and perinuclear regions in cancer cells CC (PubMed:18794797). {ECO:0000269|PubMed:18794797, CC ECO:0000269|PubMed:19573808, ECO:0000269|PubMed:20861311, CC ECO:0000269|PubMed:26158630}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; CC IsoId=P29317-1; Sequence=Displayed; CC Name=2; CC IsoId=P29317-2; Sequence=VSP_056014, VSP_056015; CC -!- TISSUE SPECIFICITY: Expressed in brain and glioma tissue and glioma CC cell lines (at protein level). Expressed most highly in tissues that CC contain a high proportion of epithelial cells, e.g. skin, intestine, CC lung, and ovary. {ECO:0000269|PubMed:17332925}. CC -!- INDUCTION: Up-regulated by UV irradiation via a TP53-independent, MAPK- CC dependent mechanism. {ECO:0000269|PubMed:18339848}. CC -!- PTM: Autophosphorylates. Phosphorylated on tyrosine upon binding and CC activation by EFNA1. Phosphorylated residues Tyr-588 and Tyr-594 are CC required for binding VAV2 and VAV3 while phosphorylated residues Tyr- CC 735 and Tyr-930 are required for binding PI3-kinase p85 subunit CC (PIK3R1, PIK3R2 or PIK3R3). These phosphorylated residues are critical CC for recruitment of VAV2 and VAV3 and PI3-kinase p85 subunit which CC transduce downstream signaling to activate RAC1 GTPase and cell CC migration. Dephosphorylation of Tyr-930 by PTPRF prevents the CC interaction of EPHA2 with NCK1. Phosphorylated at Ser-897 by PKB; CC serum-induced phosphorylation which targets EPHA2 to the cell leading CC edge and stimulates cell migration. Phosphorylation by PKB is inhibited CC by EFNA1-activated EPHA2 which regulates PKB activity via a reciprocal CC regulatory loop. Phosphorylated at Ser-897 in response to TNF by CC RPS6KA1 and RPS6KA3; RPS6KA-EPHA2 signaling pathway controls cell CC migration (PubMed:26158630). Phosphorylated at Ser-897 by PKA; blocks CC cell retraction induced by EPHA2 kinase activity (PubMed:27385333). CC Dephosphorylated by ACP1. {ECO:0000269|PubMed:10655584, CC ECO:0000269|PubMed:18794797, ECO:0000269|PubMed:19573808, CC ECO:0000269|PubMed:23358419, ECO:0000269|PubMed:26158630, CC ECO:0000269|PubMed:27385333}. CC -!- PTM: Ubiquitinated by CHIP/STUB1. Ubiquitination is regulated by the CC HSP90 chaperone and regulates the receptor stability and activity CC through proteasomal degradation. ANKS1A prevents ubiquitination and CC degradation (By similarity). {ECO:0000250}. CC -!- DISEASE: Cataract 6, multiple types (CTRCT6) [MIM:116600]: An CC opacification of the crystalline lens of the eye that frequently CC results in visual impairment or blindness. Opacities vary in CC morphology, are often confined to a portion of the lens, and may be CC static or progressive. CTRCT6 includes posterior polar and age-related CC cortical cataracts, among others. Posterior polar cataract is a CC subcapsular opacity, usually disk-shaped, located at the back of the CC lens. Age-related cortical cataract is a developmental punctate opacity CC restricted to the cortex. The cataract is white or cerulean, increases CC in number with age, but rarely affects vision. CC {ECO:0000269|PubMed:19005574, ECO:0000269|PubMed:19306328, CC ECO:0000269|PubMed:19649315, ECO:0000269|PubMed:22570727}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Note=Overexpressed in several cancer types and promotes CC malignancy. {ECO:0000269|PubMed:19573808}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein CC kinase family. Ephrin receptor subfamily. {ECO:0000255|PROSITE- CC ProRule:PRU00159}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/40462/EPHA2"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; M59371; AAA53375.1; -; mRNA. DR EMBL; EU826606; ACF47642.1; -; mRNA. DR EMBL; AL451042; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471167; EAW51769.1; -; Genomic_DNA. DR EMBL; BC037166; AAH37166.1; -; mRNA. DR CCDS; CCDS169.1; -. [P29317-1] DR PIR; A36355; A36355. DR RefSeq; NP_004422.2; NM_004431.4. [P29317-1] DR PDB; 1MQB; X-ray; 2.30 A; A/B=596-900. DR PDB; 2E8N; NMR; -; A=902-976. DR PDB; 2K9Y; NMR; -; A/B=523-563. DR PDB; 2KSO; NMR; -; A=908-972. DR PDB; 2X10; X-ray; 3.00 A; A=27-534. DR PDB; 2X11; X-ray; 4.83 A; A=27-534. DR PDB; 3C8X; X-ray; 1.95 A; A=23-202. DR PDB; 3CZU; X-ray; 2.65 A; A=23-202. DR PDB; 3FL7; X-ray; 2.50 A; A=23-531. DR PDB; 3HEI; X-ray; 2.00 A; A/C/E/G/I/K/M/O=28-201. DR PDB; 3HPN; X-ray; 2.52 A; A/B/C/D/E/F=28-201. DR PDB; 3KKA; X-ray; 2.40 A; C/D/E=903-971. DR PDB; 3MBW; X-ray; 2.81 A; A=23-326. DR PDB; 3MX0; X-ray; 3.51 A; A/C=27-435. DR PDB; 3SKJ; X-ray; 2.50 A; E/F=23-202. DR PDB; 4P2K; X-ray; 1.50 A; A=590-876. DR PDB; 4PDO; X-ray; 2.10 A; A/B=590-876. DR PDB; 4TRL; X-ray; 2.45 A; A=590-876. DR PDB; 5EK7; X-ray; 1.90 A; A/B=583-876. DR PDB; 5I9U; X-ray; 1.89 A; A=596-900. DR PDB; 5I9V; X-ray; 1.46 A; A=596-900. DR PDB; 5I9W; X-ray; 1.36 A; A=596-900. DR PDB; 5I9X; X-ray; 1.43 A; A=596-900. DR PDB; 5I9Y; X-ray; 1.23 A; A=596-900. DR PDB; 5I9Z; X-ray; 1.70 A; A=596-900. DR PDB; 5IA0; X-ray; 1.95 A; A/B/C=596-900. DR PDB; 5IA1; X-ray; 2.04 A; A=596-900. DR PDB; 5IA2; X-ray; 1.62 A; A=596-900. DR PDB; 5IA3; X-ray; 1.79 A; A=596-900. DR PDB; 5IA4; X-ray; 1.80 A; A=596-900. DR PDB; 5IA5; X-ray; 1.78 A; A=596-900. DR PDB; 5NJZ; X-ray; 1.77 A; A=596-900. DR PDB; 5NK0; X-ray; 1.60 A; A=596-900. DR PDB; 5NK1; X-ray; 1.55 A; A=596-900. DR PDB; 5NK2; X-ray; 1.65 A; A=596-900. DR PDB; 5NK3; X-ray; 1.59 A; A=596-900. DR PDB; 5NK4; X-ray; 1.45 A; A=596-900. DR PDB; 5NK5; X-ray; 1.33 A; A=596-900. DR PDB; 5NK6; X-ray; 1.27 A; A=596-900. DR PDB; 5NK7; X-ray; 1.89 A; A=596-900. DR PDB; 5NK8; X-ray; 1.76 A; A=596-900. DR PDB; 5NK9; X-ray; 1.59 A; A=596-900. DR PDB; 5NKA; X-ray; 1.38 A; A=596-900. DR PDB; 5NKB; X-ray; 1.50 A; A=596-900. DR PDB; 5NKC; X-ray; 1.45 A; A=596-900. DR PDB; 5NKD; X-ray; 1.41 A; A=596-900. DR PDB; 5NKE; X-ray; 1.39 A; A=596-900. DR PDB; 5NKF; X-ray; 1.10 A; A=596-900. DR PDB; 5NKG; X-ray; 1.10 A; A=596-900. DR PDB; 5NKH; X-ray; 1.29 A; A=596-900. DR PDB; 5NKI; X-ray; 1.68 A; A=596-900. DR PDB; 5NZ9; NMR; -; A=945-969. DR PDB; 6B9L; X-ray; 3.20 A; A/B/C/D=27-200. DR PDB; 6F7M; NMR; -; A=945-969. DR PDB; 6F7N; NMR; -; A=951-963. DR PDB; 6FNF; X-ray; 1.56 A; A=596-900. DR PDB; 6FNG; X-ray; 1.04 A; A=596-900. DR PDB; 6FNH; X-ray; 1.38 A; A/B/C=596-900. DR PDB; 6HES; X-ray; 1.13 A; A=596-900. DR PDB; 6HET; X-ray; 1.21 A; A=596-900. DR PDB; 6HEU; X-ray; 1.72 A; A=596-900. DR PDB; 6HEV; X-ray; 1.28 A; A=596-900. DR PDB; 6HEW; X-ray; 1.27 A; A=596-900. DR PDB; 6HEX; X-ray; 1.41 A; A=596-900. DR PDB; 6HEY; X-ray; 1.37 A; A=596-900. DR PDB; 6NJZ; X-ray; 1.90 A; A/B=28-200. DR PDB; 6NK0; X-ray; 1.53 A; A/B=28-200. DR PDB; 6NK1; X-ray; 1.55 A; A/B=28-200. DR PDB; 6NK2; X-ray; 2.20 A; A/B=28-200. DR PDB; 6NKP; X-ray; 2.03 A; A/B=28-200. DR PDB; 6Q7B; X-ray; 1.01 A; A=596-900. DR PDB; 6Q7C; X-ray; 1.05 A; A=596-900. DR PDB; 6Q7D; X-ray; 0.98 A; A=596-900. DR PDB; 6Q7E; X-ray; 1.06 A; A=596-900. DR PDB; 6Q7F; X-ray; 1.20 A; A=596-900. DR PDB; 6Q7G; X-ray; 1.05 A; A=596-900. DR PDB; 6RW2; X-ray; 2.26 A; A=27-201. DR PDB; 7B7N; X-ray; 2.69 A; E=23-202. DR PDB; 7CZE; X-ray; 3.00 A; I/J/K/L=26-200. DR PDB; 7CZF; X-ray; 3.20 A; A/D=28-206. DR PDB; 7KJA; X-ray; 1.75 A; A/B=590-976. DR PDB; 7KJB; X-ray; 2.80 A; A=590-976. DR PDB; 7KJC; X-ray; 2.30 A; A/B=590-976. DR PDB; 8BIN; X-ray; 1.50 A; A=596-900. DR PDB; 8BIO; X-ray; 1.60 A; A=596-900. DR PDB; 8BK0; X-ray; 1.70 A; A=596-900. DR PDB; 8BM8; X-ray; 1.68 A; A=596-900. DR PDB; 8BOC; X-ray; 1.90 A; A=596-900. DR PDB; 8BOD; X-ray; 1.50 A; A=596-900. DR PDB; 8BOF; X-ray; 1.82 A; A=596-900. DR PDB; 8BOG; X-ray; 1.47 A; A=596-900. DR PDB; 8BOH; X-ray; 1.42 A; A=596-900. DR PDB; 8BOI; X-ray; 1.63 A; A=596-900. DR PDB; 8BOK; X-ray; 2.02 A; A=596-900. DR PDB; 8BOM; X-ray; 1.12 A; A=596-900. DR PDB; 8QQY; X-ray; 1.80 A; A=596-900. DR PDB; 8T9B; X-ray; 4.20 A; I/J/K/L=436-529. DR PDB; 8TRS; X-ray; 1.90 A; D=199-326. DR PDB; 8TRT; X-ray; 3.00 A; D/E=199-326. DR PDB; 8TRV; X-ray; 3.25 A; A/B=23-326. DR PDB; 8TV1; X-ray; 2.60 A; C=23-326. DR PDB; 8TV5; X-ray; 4.60 A; C/F=23-326. DR PDB; 8XPV; X-ray; 1.55 A; A=596-900. DR PDBsum; 1MQB; -. DR PDBsum; 2E8N; -. DR PDBsum; 2K9Y; -. DR PDBsum; 2KSO; -. DR PDBsum; 2X10; -. DR PDBsum; 2X11; -. DR PDBsum; 3C8X; -. DR PDBsum; 3CZU; -. DR PDBsum; 3FL7; -. DR PDBsum; 3HEI; -. DR PDBsum; 3HPN; -. DR PDBsum; 3KKA; -. DR PDBsum; 3MBW; -. DR PDBsum; 3MX0; -. DR PDBsum; 3SKJ; -. DR PDBsum; 4P2K; -. DR PDBsum; 4PDO; -. DR PDBsum; 4TRL; -. DR PDBsum; 5EK7; -. DR PDBsum; 5I9U; -. DR PDBsum; 5I9V; -. DR PDBsum; 5I9W; -. DR PDBsum; 5I9X; -. DR PDBsum; 5I9Y; -. DR PDBsum; 5I9Z; -. DR PDBsum; 5IA0; -. DR PDBsum; 5IA1; -. DR PDBsum; 5IA2; -. DR PDBsum; 5IA3; -. DR PDBsum; 5IA4; -. DR PDBsum; 5IA5; -. DR PDBsum; 5NJZ; -. DR PDBsum; 5NK0; -. DR PDBsum; 5NK1; -. DR PDBsum; 5NK2; -. DR PDBsum; 5NK3; -. DR PDBsum; 5NK4; -. DR PDBsum; 5NK5; -. DR PDBsum; 5NK6; -. DR PDBsum; 5NK7; -. DR PDBsum; 5NK8; -. DR PDBsum; 5NK9; -. DR PDBsum; 5NKA; -. DR PDBsum; 5NKB; -. DR PDBsum; 5NKC; -. DR PDBsum; 5NKD; -. DR PDBsum; 5NKE; -. DR PDBsum; 5NKF; -. DR PDBsum; 5NKG; -. DR PDBsum; 5NKH; -. DR PDBsum; 5NKI; -. DR PDBsum; 5NZ9; -. DR PDBsum; 6B9L; -. DR PDBsum; 6F7M; -. DR PDBsum; 6F7N; -. DR PDBsum; 6FNF; -. DR PDBsum; 6FNG; -. DR PDBsum; 6FNH; -. DR PDBsum; 6HES; -. DR PDBsum; 6HET; -. DR PDBsum; 6HEU; -. DR PDBsum; 6HEV; -. DR PDBsum; 6HEW; -. DR PDBsum; 6HEX; -. DR PDBsum; 6HEY; -. DR PDBsum; 6NJZ; -. DR PDBsum; 6NK0; -. DR PDBsum; 6NK1; -. DR PDBsum; 6NK2; -. DR PDBsum; 6NKP; -. DR PDBsum; 6Q7B; -. DR PDBsum; 6Q7C; -. DR PDBsum; 6Q7D; -. DR PDBsum; 6Q7E; -. DR PDBsum; 6Q7F; -. DR PDBsum; 6Q7G; -. DR PDBsum; 6RW2; -. DR PDBsum; 7B7N; -. DR PDBsum; 7CZE; -. DR PDBsum; 7CZF; -. DR PDBsum; 7KJA; -. DR PDBsum; 7KJB; -. DR PDBsum; 7KJC; -. DR PDBsum; 8BIN; -. DR PDBsum; 8BIO; -. DR PDBsum; 8BK0; -. DR PDBsum; 8BM8; -. DR PDBsum; 8BOC; -. DR PDBsum; 8BOD; -. DR PDBsum; 8BOF; -. DR PDBsum; 8BOG; -. DR PDBsum; 8BOH; -. DR PDBsum; 8BOI; -. DR PDBsum; 8BOK; -. DR PDBsum; 8BOM; -. DR PDBsum; 8QQY; -. DR PDBsum; 8T9B; -. DR PDBsum; 8TRS; -. DR PDBsum; 8TRT; -. DR PDBsum; 8TRV; -. DR PDBsum; 8TV1; -. DR PDBsum; 8TV5; -. DR PDBsum; 8XPV; -. DR AlphaFoldDB; P29317; -. DR BMRB; P29317; -. DR SMR; P29317; -. DR BioGRID; 108288; 748. DR CORUM; P29317; -. DR DIP; DIP-96N; -. DR FunCoup; P29317; 946. DR IntAct; P29317; 207. DR MINT; P29317; -. DR STRING; 9606.ENSP00000351209; -. DR BindingDB; P29317; -. DR ChEMBL; CHEMBL2068; -. DR DrugBank; DB01254; Dasatinib. DR DrugBank; DB12010; Fostamatinib. DR DrugBank; DB04395; Phosphoaminophosphonic Acid-Adenylate Ester. DR DrugBank; DB08896; Regorafenib. DR DrugCentral; P29317; -. DR GuidetoPHARMACOLOGY; 1822; -. DR GlyConnect; 777; 3 N-Linked glycans (1 site). DR GlyCosmos; P29317; 2 sites, 4 glycans. DR GlyGen; P29317; 4 sites, 6 N-linked glycans (2 sites), 2 O-linked glycans (2 sites). DR iPTMnet; P29317; -. DR PhosphoSitePlus; P29317; -. DR SwissPalm; P29317; -. DR BioMuta; EPHA2; -. DR DMDM; 229462861; -. DR CPTAC; CPTAC-1784; -. DR CPTAC; CPTAC-2783; -. DR CPTAC; CPTAC-3201; -. DR jPOST; P29317; -. DR MassIVE; P29317; -. DR PaxDb; 9606-ENSP00000351209; -. DR PeptideAtlas; P29317; -. DR ProteomicsDB; 54535; -. [P29317-1] DR Pumba; P29317; -. DR ABCD; P29317; 32 sequenced antibodies. DR Antibodypedia; 4183; 1411 antibodies from 48 providers. DR DNASU; 1969; -. DR Ensembl; ENST00000358432.8; ENSP00000351209.5; ENSG00000142627.14. [P29317-1] DR GeneID; 1969; -. DR KEGG; hsa:1969; -. DR MANE-Select; ENST00000358432.8; ENSP00000351209.5; NM_004431.5; NP_004422.2. DR UCSC; uc001aya.2; human. [P29317-1] DR AGR; HGNC:3386; -. DR ClinPGx; PA27818; -. DR CTD; 1969; -. DR DisGeNET; 1969; -. DR GeneCards; EPHA2; -. DR HGNC; HGNC:3386; EPHA2. DR HPA; ENSG00000142627; Tissue enhanced (esophagus). DR MalaCards; EPHA2; -. DR MIM; 116600; phenotype. DR MIM; 176946; gene. DR OpenTargets; ENSG00000142627; -. DR Orphanet; 98991; Early-onset nuclear cataract. DR Orphanet; 98993; Early-onset posterior polar cataract. DR Orphanet; 441447; Early-onset posterior subcapsular cataract. DR Orphanet; 98994; Total early-onset cataract. DR VEuPathDB; HostDB:ENSG00000142627; -. DR eggNOG; KOG0196; Eukaryota. DR GeneTree; ENSGT00940000160786; -. DR HOGENOM; CLU_000288_141_4_1; -. DR InParanoid; P29317; -. DR OMA; CLECPVH; -. DR OrthoDB; 4062651at2759; -. DR PAN-GO; P29317; 8 GO annotations based on evolutionary models. DR PhylomeDB; P29317; -. DR BRENDA; 2.7.10.1; 2681. DR PathwayCommons; P29317; -. DR Reactome; R-HSA-2682334; EPH-Ephrin signaling. DR Reactome; R-HSA-3928663; EPHA-mediated growth cone collapse. DR Reactome; R-HSA-3928665; EPH-ephrin mediated repulsion of cells. DR Reactome; R-HSA-9013149; RAC1 GTPase cycle. DR Reactome; R-HSA-9013404; RAC2 GTPase cycle. DR Reactome; R-HSA-9013408; RHOG GTPase cycle. DR Reactome; R-HSA-9013420; RHOU GTPase cycle. DR Reactome; R-HSA-9013423; RAC3 GTPase cycle. DR Reactome; R-HSA-9013424; RHOV GTPase cycle. DR Reactome; R-HSA-9696264; RND3 GTPase cycle. DR Reactome; R-HSA-9696270; RND2 GTPase cycle. DR Reactome; R-HSA-9696273; RND1 GTPase cycle. DR SignaLink; P29317; -. DR SIGNOR; P29317; -. DR Agora; ENSG00000142627; -. DR BioGRID-ORCS; 1969; 20 hits in 1214 CRISPR screens. DR ChiTaRS; EPHA2; human. DR EvolutionaryTrace; P29317; -. DR GeneWiki; EPH_receptor_A2; -. DR GenomeRNAi; 1969; -. DR Pharos; P29317; Tclin. DR PRO; PR:P29317; -. DR Proteomes; UP000005640; Chromosome 1. DR RNAct; P29317; protein. DR Bgee; ENSG00000142627; Expressed in lower esophagus mucosa and 143 other cell types or tissues. DR ExpressionAtlas; P29317; baseline and differential. DR GO; GO:0009986; C:cell surface; IDA:UniProtKB. DR GO; GO:0005925; C:focal adhesion; IDA:UniProtKB. DR GO; GO:0030027; C:lamellipodium; IDA:UniProtKB. DR GO; GO:0031258; C:lamellipodium membrane; IEA:UniProtKB-SubCell. DR GO; GO:0031256; C:leading edge membrane; IDA:UniProtKB. DR GO; GO:0005886; C:plasma membrane; IDA:UniProtKB. DR GO; GO:0043235; C:receptor complex; IBA:GO_Central. DR GO; GO:0032587; C:ruffle membrane; IEA:UniProtKB-SubCell. DR GO; GO:0070160; C:tight junction; IDA:ARUK-UCL. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0045296; F:cadherin binding; HDA:BHF-UCL. DR GO; GO:0005003; F:ephrin receptor activity; IDA:UniProtKB. DR GO; GO:0019838; F:growth factor binding; IPI:ARUK-UCL. DR GO; GO:0140677; F:molecular function activator activity; EXP:DisProt. DR GO; GO:0004714; F:transmembrane receptor protein tyrosine kinase activity; IBA:GO_Central. DR GO; GO:0001618; F:virus receptor activity; IEA:UniProtKB-KW. DR GO; GO:0090630; P:activation of GTPase activity; IMP:UniProtKB. DR GO; GO:0001525; P:angiogenesis; IBA:GO_Central. DR GO; GO:0048320; P:axial mesoderm formation; IEA:Ensembl. DR GO; GO:0002043; P:blood vessel endothelial cell proliferation involved in sprouting angiogenesis; IEA:Ensembl. DR GO; GO:0046849; P:bone remodeling; ISS:UniProtKB. DR GO; GO:0060444; P:branching involved in mammary gland duct morphogenesis; ISS:UniProtKB. DR GO; GO:0046058; P:cAMP metabolic process; IMP:UniProtKB. DR GO; GO:0007155; P:cell adhesion; IEA:UniProtKB-KW. DR GO; GO:0060326; P:cell chemotaxis; IMP:UniProtKB. DR GO; GO:0016477; P:cell migration; IMP:UniProtKB. DR GO; GO:0048870; P:cell motility; IMP:UniProtKB. DR GO; GO:0007169; P:cell surface receptor protein tyrosine kinase signaling pathway; IBA:GO_Central. DR GO; GO:0021953; P:central nervous system neuron differentiation; IEA:Ensembl. DR GO; GO:0050830; P:defense response to Gram-positive bacterium; IEA:Ensembl. DR GO; GO:0048013; P:ephrin receptor signaling pathway; IDA:UniProtKB. DR GO; GO:0006954; P:inflammatory response; IEA:Ensembl. DR GO; GO:0008630; P:intrinsic apoptotic signaling pathway in response to DNA damage; IDA:UniProtKB. DR GO; GO:0030216; P:keratinocyte differentiation; IMP:UniProtKB. DR GO; GO:0070309; P:lens fiber cell morphogenesis; ISS:UniProtKB. DR GO; GO:0033598; P:mammary gland epithelial cell proliferation; ISS:UniProtKB. DR GO; GO:0016525; P:negative regulation of angiogenesis; IEA:Ensembl. DR GO; GO:0033629; P:negative regulation of cell adhesion mediated by integrin; IDA:UniProtKB. DR GO; GO:0032682; P:negative regulation of chemokine production; IEA:Ensembl. DR GO; GO:1901491; P:negative regulation of lymphangiogenesis; IEA:Ensembl. DR GO; GO:0021915; P:neural tube development; IEA:Ensembl. DR GO; GO:0060035; P:notochord cell development; IEA:Ensembl. DR GO; GO:0014028; P:notochord formation; IEA:Ensembl. DR GO; GO:0001649; P:osteoblast differentiation; ISS:UniProtKB. DR GO; GO:0030316; P:osteoclast differentiation; ISS:UniProtKB. DR GO; GO:1904238; P:pericyte cell differentiation; IEA:Ensembl. DR GO; GO:1903348; P:positive regulation of bicellular tight junction assembly; IMP:ARUK-UCL. DR GO; GO:0030335; P:positive regulation of cell migration; IDA:ARUK-UCL. DR GO; GO:1903078; P:positive regulation of protein localization to plasma membrane; IMP:UniProtKB. DR GO; GO:0036342; P:post-anal tail morphogenesis; IEA:Ensembl. DR GO; GO:0072659; P:protein localization to plasma membrane; IMP:ARUK-UCL. DR GO; GO:0045765; P:regulation of angiogenesis; ISS:UniProtKB. DR GO; GO:0043535; P:regulation of blood vessel endothelial cell migration; ISS:UniProtKB. DR GO; GO:0070372; P:regulation of ERK1 and ERK2 cascade; IMP:UniProtKB. DR GO; GO:0010591; P:regulation of lamellipodium assembly; IMP:UniProtKB. DR GO; GO:0070848; P:response to growth factor; IMP:UniProtKB. DR GO; GO:0001501; P:skeletal system development; IEA:Ensembl. DR GO; GO:0001570; P:vasculogenesis; IEA:Ensembl. DR CDD; cd10480; EphR_LBD_A2; 1. DR CDD; cd00063; FN3; 2. DR CDD; cd05063; PTKc_EphR_A2; 1. DR CDD; cd09543; SAM_EPH-A2; 1. DR DisProt; DP03145; -. DR FunFam; 1.10.150.50:FF:000029; Ephrin type-A receptor 1; 1. DR FunFam; 1.20.5.510:FF:000004; Ephrin type-A receptor 2; 1. DR FunFam; 2.60.120.260:FF:000023; Ephrin type-A receptor 2; 1. DR FunFam; 2.60.40.10:FF:000724; ephrin type-A receptor 2; 1. DR FunFam; 2.60.40.1770:FF:000002; ephrin type-A receptor 2; 1. DR FunFam; 1.10.510.10:FF:000019; Ephrin type-A receptor 5; 1. DR FunFam; 2.10.50.10:FF:000001; Ephrin type-A receptor 5; 1. DR FunFam; 3.30.200.20:FF:000001; Ephrin type-A receptor 5; 1. DR FunFam; 2.60.40.10:FF:000059; Ephrin type-A receptor 6; 1. DR Gene3D; 2.60.40.1770; ephrin a2 ectodomain; 1. DR Gene3D; 2.60.120.260; Galactose-binding domain-like; 1. DR Gene3D; 2.60.40.10; Immunoglobulins; 2. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.20.5.510; Single helix bin; 1. DR Gene3D; 1.10.150.50; Transcription Factor, Ets-1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR Gene3D; 2.10.50.10; Tumor Necrosis Factor Receptor, subunit A, domain 2; 1. DR InterPro; IPR027936; Eph_TM. DR InterPro; IPR034263; EphA2_rcpt_lig-bd. DR InterPro; IPR001090; Ephrin_rcpt_lig-bd_dom. DR InterPro; IPR050449; Ephrin_rcpt_TKs. DR InterPro; IPR003961; FN3_dom. DR InterPro; IPR036116; FN3_sf. DR InterPro; IPR008979; Galactose-bd-like_sf. DR InterPro; IPR009030; Growth_fac_rcpt_cys_sf. DR InterPro; IPR013783; Ig-like_fold. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR001660; SAM. DR InterPro; IPR013761; SAM/pointed_sf. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR008266; Tyr_kinase_AS. DR InterPro; IPR020635; Tyr_kinase_cat_dom. DR InterPro; IPR016257; Tyr_kinase_ephrin_rcpt. DR InterPro; IPR001426; Tyr_kinase_rcpt_V_CS. DR PANTHER; PTHR46877; EPH RECEPTOR A5; 1. DR PANTHER; PTHR46877:SF20; RECEPTOR PROTEIN-TYROSINE KINASE; 1. DR Pfam; PF14575; EphA2_TM; 1. DR Pfam; PF25599; Ephrin_CRD; 1. DR Pfam; PF01404; Ephrin_lbd; 1. DR Pfam; PF00041; fn3; 2. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR Pfam; PF00536; SAM_1; 1. DR PIRSF; PIRSF000666; TyrPK_ephrin_receptor; 1. DR PRINTS; PR00109; TYRKINASE. DR SMART; SM00615; EPH_lbd; 1. DR SMART; SM01411; Ephrin_rec_like; 1. DR SMART; SM00060; FN3; 2. DR SMART; SM00454; SAM; 1. DR SMART; SM00219; TyrKc; 1. DR SUPFAM; SSF49265; Fibronectin type III; 1. DR SUPFAM; SSF49785; Galactose-binding domain-like; 1. DR SUPFAM; SSF57184; Growth factor receptor domain; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR SUPFAM; SSF47769; SAM/Pointed domain; 1. DR PROSITE; PS51550; EPH_LBD; 1. DR PROSITE; PS50853; FN3; 2. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00109; PROTEIN_KINASE_TYR; 1. DR PROSITE; PS00790; RECEPTOR_TYR_KIN_V_1; 1. DR PROSITE; PS00791; RECEPTOR_TYR_KIN_V_2; 1. DR PROSITE; PS50105; SAM_DOMAIN; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; Angiogenesis; Apoptosis; ATP-binding; KW Cataract; Cell adhesion; Cell junction; Cell membrane; Cell projection; KW Differentiation; Disease variant; Disulfide bond; Glycoprotein; KW Host cell receptor for virus entry; Host-virus interaction; Kinase; KW Membrane; Nucleotide-binding; Phosphoprotein; Proteomics identification; KW Receptor; Reference proteome; Repeat; Signal; Transferase; Transmembrane; KW Transmembrane helix; Tyrosine-protein kinase; Ubl conjugation. FT SIGNAL 1..23 FT /evidence="ECO:0000255" FT CHAIN 24..976 FT /note="Ephrin type-A receptor 2" FT /id="PRO_0000016800" FT TOPO_DOM 24..537 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 538..558 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 559..976 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT DOMAIN 28..206 FT /note="Eph LBD" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00883" FT DOMAIN 328..432 FT /note="Fibronectin type-III 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 438..529 FT /note="Fibronectin type-III 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 613..875 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT DOMAIN 904..968 FT /note="SAM" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00184" FT REGION 1..206 FT /note="Mediates interaction with CLDN4" FT /evidence="ECO:0000269|PubMed:16236711" FT REGION 606..906 FT /note="Mediates interaction with ARHGEF16 and ELMO2" FT /evidence="ECO:0000269|PubMed:20679435" FT REGION 886..976 FT /note="Negatively regulates interaction with ARHGEF16" FT /evidence="ECO:0000269|PubMed:20679435" FT MOTIF 974..976 FT /note="PDZ-binding" FT /evidence="ECO:0000255" FT ACT_SITE 739 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10028" FT BINDING 619..627 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 646 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 570 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:18691976, ECO:0007744|PubMed:19369195" FT MOD_RES 575 FT /note="Phosphotyrosine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 579 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18691976" FT MOD_RES 588 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000250" FT MOD_RES 594 FT /note="Phosphotyrosine" FT /evidence="ECO:0000250|UniProtKB:Q03145" FT MOD_RES 628 FT /note="Phosphotyrosine" FT /evidence="ECO:0007744|PubMed:19369195" FT MOD_RES 647 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:18691976, FT ECO:0007744|PubMed:19369195" FT MOD_RES 735 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000250|UniProtKB:Q03145" FT MOD_RES 772 FT /note="Phosphotyrosine" FT /evidence="ECO:0000250|UniProtKB:Q03145" FT MOD_RES 869 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:19369195" FT MOD_RES 892 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:23186163" FT MOD_RES 897 FT /note="Phosphoserine; by PKB/AKT1, RPS6KA1, RPS6KA3 AND FT PKA" FT /evidence="ECO:0000269|PubMed:19573808, FT ECO:0000269|PubMed:26158630, ECO:0000269|PubMed:27385333, FT ECO:0007744|PubMed:23186163" FT MOD_RES 901 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:27385333, FT ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:23186163" FT MOD_RES 921 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000255" FT MOD_RES 930 FT /note="Phosphotyrosine" FT /evidence="ECO:0000269|PubMed:23358419" FT CARBOHYD 407 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 435 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:19159218" FT DISULFID 70..188 FT DISULFID 105..115 FT VAR_SEQ 477..497 FT /note="GDSNSYNVRRTEGFSVTLDDL -> VTPRGAGLALAGPTAGDRLVT (in FT isoform 2)" FT /evidence="ECO:0000303|PubMed:18593464" FT /id="VSP_056014" FT VAR_SEQ 498..976 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:18593464" FT /id="VSP_056015" FT VARIANT 99 FT /note="K -> N (in dbSNP:rs1058372)" FT /id="VAR_055989" FT VARIANT 391 FT /note="G -> R (in dbSNP:rs34192549)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042121" FT VARIANT 511 FT /note="T -> M (in dbSNP:rs55747232)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042122" FT VARIANT 568 FT /note="R -> H (in dbSNP:rs56198600)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042123" FT VARIANT 631 FT /note="M -> T (in dbSNP:rs34021505)" FT /id="VAR_055990" FT VARIANT 721 FT /note="R -> Q (in CTRCT6; retained in the cytoplasm and FT constitutively active it alters EPHA2 signaling; FT dbSNP:rs116506614)" FT /evidence="ECO:0000269|PubMed:19649315" FT /id="VAR_062532" FT VARIANT 777 FT /note="G -> S (in a gastric adenocarcinoma sample; somatic FT mutation; dbSNP:rs922655349)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042124" FT VARIANT 876 FT /note="R -> H (in dbSNP:rs35903225)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042125" FT VARIANT 940 FT /note="T -> I (in CTRCT6; reduced protein stability and FT reduced ability to stimulate cell migration in absence of FT its ephrin ligand; dbSNP:rs137853200)" FT /evidence="ECO:0000269|PubMed:19306328, FT ECO:0000269|PubMed:22570727" FT /id="VAR_058907" FT VARIANT 948 FT /note="G -> W (in CTRCT6; reduced protein stability and FT reduced ability to stimulate cell migration in absence of FT its ephrin ligand; dbSNP:rs137853199)" FT /evidence="ECO:0000269|PubMed:19005574, FT ECO:0000269|PubMed:22570727" FT /id="VAR_058908" FT MUTAGEN 103 FT /note="R->E: Significantly reduced response to EFNA1." FT /evidence="ECO:0000269|PubMed:19525919" FT MUTAGEN 646 FT /note="K->M: Loss of kinase activity." FT /evidence="ECO:0000269|PubMed:16236711" FT MUTAGEN 739 FT /note="D->N: Increases serum-induced chemotaxis. Loss of FT EFNA1-dependent regulation of cell migration." FT /evidence="ECO:0000269|PubMed:19573808" FT MUTAGEN 897 FT /note="S->A,D: Loss of serum-induced phosphorylation by FT PKB. Loss of serum-induced chemotaxis." FT /evidence="ECO:0000269|PubMed:19573808" FT CONFLICT 94..99 FT /note="IFIELK -> NNFELN (in Ref. 1; AAA53375)" FT /evidence="ECO:0000305" FT STRAND 28..33 FT /evidence="ECO:0007829|PDB:6NK0" FT HELIX 34..37 FT /evidence="ECO:0007829|PDB:6NK0" FT STRAND 44..47 FT /evidence="ECO:0007829|PDB:6NK0" FT TURN 48..50 FT /evidence="ECO:0007829|PDB:6NK1" FT STRAND 53..57 FT /evidence="ECO:0007829|PDB:6NK0" FT STRAND 59..62 FT /evidence="ECO:0007829|PDB:6NK0" FT STRAND 64..70 FT /evidence="ECO:0007829|PDB:6NK0" FT STRAND 73..75 FT /evidence="ECO:0007829|PDB:6NK0" FT STRAND 79..82 FT /evidence="ECO:0007829|PDB:6NK0" FT STRAND 92..103 FT /evidence="ECO:0007829|PDB:6NK0" FT HELIX 105..107 FT /evidence="ECO:0007829|PDB:6NK0" FT STRAND 108..110 FT /evidence="ECO:0007829|PDB:3HEI" FT TURN 112..114 FT /evidence="ECO:0007829|PDB:6NK0" FT STRAND 119..128 FT /evidence="ECO:0007829|PDB:6NK0" FT HELIX 136..138 FT /evidence="ECO:0007829|PDB:6NK0" FT STRAND 140..145 FT /evidence="ECO:0007829|PDB:6NK0" FT STRAND 148..151 FT /evidence="ECO:0007829|PDB:6RW2" FT HELIX 153..157 FT /evidence="ECO:0007829|PDB:6NK0" FT STRAND 164..170 FT /evidence="ECO:0007829|PDB:6NK0" FT STRAND 175..199 FT /evidence="ECO:0007829|PDB:6NK0" FT STRAND 204..206 FT /evidence="ECO:0007829|PDB:8TRS" FT STRAND 209..211 FT /evidence="ECO:0007829|PDB:8TRS" FT STRAND 214..217 FT /evidence="ECO:0007829|PDB:8TRS" FT HELIX 221..224 FT /evidence="ECO:0007829|PDB:8TRS" FT STRAND 225..227 FT /evidence="ECO:0007829|PDB:8TRS" FT STRAND 238..240 FT /evidence="ECO:0007829|PDB:3MBW" FT STRAND 244..247 FT /evidence="ECO:0007829|PDB:8TRS" FT STRAND 253..257 FT /evidence="ECO:0007829|PDB:8TV1" FT STRAND 266..269 FT /evidence="ECO:0007829|PDB:8TRS" FT STRAND 272..275 FT /evidence="ECO:0007829|PDB:8TRS" FT STRAND 284..287 FT /evidence="ECO:0007829|PDB:8TRS" FT STRAND 295..298 FT /evidence="ECO:0007829|PDB:3FL7" FT STRAND 304..306 FT /evidence="ECO:0007829|PDB:8TV1" FT STRAND 335..338 FT /evidence="ECO:0007829|PDB:3FL7" FT STRAND 343..348 FT /evidence="ECO:0007829|PDB:3FL7" FT STRAND 361..369 FT /evidence="ECO:0007829|PDB:3FL7" FT STRAND 376..378 FT /evidence="ECO:0007829|PDB:3FL7" FT STRAND 384..387 FT /evidence="ECO:0007829|PDB:3FL7" FT STRAND 389..392 FT /evidence="ECO:0007829|PDB:3FL7" FT STRAND 394..400 FT /evidence="ECO:0007829|PDB:3FL7" FT STRAND 407..415 FT /evidence="ECO:0007829|PDB:3FL7" FT HELIX 419..421 FT /evidence="ECO:0007829|PDB:3FL7" FT STRAND 427..433 FT /evidence="ECO:0007829|PDB:3FL7" FT STRAND 441..446 FT /evidence="ECO:0007829|PDB:3FL7" FT STRAND 453..457 FT /evidence="ECO:0007829|PDB:3FL7" FT TURN 460..465 FT /evidence="ECO:0007829|PDB:3FL7" FT STRAND 467..475 FT /evidence="ECO:0007829|PDB:3FL7" FT STRAND 483..493 FT /evidence="ECO:0007829|PDB:3FL7" FT STRAND 502..510 FT /evidence="ECO:0007829|PDB:3FL7" FT STRAND 522..525 FT /evidence="ECO:0007829|PDB:3FL7" FT HELIX 536..556 FT /evidence="ECO:0007829|PDB:2K9Y" FT STRAND 557..561 FT /evidence="ECO:0007829|PDB:2K9Y" FT HELIX 591..594 FT /evidence="ECO:0007829|PDB:5EK7" FT HELIX 597..600 FT /evidence="ECO:0007829|PDB:4PDO" FT TURN 601..604 FT /evidence="ECO:0007829|PDB:6Q7D" FT HELIX 610..612 FT /evidence="ECO:0007829|PDB:6Q7D" FT STRAND 613..622 FT /evidence="ECO:0007829|PDB:6Q7D" FT STRAND 625..632 FT /evidence="ECO:0007829|PDB:6Q7D" FT HELIX 635..637 FT /evidence="ECO:0007829|PDB:5NKH" FT STRAND 641..648 FT /evidence="ECO:0007829|PDB:6Q7D" FT HELIX 654..669 FT /evidence="ECO:0007829|PDB:6Q7D" FT STRAND 678..682 FT /evidence="ECO:0007829|PDB:6Q7D" FT STRAND 684..693 FT /evidence="ECO:0007829|PDB:6Q7D" FT HELIX 700..706 FT /evidence="ECO:0007829|PDB:6Q7D" FT TURN 707..709 FT /evidence="ECO:0007829|PDB:6Q7E" FT HELIX 713..732 FT /evidence="ECO:0007829|PDB:6Q7D" FT HELIX 742..744 FT /evidence="ECO:0007829|PDB:6Q7D" FT STRAND 745..747 FT /evidence="ECO:0007829|PDB:6Q7D" FT STRAND 753..755 FT /evidence="ECO:0007829|PDB:6Q7D" FT HELIX 762..766 FT /evidence="ECO:0007829|PDB:5NKF" FT STRAND 770..772 FT /evidence="ECO:0007829|PDB:5NKF" FT STRAND 776..778 FT /evidence="ECO:0007829|PDB:5NKH" FT HELIX 781..783 FT /evidence="ECO:0007829|PDB:6Q7D" FT HELIX 786..791 FT /evidence="ECO:0007829|PDB:6Q7D" FT HELIX 796..811 FT /evidence="ECO:0007829|PDB:6Q7D" FT TURN 817..820 FT /evidence="ECO:0007829|PDB:6Q7D" FT HELIX 823..831 FT /evidence="ECO:0007829|PDB:6Q7D" FT HELIX 844..853 FT /evidence="ECO:0007829|PDB:6Q7D" FT HELIX 858..860 FT /evidence="ECO:0007829|PDB:6Q7D" FT HELIX 864..876 FT /evidence="ECO:0007829|PDB:6Q7D" FT HELIX 878..881 FT /evidence="ECO:0007829|PDB:6Q7D" FT STRAND 882..884 FT /evidence="ECO:0007829|PDB:6Q7D" FT HELIX 889..892 FT /evidence="ECO:0007829|PDB:8QQY" FT HELIX 909..915 FT /evidence="ECO:0007829|PDB:7KJA" FT HELIX 919..921 FT /evidence="ECO:0007829|PDB:7KJA" FT HELIX 922..927 FT /evidence="ECO:0007829|PDB:7KJA" FT HELIX 933..936 FT /evidence="ECO:0007829|PDB:7KJA" FT HELIX 941..946 FT /evidence="ECO:0007829|PDB:7KJA" FT HELIX 952..969 FT /evidence="ECO:0007829|PDB:7KJA" SQ SEQUENCE 976 AA; 108266 MW; 845D7E1BBCCAACCC CRC64; MELQAARACF ALLWGCALAA AAAAQGKEVV LLDFAAAGGE LGWLTHPYGK GWDLMQNIMN DMPIYMYSVC NVMSGDQDNW LRTNWVYRGE AERIFIELKF TVRDCNSFPG GASSCKETFN LYYAESDLDY GTNFQKRLFT KIDTIAPDEI TVSSDFEARH VKLNVEERSV GPLTRKGFYL AFQDIGACVA LLSVRVYYKK CPELLQGLAH FPETIAGSDA PSLATVAGTC VDHAVVPPGG EEPRMHCAVD GEWLVPIGQC LCQAGYEKVE DACQACSPGF FKFEASESPC LECPEHTLPS PEGATSCECE EGFFRAPQDP ASMPCTRPPS APHYLTAVGM GAKVELRWTP PQDSGGREDI VYSVTCEQCW PESGECGPCE ASVRYSEPPH GLTRTSVTVS DLEPHMNYTF TVEARNGVSG LVTSRSFRTA SVSINQTEPP KVRLEGRSTT SLSVSWSIPP PQQSRVWKYE VTYRKKGDSN SYNVRRTEGF SVTLDDLAPD TTYLVQVQAL TQEGQGAGSK VHEFQTLSPE GSGNLAVIGG VAVGVVLLLV LAGVGFFIHR RRKNQRARQS PEDVYFSKSE QLKPLKTYVD PHTYEDPNQA VLKFTTEIHP SCVTRQKVIG AGEFGEVYKG MLKTSSGKKE VPVAIKTLKA GYTEKQRVDF LGEAGIMGQF SHHNIIRLEG VISKYKPMMI ITEYMENGAL DKFLREKDGE FSVLQLVGML RGIAAGMKYL ANMNYVHRDL AARNILVNSN LVCKVSDFGL SRVLEDDPEA TYTTSGGKIP IRWTAPEAIS YRKFTSASDV WSFGIVMWEV MTYGERPYWE LSNHEVMKAI NDGFRLPTPM DCPSAIYQLM MQCWQQERAR RPKFADIVSI LDKLIRAPDS LKTLADFDPR VSIRLPSTSG SEGVPFRTVS EWLESIKMQQ YTEHFMAAGY TAIEKVVQMT NDDIKRIGVR LPGHQKRIAY SLLGLKDQVN TVGIPI // ID HNRDL_HUMAN Reviewed; 420 AA. AC O14979; Q6SPF2; Q7KZ74; Q7KZ75; Q96IM0; Q96S43; DT 15-MAY-2007, integrated into UniProtKB/Swiss-Prot. DT 01-AUG-1999, sequence version 3. DT 28-JAN-2026, entry version 212. DE RecName: Full=Heterogeneous nuclear ribonucleoprotein D-like; DE Short=hnRNP D-like; DE Short=hnRNP DL; DE AltName: Full=AU-rich element RNA-binding factor; DE AltName: Full=JKT41-binding protein; DE AltName: Full=Protein laAUF1; GN Name=HNRNPDL; Synonyms=HNRPDL, JKTBP; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), FUNCTION, TISSUE RP SPECIFICITY, RNA-BINDING, AND DNA-BINDING. RC TISSUE=Erythroleukemia, and Placenta; RX PubMed=9538234; DOI=10.1093/oxfordjournals.jbchem.a021964; RA Tsuchiya N., Kamei D., Takano A., Matsui T., Yamada M.; RT "Cloning and characterization of a cDNA encoding a novel heterogeneous RT nuclear ribonucleoprotein-like protein and its expression in myeloid RT leukemia cells."; RL J. Biochem. 123:499-507(1998). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), INDUCTION, AND TISSUE RP SPECIFICITY. RC TISSUE=Placenta; RX PubMed=10072754; DOI=10.1016/s0378-1119(99)00020-7; RA Kamei D., Tsuchiya N., Yamazaki M., Meguro H., Yamada M.; RT "Two forms of expression and genomic structure of the human heterogeneous RT nuclear ribonucleoprotein D-like JKTBP gene (HNRPDL)."; RL Gene 228:13-22(1999). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3), SUBCELLULAR LOCATION, AND RP RNA-BINDING. RX PubMed=11705999; DOI=10.1074/jbc.m108477200; RA Kawamura H., Tomozoe Y., Akagi T., Kamei D., Ochiai M., Yamada M.; RT "Identification of the nucleocytoplasmic shuttling sequence of RT heterogeneous nuclear ribonucleoprotein D-like protein JKTBP and its RT interaction with mRNA."; RL J. Biol. Chem. 277:2732-2739(2002). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RA Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.; RT "Cloning of human full open reading frames in Gateway(TM) system entry RT vector (pDONR201)."; RL Submitted (MAY-2004) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15815621; DOI=10.1038/nature03466; RA Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P., RA Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C., RA Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L., RA Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A., RA Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J., RA Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M., RA Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T., RA Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S., RA Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K., RA McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C., RA Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S., RA Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C., RA Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M., RA Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C., RA Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J., RA Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E., RA Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X., RA Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M., RA Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C., RA Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S., RA Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H., RA Wilson R.K.; RT "Generation and annotation of the DNA sequences of human chromosomes 2 and RT 4."; RL Nature 434:724-731(2005). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Lung, Ovary, and Skin; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [7] RP NUCLEOTIDE SEQUENCE [MRNA] OF 123-420. RC TISSUE=Brain; RX PubMed=15190078; DOI=10.1074/jbc.m403160200; RA Boopathi E., Lenka N., Prabu S.K., Fang J.-K., Wilkinson F., Atchison M., RA Giallongo A., Avadhani N.G.; RT "Regulation of murine cytochrome c oxidase Vb gene expression during RT myogenesis: YY-1 and heterogeneous nuclear ribonucleoprotein D-like protein RT (JKTBP1) reciprocally regulate transcription activity by physical RT interaction with the BERF-1/ZBP-89 factor."; RL J. Biol. Chem. 279:35242-35254(2004). RN [8] RP NUCLEOTIDE SEQUENCE [MRNA] OF 131-420, INTERACTION WITH TNPO1, MUTAGENESIS RP OF GLY-404, INDUCTION, AND RNA-BINDING. RX PubMed=9524220; DOI=10.1016/s0167-4781(97)00223-6; RA Doi A., Shiosaka T., Takaoka Y., Yanagisawa K., Fujita S.; RT "Molecular cloning of the cDNA encoding A + U-rich element RNA binding RT factor."; RL Biochim. Biophys. Acta 1396:51-56(1998). RN [9] RP PROTEIN SEQUENCE OF 150-180; 190-209; 234-269; 275-289 AND 406-420, RP METHYLATION AT LYS-161 AND ARG-408, AND IDENTIFICATION BY MASS RP SPECTROMETRY. RC TISSUE=Colon carcinoma, and Ovarian carcinoma; RA Bienvenut W.V., Zebisch A., Lilla S., von Kriegsheim A., Lempens A., RA Kolch W.; RL Submitted (DEC-2008) to UniProtKB. RN [10] RP PROTEIN SEQUENCE OF 235-269 AND 275-289. RC TISSUE=Fetal brain cortex; RA Lubec G., Chen W.-Q., Sun Y.; RL Submitted (DEC-2008) to UniProtKB. RN [11] RP SUBCELLULAR LOCATION, AND RNA-BINDING. RX PubMed=12406575; DOI=10.1016/s0378-1119(02)00926-5; RA Kamei D., Yamada M.; RT "Interactions of heterogeneous nuclear ribonucleoprotein D-like protein RT JKTBP and its domains with high-affinity binding sites."; RL Gene 298:49-57(2002). RN [12] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-241, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=17081983; DOI=10.1016/j.cell.2006.09.026; RA Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.; RT "Global, in vivo, and site-specific phosphorylation dynamics in signaling RT networks."; RL Cell 127:635-648(2006). RN [13] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19413330; DOI=10.1021/ac9004309; RA Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.; RT "Lys-N and trypsin cover complementary parts of the phosphoproteome in a RT refined SCX-based approach."; RL Anal. Chem. 81:4493-4501(2009). RN [14] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-241, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [15] RP ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-216, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19608861; DOI=10.1126/science.1175371; RA Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C., RA Olsen J.V., Mann M.; RT "Lysine acetylation targets protein complexes and co-regulates major RT cellular functions."; RL Science 325:834-840(2009). RN [16] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-241, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [17] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [18] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-241, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [19] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-241, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [20] RP INVOLVEMENT IN LGMDD3, AND VARIANTS LGMDD3 ASN-378 AND HIS-378. RX PubMed=24647604; DOI=10.1093/hmg/ddu127; RA Vieira N.M., Naslavsky M.S., Licinio L., Kok F., Schlesinger D., RA Vainzof M., Sanchez N., Kitajima J.P., Gal L., Cavacana N., Serafini P.R., RA Chuartzman S., Vasquez C., Mimbacas A., Nigro V., Pavanello R.C., RA Schuldiner M., Kunkel L.M., Zatz M.; RT "A defect in the RNA-processing protein HNRPDL causes limb-girdle muscular RT dystrophy 1G (LGMD1G)."; RL Hum. Mol. Genet. 23:4103-4110(2014). RN [21] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-241, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [22] RP METHYLATION [LARGE SCALE ANALYSIS] AT ARG-25, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Colon carcinoma; RX PubMed=24129315; DOI=10.1074/mcp.o113.027870; RA Guo A., Gu H., Zhou J., Mulhern D., Wang Y., Lee K.A., Yang V., Aguiar M., RA Kornhauser J., Jia X., Ren J., Beausoleil S.A., Silva J.C., Vemulapalli V., RA Bedford M.T., Comb M.J.; RT "Immunoaffinity enrichment and mass spectrometry analysis of protein RT methylation."; RL Mol. Cell. Proteomics 13:372-387(2014). RN [23] RP SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-209, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=28112733; DOI=10.1038/nsmb.3366; RA Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C., RA Nielsen M.L.; RT "Site-specific mapping of the human SUMO proteome reveals co-modification RT with phosphorylation."; RL Nat. Struct. Mol. Biol. 24:325-336(2017). CC -!- FUNCTION: Acts as a transcriptional regulator. Promotes transcription CC repression. Promotes transcription activation in differentiated CC myotubes (By similarity). Binds to double- and single-stranded DNA CC sequences. Binds to the transcription suppressor CATR sequence of the CC COX5B promoter (By similarity). Binds with high affinity to RNA CC molecules that contain AU-rich elements (AREs) found within the 3'-UTR CC of many proto-oncogenes and cytokine mRNAs. Binds both to nuclear and CC cytoplasmic poly(A) mRNAs. Binds to poly(G) and poly(A), but not to CC poly(U) or poly(C) RNA homopolymers. Binds to the 5'-ACUAGC-3' RNA CC consensus sequence. {ECO:0000250, ECO:0000269|PubMed:9538234}. CC -!- SUBUNIT: Interacts with ZNF148 (By similarity). Interacts with TNPO1. CC {ECO:0000250, ECO:0000269|PubMed:9524220}. CC -!- INTERACTION: CC O14979; P22626: HNRNPA2B1; NbExp=2; IntAct=EBI-299727, EBI-299649; CC O14979; Q14103: HNRNPD; NbExp=2; IntAct=EBI-299727, EBI-299674; CC O14979; Q15637: SF1; NbExp=4; IntAct=EBI-299727, EBI-744603; CC O14979; P09234: SNRPC; NbExp=4; IntAct=EBI-299727, EBI-766589; CC O14979; Q13148: TARDBP; NbExp=3; IntAct=EBI-299727, EBI-372899; CC O14979; O76024: WFS1; NbExp=3; IntAct=EBI-299727, EBI-720609; CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:11705999, CC ECO:0000269|PubMed:12406575}. Cytoplasm {ECO:0000269|PubMed:11705999, CC ECO:0000269|PubMed:12406575}. Note=Shuttles between the nucleus and the CC cytoplasm in a TNPO1-dependent manner. {ECO:0000269|PubMed:11705999, CC ECO:0000269|PubMed:12406575}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=3; CC Name=1; Synonyms=JKTBP2 {ECO:0000303|PubMed:10072754}; CC IsoId=O14979-1; Sequence=Displayed; CC Name=2; Synonyms=JKTBP1 {ECO:0000303|PubMed:10072754}; CC IsoId=O14979-2; Sequence=VSP_025410; CC Name=3; CC IsoId=O14979-3; Sequence=VSP_025410, VSP_025411; CC -!- TISSUE SPECIFICITY: Expressed in heart, brain, placenta, lung, liver, CC skeletal muscle, kidney, pancreas, spleen, thymus, prostate, testis, CC ovary, small intestine, colon and leukocytes. Expressed in myeloid CC leukemia, gastric adenocarcinoma, cervical carcinoma, hepatoma, CC fibrosarcoma, colon adenocarcinoma, epidermoid carcinoma, osteosarcoma CC and urinary bladder carcinoma cells. {ECO:0000269|PubMed:10072754, CC ECO:0000269|PubMed:9538234}. CC -!- INDUCTION: Up-regulated by 12-O-tetradecanoylphorbol-13-acetate (TPA) CC in macrophages and retinoic acid (RA) in granulocytes (at protein CC level). Down-regulated by IL4/interleukin-4. CC {ECO:0000269|PubMed:10072754, ECO:0000269|PubMed:9524220}. CC -!- PTM: Dimethylation of Arg-408 is probably of the asymmetric type. CC -!- DISEASE: Muscular dystrophy, limb-girdle, autosomal dominant 3 (LGMDD3) CC [MIM:609115]: An autosomal dominant degenerative myopathy characterized CC by slowly progressive wasting and weakness of the proximal muscles of CC arms and legs around the pelvic or shoulder girdles, elevated creatine CC kinase levels and dystrophic features on muscle biopsy. LGMDD3 is CC characterized by a mild late-onset and is associated with progressive CC fingers and toes flexion limitation. Affected individuals may also CC develop cataracts before age 50. {ECO:0000269|PubMed:24647604}. CC Note=The disease is caused by variants affecting the gene represented CC in this entry. CC -!- SEQUENCE CAUTION: CC Sequence=BAA22860.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AB017019; BAA75241.1; -; mRNA. DR EMBL; D89092; BAA24361.1; -; mRNA. DR EMBL; AB066484; BAB62188.1; -; mRNA. DR EMBL; CR407623; CAG28551.1; -; mRNA. DR EMBL; AC124016; AAY40914.1; -; Genomic_DNA. DR EMBL; AB017018; BAA75239.1; -; Genomic_DNA. DR EMBL; AB017018; BAA75240.1; -; Genomic_DNA. DR EMBL; BC007392; AAH07392.2; -; mRNA. DR EMBL; BC011714; AAH11714.1; -; mRNA. DR EMBL; BC071944; AAH71944.1; -; mRNA. DR EMBL; AY453824; AAR17782.1; -; mRNA. DR EMBL; D89678; BAA22860.1; ALT_INIT; mRNA. DR CCDS; CCDS3593.1; -. [O14979-1] DR PIR; JW0079; JW0079. DR RefSeq; NP_001193929.1; NM_001207000.1. DR RefSeq; NP_112740.1; NM_031372.4. [O14979-1] DR PDB; 7ZIR; EM; 2.50 A; A/B/C/D/E=121-420. DR PDBsum; 7ZIR; -. DR AlphaFoldDB; O14979; -. DR EMDB; EMD-14738; -. DR SMR; O14979; -. DR BioGRID; 115308; 392. DR CORUM; O14979; -. DR FunCoup; O14979; 3959. DR IntAct; O14979; 166. DR MINT; O14979; -. DR STRING; 9606.ENSP00000483254; -. DR GlyGen; O14979; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; O14979; -. DR MetOSite; O14979; -. DR PhosphoSitePlus; O14979; -. DR SwissPalm; O14979; -. DR BioMuta; HNRNPDL; -. DR jPOST; O14979; -. DR MassIVE; O14979; -. DR PaxDb; 9606-ENSP00000483254; -. DR PeptideAtlas; O14979; -. DR ProteomicsDB; 48353; -. [O14979-1] DR ProteomicsDB; 48354; -. [O14979-2] DR ProteomicsDB; 48355; -. [O14979-3] DR Pumba; O14979; -. DR Antibodypedia; 25039; 160 antibodies from 24 providers. DR DNASU; 9987; -. DR Ensembl; ENST00000295470.10; ENSP00000295470.5; ENSG00000152795.19. [O14979-1] DR Ensembl; ENST00000349655.8; ENSP00000338552.5; ENSG00000152795.19. [O14979-2] DR Ensembl; ENST00000502762.4; ENSP00000422040.1; ENSG00000152795.19. [O14979-1] DR Ensembl; ENST00000507721.5; ENSP00000480156.1; ENSG00000152795.19. [O14979-2] DR Ensembl; ENST00000602300.5; ENSP00000473677.1; ENSG00000152795.19. [O14979-2] DR Ensembl; ENST00000621267.4; ENSP00000483254.1; ENSG00000152795.19. [O14979-1] DR Ensembl; ENST00000630114.2; ENSP00000486452.1; ENSG00000152795.19. [O14979-2] DR Ensembl; ENST00000630827.1; ENSP00000485954.1; ENSG00000152795.19. [O14979-2] DR GeneID; 9987; -. DR KEGG; hsa:9987; -. DR MANE-Select; ENST00000295470.10; ENSP00000295470.5; NM_031372.4; NP_112740.1. DR UCSC; uc003hmr.4; human. [O14979-1] DR AGR; HGNC:5037; -. DR ClinPGx; PA29362; -. DR CTD; 9987; -. DR DisGeNET; 9987; -. DR GeneCards; HNRNPDL; -. DR HGNC; HGNC:5037; HNRNPDL. DR HPA; ENSG00000152795; Low tissue specificity. DR MalaCards; HNRNPDL; -. DR MIM; 607137; gene. DR MIM; 609115; phenotype. DR OpenTargets; ENSG00000152795; -. DR Orphanet; 55596; HNRNPDL-related limb-girdle muscular dystrophy D3. DR VEuPathDB; HostDB:ENSG00000152795; -. DR eggNOG; KOG0118; Eukaryota. DR GeneTree; ENSGT00940000154426; -. DR HOGENOM; CLU_012062_1_1_1; -. DR InParanoid; O14979; -. DR OMA; QVDTEMN; -. DR OrthoDB; 1875751at2759; -. DR PAN-GO; O14979; 4 GO annotations based on evolutionary models. DR PhylomeDB; O14979; -. DR PathwayCommons; O14979; -. DR Reactome; R-HSA-8950505; Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation. DR SignaLink; O14979; -. DR Agora; ENSG00000152795; -. DR BioGRID-ORCS; 9987; 19 hits in 1107 CRISPR screens. DR CD-CODE; 232F8A39; P-body. DR CD-CODE; 91857CE7; Nucleolus. DR CD-CODE; D0F20FEF; Synthetic Condensate 000090. DR CD-CODE; DEE660B4; Stress granule. DR ChiTaRS; HNRNPDL; human. DR GeneWiki; HNRPDL; -. DR GenomeRNAi; 9987; -. DR Pharos; O14979; Tbio. DR PRO; PR:O14979; -. DR Proteomes; UP000005640; Chromosome 4. DR RNAct; O14979; protein. DR Bgee; ENSG00000152795; Expressed in primordial germ cell in gonad and 212 other cell types or tissues. DR ExpressionAtlas; O14979; baseline and differential. DR GO; GO:0000785; C:chromatin; IBA:GO_Central. DR GO; GO:0005829; C:cytosol; TAS:Reactome. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0005681; C:spliceosomal complex; NAS:UniProtKB. DR GO; GO:0003677; F:DNA binding; IEA:UniProtKB-KW. DR GO; GO:0003690; F:double-stranded DNA binding; IDA:UniProtKB. DR GO; GO:0008143; F:poly(A) binding; IDA:UniProtKB. DR GO; GO:0034046; F:poly(G) binding; IDA:UniProtKB. DR GO; GO:0003723; F:RNA binding; HDA:UniProtKB. DR GO; GO:0003697; F:single-stranded DNA binding; IDA:UniProtKB. DR GO; GO:0010468; P:regulation of gene expression; IDA:UniProtKB. DR GO; GO:0006396; P:RNA processing; NAS:UniProtKB. DR CDD; cd12758; RRM1_hnRPDL; 1. DR CDD; cd12585; RRM2_hnRPDL; 1. DR FunFam; 3.30.70.330:FF:000220; Heterogeneous nuclear ribonucleoprotein D-like protein; 1. DR FunFam; 3.30.70.330:FF:000030; Heterogeneous nuclear ribonucleoprotein d0 isoform; 1. DR Gene3D; 3.30.70.330; -; 2. DR InterPro; IPR034847; hnRPDL_RRM1. DR InterPro; IPR012677; Nucleotide-bd_a/b_plait_sf. DR InterPro; IPR035979; RBD_domain_sf. DR InterPro; IPR000504; RRM_dom. DR PANTHER; PTHR48033:SF2; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN D-LIKE; 1. DR PANTHER; PTHR48033; RNA-BINDING (RRM/RBD/RNP MOTIFS) FAMILY PROTEIN; 1. DR Pfam; PF00076; RRM_1; 2. DR SMART; SM00360; RRM; 2. DR SUPFAM; SSF54928; RNA-binding domain, RBD; 2. DR PROSITE; PS50102; RRM; 2. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Activator; Alternative splicing; Cytoplasm; KW Direct protein sequencing; Disease variant; DNA-binding; Isopeptide bond; KW Limb-girdle muscular dystrophy; Methylation; Nucleus; Phosphoprotein; KW Proteomics identification; Reference proteome; Repeat; Repressor; KW RNA-binding; Transcription; Transcription regulation; Ubl conjugation. FT CHAIN 1..420 FT /note="Heterogeneous nuclear ribonucleoprotein D-like" FT /id="PRO_0000287239" FT DOMAIN 148..230 FT /note="RRM 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00176" FT DOMAIN 233..312 FT /note="RRM 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00176" FT REGION 1..83 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 96..120 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 313..348 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 342..420 FT /note="Necessary for interaction with TNPO1" FT /evidence="ECO:0000269|PubMed:9524220" FT REGION 396..420 FT /note="Necessary for its nuclear import and export" FT REGION 398..420 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 36..52 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 323..342 FT /note="Gly residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOD_RES 25 FT /note="Omega-N-methylarginine" FT /evidence="ECO:0007744|PubMed:24129315" FT MOD_RES 161 FT /note="N6-methyllysine" FT /evidence="ECO:0000269|Ref.9" FT MOD_RES 216 FT /note="N6-acetyllysine" FT /evidence="ECO:0007744|PubMed:19608861" FT MOD_RES 241 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:17081983, FT ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:20068231, FT ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163, FT ECO:0007744|PubMed:24275569" FT MOD_RES 408 FT /note="Dimethylated arginine; alternate" FT /evidence="ECO:0000269|Ref.9" FT MOD_RES 408 FT /note="Omega-N-methylarginine; alternate" FT /evidence="ECO:0000250|UniProtKB:Q9Z130" FT CROSSLNK 209 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:28112733" FT VAR_SEQ 1..119 FT /note="Missing (in isoform 2 and isoform 3)" FT /evidence="ECO:0000303|PubMed:10072754, FT ECO:0000303|PubMed:11705999, ECO:0000303|PubMed:9538234" FT /id="VSP_025410" FT VAR_SEQ 341..397 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|PubMed:11705999" FT /id="VSP_025411" FT VARIANT 378 FT /note="D -> H (in LGMDD3; dbSNP:rs587777669)" FT /evidence="ECO:0000269|PubMed:24647604" FT /id="VAR_072567" FT VARIANT 378 FT /note="D -> N (in LGMDD3; dbSNP:rs587777669)" FT /evidence="ECO:0000269|PubMed:24647604" FT /id="VAR_072568" FT MUTAGEN 404 FT /note="G->A: Reduces significantly its nuclear FT localization." FT /evidence="ECO:0000269|PubMed:9524220" FT STRAND 358..362 FT /evidence="ECO:0007829|PDB:7ZIR" FT STRAND 369..371 FT /evidence="ECO:0007829|PDB:7ZIR" FT STRAND 376..378 FT /evidence="ECO:0007829|PDB:7ZIR" FT STRAND 380..383 FT /evidence="ECO:0007829|PDB:7ZIR" FT STRAND 388..394 FT /evidence="ECO:0007829|PDB:7ZIR" SQ SEQUENCE 420 AA; 46438 MW; 00F631863859D0CA CRC64; MEVPPRLSHV PPPLFPSAPA TLASRSLSHW RPRPPRQLAP LLPSLAPSSA RQGARRAQRH VTAQQPSRLA GGAAIKGGRR RRPDLFRRHF KSSSIQRSAA AAAATRTARQ HPPADSSVTM EDMNEYSNIE EFAEGSKINA SKNQQDDGKM FIGGLSWDTS KKDLTEYLSR FGEVVDCTIK TDPVTGRSRG FGFVLFKDAA SVDKVLELKE HKLDGKLIDP KRAKALKGKE PPKKVFVGGL SPDTSEEQIK EYFGAFGEIE NIELPMDTKT NERRGFCFIT YTDEEPVKKL LESRYHQIGS GKCEIKVAQP KEVYRQQQQQ QKGGRGAAAG GRGGTRGRGR GQGQNWNQGF NNYYDQGYGN YNSAYGGDQN YSGYGGYDYT GYNYGNYGYG QGYADYSGQQ STYGKASRGG GNHQNNYQPY // ID RIR2B_HUMAN Reviewed; 351 AA. AC Q7LG56; B4E2N4; Q17R22; Q75PQ6; Q75PQ7; Q75PY8; Q75PY9; Q86YE3; Q9NPD6; AC Q9NTD8; Q9NUW3; DT 21-MAR-2006, integrated into UniProtKB/Swiss-Prot. DT 05-JUL-2004, sequence version 1. DT 28-JAN-2026, entry version 197. DE RecName: Full=Ribonucleoside-diphosphate reductase subunit M2 B; DE EC=1.17.4.1; DE AltName: Full=TP53-inducible ribonucleotide reductase M2 B; DE AltName: Full=p53-inducible ribonucleotide reductase small subunit 2-like protein; DE Short=p53R2; GN Name=RRM2B; Synonyms=P53R2; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORM 1), FUNCTION, AND RP INDUCTION. RX PubMed=10716435; DOI=10.1038/35003506; RA Tanaka H., Arakawa H., Yamaguchi T., Shiraishi K., Fukuda S., Matsui K., RA Takei Y., Nakamura Y.; RT "A ribonucleotide reductase gene involved in a p53-dependent cell-cycle RT checkpoint for DNA damage."; RL Nature 404:42-49(2000). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1; 2; 3; 4 AND 5). RA Ugai H., Yokoyama K.K.; RT "Homo sapiens p53-inducible ribonucleotide reductase small subunit 2 RT splicing variants."; RL Submitted (MAR-2004) to the EMBL/GenBank/DDBJ databases. RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND NUCLEOTIDE SEQUENCE RP [LARGE SCALE MRNA] OF 1-351 (ISOFORM 6). RC TISSUE=Placenta, and Trachea; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Amygdala; RX PubMed=17974005; DOI=10.1186/1471-2164-8-399; RA Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U., RA Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D., RA Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A., RA Wiemann S., Schupp I.; RT "The full-ORF clone resource of the German cDNA consortium."; RL BMC Genomics 8:399-399(2007). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16421571; DOI=10.1038/nature04406; RA Nusbaum C., Mikkelsen T.S., Zody M.C., Asakawa S., Taudien S., Garber M., RA Kodira C.D., Schueler M.G., Shimizu A., Whittaker C.A., Chang J.L., RA Cuomo C.A., Dewar K., FitzGerald M.G., Yang X., Allen N.R., Anderson S., RA Asakawa T., Blechschmidt K., Bloom T., Borowsky M.L., Butler J., Cook A., RA Corum B., DeArellano K., DeCaprio D., Dooley K.T., Dorris L. III, RA Engels R., Gloeckner G., Hafez N., Hagopian D.S., Hall J.L., Ishikawa S.K., RA Jaffe D.B., Kamat A., Kudoh J., Lehmann R., Lokitsang T., Macdonald P., RA Major J.E., Matthews C.D., Mauceli E., Menzel U., Mihalev A.H., RA Minoshima S., Murayama Y., Naylor J.W., Nicol R., Nguyen C., O'Leary S.B., RA O'Neill K., Parker S.C.J., Polley A., Raymond C.K., Reichwald K., RA Rodriguez J., Sasaki T., Schilhabel M., Siddiqui R., Smith C.L., RA Sneddon T.P., Talamas J.A., Tenzin P., Topham K., Venkataraman V., Wen G., RA Yamazaki S., Young S.K., Zeng Q., Zimmer A.R., Rosenthal A., Birren B.W., RA Platzer M., Shimizu N., Lander E.S.; RT "DNA sequence and analysis of human chromosome 8."; RL Nature 439:331-335(2006). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [7] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RG NIEHS SNPs program; RL Submitted (MAY-2005) to the EMBL/GenBank/DDBJ databases. RN [8] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Brain, and Eye; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [9] RP FUNCTION, AND SUBUNIT. RX PubMed=11517226; DOI=10.1074/jbc.m106088200; RA Guittet O., Haakansson P., Voevodskaya N., Fridd S., Graeslund A., RA Arakawa H., Nakamura Y., Thelander L.; RT "Mammalian p53R2 protein forms an active ribonucleotide reductase in vitro RT with the R1 protein, which is expressed both in resting cells in response RT to DNA damage and in proliferating cells."; RL J. Biol. Chem. 276:40647-40651(2001). RN [10] RP FUNCTION, SUBCELLULAR LOCATION, AND VARIANT LEU-115. RX PubMed=11719458; RA Yamaguchi T., Matsuda K., Sagiya Y., Iwadate M., Fujino M.A., Nakamura Y., RA Arakawa H.; RT "p53R2-dependent pathway for DNA synthesis in a p53-regulated cell cycle RT checkpoint."; RL Cancer Res. 61:8256-8262(2001). RN [11] RP SUBCELLULAR LOCATION, AND INTERACTION WITH TP53 AND RRM1. RX PubMed=12615712; RA Xue L., Zhou B., Liu X., Qiu W., Jin Z., Yen Y.; RT "Wild-type p53 regulates human ribonucleotide reductase by protein-protein RT interaction with p53R2 as well as hRRM2 subunits."; RL Cancer Res. 63:980-986(2003). RN [12] RP TISSUE SPECIFICITY. RX PubMed=14583450; RA Zhou B., Liu X., Mo X., Xue L., Darwish D., Qiu W., Shih J., Hwu E.B., RA Luh F., Yen Y.; RT "The human ribonucleotide reductase subunit hRRM2 complements p53R2 in RT response to UV-induced DNA repair in cells with mutant p53."; RL Cancer Res. 63:6583-6594(2003). RN [13] RP CATALYTIC ACTIVITY, AND SUBUNIT. RX PubMed=16376858; DOI=10.1016/j.bbrc.2005.12.019; RA Qiu W., Zhou B., Darwish D., Shao J., Yen Y.; RT "Characterization of enzymatic properties of human ribonucleotide reductase RT holoenzyme reconstituted in vitro from hRRM1, hRRM2, and p53R2 subunits."; RL Biochem. Biophys. Res. Commun. 340:428-434(2006). RN [14] RP INVOLVEMENT IN PEOA5. RX PubMed=19664747; DOI=10.1016/j.ajhg.2009.07.009; RA Tyynismaa H., Ylikallio E., Patel M., Molnar M.J., Haller R.G., RA Suomalainen A.; RT "A heterozygous truncating mutation in RRM2B causes autosomal-dominant RT progressive external ophthalmoplegia with multiple mtDNA deletions."; RL Am. J. Hum. Genet. 85:290-295(2009). RN [15] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [16] RP X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) IN COMPLEX WITH IRON IONS, AND RP COFACTOR. RX PubMed=19728742; DOI=10.1021/bi9001425; RA Smith P., Zhou B., Ho N., Yuan Y.C., Su L., Tsai S.C., Yen Y.; RT "2.6 A X-ray crystal structure of human p53R2, a p53-inducible RT ribonucleotide reductase."; RL Biochemistry 48:11134-11141(2009). RN [17] RP X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 20-322 IN COMPLEX WITH IRON IONS. RG Structural genomics consortium (SGC); RT "Human ribonucleotide reductase, subunit M2 B."; RL Submitted (FEB-2009) to the PDB data bank. RN [18] RP VARIANTS MTDPS8A ARG-64; GLU-85 DEL; GLY-194; LYS-194 AND PHE-236. RX PubMed=17486094; DOI=10.1038/ng2040; RA Bourdon A., Minai L., Serre V., Jais J.-P., Sarzi E., Aubert S., RA Chretien D., de Lonlay P., Paquis-Flucklinger V., Arakawa H., Nakamura Y., RA Munnich A., Roetig A.; RT "Mutation of RRM2B, encoding p53-controlled ribonucleotide reductase RT (p53R2), causes severe mitochondrial DNA depletion."; RL Nat. Genet. 39:776-780(2007). RN [19] RP VARIANTS MTDPS8A SER-224; ILE-282 AND VAL-317. RX PubMed=18504129; DOI=10.1016/j.nmd.2008.04.006; RA Bornstein B., Area E., Flanigan K.M., Ganesh J., Jayakar P., Swoboda K.J., RA Coku J., Naini A., Shanske S., Tanji K., Hirano M., DiMauro S.; RT "Mitochondrial DNA depletion syndrome due to mutations in the RRM2B gene."; RL Neuromuscul. Disord. 18:453-459(2008). RN [20] RP VARIANTS MTDPS8B HIS-110 AND HIS-121. RX PubMed=19667227; DOI=10.1001/archneurol.2009.139; RA Shaibani A., Shchelochkov O.A., Zhang S., Katsonis P., Lichtarge O., RA Wong L.J., Shinawi M.; RT "Mitochondrial neurogastrointestinal encephalopathy due to mutations in RT RRM2B."; RL Arch. Neurol. 66:1028-1032(2009). RN [21] RP VARIANT SER-33. RX PubMed=26741492; DOI=10.1371/journal.pgen.1005679; RA Kohda M., Tokuzawa Y., Kishita Y., Nyuzuki H., Moriyama Y., Mizuno Y., RA Hirata T., Yatsuka Y., Yamashita-Sugahara Y., Nakachi Y., Kato H., RA Okuda A., Tamaru S., Borna N.N., Banshoya K., Aigaki T., Sato-Miyata Y., RA Ohnuma K., Suzuki T., Nagao A., Maehata H., Matsuda F., Higasa K., RA Nagasaki M., Yasuda J., Yamamoto M., Fushimi T., Shimura M., RA Kaiho-Ichimoto K., Harashima H., Yamazaki T., Mori M., Murayama K., RA Ohtake A., Okazaki Y.; RT "A comprehensive genomic analysis reveals the genetic landscape of RT mitochondrial respiratory chain complex deficiencies."; RL PLoS Genet. 12:E1005679-E1005679(2016). RN [22] RP VARIANT RCDFRD ASP-262, AND INVOLVEMENT IN RCDFRD. RX PubMed=32827185; DOI=10.1002/humu.24094; RA Roberts L., Julius S., Dawlat S., Yildiz S., Rebello G., Meldau S., RA Pillay K., Esterhuizen A., Vorster A., Benefeld G., da Rocha J., RA Beighton P., Sellars S.L., Thandrayen K., Pettifor J.M., Ramesar R.S.; RT "Renal dysfunction, rod-cone dystrophy, and sensorineural hearing loss RT caused by a mutation in RRM2B."; RL Hum. Mutat. 41:1871-1876(2020). CC -!- FUNCTION: Plays a pivotal role in cell survival by repairing damaged CC DNA in a p53/TP53-dependent manner. Supplies deoxyribonucleotides for CC DNA repair in cells arrested at G1 or G2. Contains an iron-tyrosyl free CC radical center required for catalysis. Forms an active ribonucleotide CC reductase (RNR) complex with RRM1 which is expressed both in resting CC and proliferating cells in response to DNA damage. CC {ECO:0000269|PubMed:10716435, ECO:0000269|PubMed:11517226, CC ECO:0000269|PubMed:11719458}. CC -!- CATALYTIC ACTIVITY: CC Reaction=a 2'-deoxyribonucleoside 5'-diphosphate + [thioredoxin]- CC disulfide + H2O = a ribonucleoside 5'-diphosphate + [thioredoxin]- CC dithiol; Xref=Rhea:RHEA:23252, Rhea:RHEA-COMP:10698, Rhea:RHEA- CC COMP:10700, ChEBI:CHEBI:15377, ChEBI:CHEBI:29950, ChEBI:CHEBI:50058, CC ChEBI:CHEBI:57930, ChEBI:CHEBI:73316; EC=1.17.4.1; CC Evidence={ECO:0000255|PROSITE-ProRule:PRU10014, CC ECO:0000269|PubMed:16376858}; CC -!- COFACTOR: CC Name=Fe cation; Xref=ChEBI:CHEBI:24875; CC Evidence={ECO:0000269|PubMed:19728742}; CC Note=Binds 2 iron ions per subunit. {ECO:0000269|PubMed:19728742}; CC -!- SUBUNIT: Heterotetramer with large (RRM1) subunit. Interacts with CC p53/TP53. Interacts with RRM1 in response to DNA damage. CC {ECO:0000269|PubMed:11517226, ECO:0000269|PubMed:12615712, CC ECO:0000269|PubMed:16376858, ECO:0000269|PubMed:19728742, CC ECO:0000269|Ref.17}. CC -!- INTERACTION: CC Q7LG56; Q13315: ATM; NbExp=3; IntAct=EBI-9009083, EBI-495465; CC Q7LG56; Q00987: MDM2; NbExp=2; IntAct=EBI-9009083, EBI-389668; CC Q7LG56; O43929: ORC4; NbExp=4; IntAct=EBI-9009083, EBI-374889; CC Q7LG56; Q9H4P4: RNF41; NbExp=3; IntAct=EBI-9009083, EBI-2130266; CC Q7LG56; Q7LG56: RRM2B; NbExp=3; IntAct=EBI-9009083, EBI-9009083; CC Q7LG56-1; Q00987: MDM2; NbExp=2; IntAct=EBI-15741413, EBI-389668; CC -!- SUBCELLULAR LOCATION: Cytoplasm. Nucleus. Note=Translocates from CC cytoplasm to nucleus in response to DNA damage. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=6; CC Name=1; CC IsoId=Q7LG56-1; Sequence=Displayed; CC Name=2; Synonyms=Long form; CC IsoId=Q7LG56-2; Sequence=VSP_017670; CC Name=3; Synonyms=Short form gamma; CC IsoId=Q7LG56-3; Sequence=VSP_017669; CC Name=4; Synonyms=Short form beta; CC IsoId=Q7LG56-4; Sequence=VSP_017668; CC Name=5; Synonyms=Short form; CC IsoId=Q7LG56-5; Sequence=VSP_017671, VSP_017672; CC Name=6; CC IsoId=Q7LG56-6; Sequence=VSP_053585; CC -!- TISSUE SPECIFICITY: Widely expressed at a high level in skeletal muscle CC and at a weak level in thymus. Expressed in epithelial dysplasias and CC squamous cell carcinoma. {ECO:0000269|PubMed:14583450}. CC -!- INDUCTION: In response to DNA damage in a wild-type p53/TP53-dependent CC manner. {ECO:0000269|PubMed:10716435}. CC -!- DISEASE: Mitochondrial DNA depletion syndrome 8A (MTDPS8A) CC [MIM:612075]: A disorder due to mitochondrial dysfunction characterized CC by various combinations of neonatal hypotonia, neurological CC deterioration, respiratory distress, lactic acidosis, and renal CC tubulopathy. {ECO:0000269|PubMed:17486094, CC ECO:0000269|PubMed:18504129}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Mitochondrial DNA depletion syndrome 8B (MTDPS8B) CC [MIM:612075]: A disease due to mitochondrial dysfunction and CC characterized by ophthalmoplegia, ptosis, gastrointestinal dysmotility, CC cachexia, peripheral neuropathy. {ECO:0000269|PubMed:19667227}. CC Note=The disease is caused by variants affecting the gene represented CC in this entry. CC -!- DISEASE: Progressive external ophthalmoplegia with mitochondrial DNA CC deletions, autosomal dominant, 5 (PEOA5) [MIM:613077]: A disorder CC characterized by progressive weakness of ocular muscles and levator CC muscle of the upper eyelid. In a minority of cases, it is associated CC with skeletal myopathy, which predominantly involves axial or proximal CC muscles and which causes abnormal fatigability and even permanent CC muscle weakness. Ragged-red fibers and atrophy are found on muscle CC biopsy. A large proportion of chronic ophthalmoplegias are associated CC with other symptoms, leading to a multisystemic pattern of this CC disease. Additional symptoms are variable, and may include cataracts, CC hearing loss, sensory axonal neuropathy, ataxia, depression, CC hypogonadism, and parkinsonism. {ECO:0000269|PubMed:19664747}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Rod-cone dystrophy, sensorineural deafness, and Fanconi-type CC renal dysfunction (RCDFRD) [MIM:268315]: An autosomal recessive disease CC characterized by visual impairment due to rod-cone dystrophy, CC sensorineural hearing loss, and Fanconi-type renal dysfunction CC resulting in rickets-like skeletal changes. Death may occur in CC childhood or young adulthood due to renal failure. Disease onset is CC before age 5 years. {ECO:0000269|PubMed:32827185}. Note=The disease is CC caused by variants affecting the gene represented in this entry. CC -!- MISCELLANEOUS: [Isoform 5]: May be produced at very low levels due to a CC premature stop codon in the mRNA, leading to nonsense-mediated mRNA CC decay. {ECO:0000305}. CC -!- SIMILARITY: Belongs to the ribonucleoside diphosphate reductase small CC chain family. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=BAG65196.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305}; CC Sequence=EAW91842.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AB036063; BAA92434.1; -; mRNA. DR EMBL; AB036532; BAA92493.1; -; Genomic_DNA. DR EMBL; AB163437; BAD11774.1; -; mRNA. DR EMBL; AB163438; BAD11775.1; -; mRNA. DR EMBL; AB166669; BAD12265.1; -; mRNA. DR EMBL; AB166670; BAD12266.1; -; mRNA. DR EMBL; AB166671; BAD12267.1; -; mRNA. DR EMBL; AK001965; BAA92005.1; -; mRNA. DR EMBL; AK304354; BAG65196.1; ALT_INIT; mRNA. DR EMBL; DC308409; -; NOT_ANNOTATED_CDS; mRNA. DR EMBL; AL137348; CAB70703.2; -; mRNA. DR EMBL; DQ027001; AAY29059.1; -; Genomic_DNA. DR EMBL; AP001328; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AP002907; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471060; EAW91842.1; ALT_SEQ; Genomic_DNA. DR EMBL; BC042468; AAH42468.1; -; mRNA. DR EMBL; BC108261; AAI08262.1; -; mRNA. DR EMBL; BC117496; AAI17497.1; -; mRNA. DR EMBL; BC130628; AAI30629.1; -; mRNA. DR CCDS; CCDS34932.1; -. [Q7LG56-1] DR CCDS; CCDS55267.1; -. [Q7LG56-2] DR PIR; T46249; T46249. DR RefSeq; NP_001165948.1; NM_001172477.1. [Q7LG56-6] DR RefSeq; NP_001165949.1; NM_001172478.2. [Q7LG56-2] DR RefSeq; NP_056528.2; NM_015713.4. [Q7LG56-1] DR PDB; 2VUX; X-ray; 2.80 A; A/B=20-322. DR PDB; 3HF1; X-ray; 2.60 A; A/B=1-351. DR PDB; 4DJN; X-ray; 2.20 A; A/B=13-322. DR PDBsum; 2VUX; -. DR PDBsum; 3HF1; -. DR PDBsum; 4DJN; -. DR AlphaFoldDB; Q7LG56; -. DR SMR; Q7LG56; -. DR BioGRID; 119071; 74. DR ComplexPortal; CPX-369; Ribonucleoside-diphosphate reductase RR1 complex, RRM2B variant. DR CORUM; Q7LG56; -. DR DIP; DIP-24264N; -. DR DIP; DIP-48627N; -. DR FunCoup; Q7LG56; 2091. DR IntAct; Q7LG56; 34. DR STRING; 9606.ENSP00000251810; -. DR BindingDB; Q7LG56; -. DR ChEMBL; CHEMBL3301398; -. DR DrugBank; DB00242; Cladribine. DR DrugBank; DB00631; Clofarabine. DR DrugBank; DB12948; Didox. DR GlyGen; Q7LG56; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; Q7LG56; -. DR PhosphoSitePlus; Q7LG56; -. DR BioMuta; RRM2B; -. DR DMDM; 74727333; -. DR jPOST; Q7LG56; -. DR MassIVE; Q7LG56; -. DR PaxDb; 9606-ENSP00000251810; -. DR PeptideAtlas; Q7LG56; -. DR ProteomicsDB; 5837; -. DR ProteomicsDB; 68860; -. [Q7LG56-1] DR ProteomicsDB; 68861; -. [Q7LG56-2] DR ProteomicsDB; 68862; -. [Q7LG56-3] DR ProteomicsDB; 68863; -. [Q7LG56-4] DR ProteomicsDB; 68864; -. [Q7LG56-5] DR Pumba; Q7LG56; -. DR Antibodypedia; 3483; 343 antibodies from 38 providers. DR DNASU; 50484; -. DR Ensembl; ENST00000251810.8; ENSP00000251810.3; ENSG00000048392.14. [Q7LG56-1] DR Ensembl; ENST00000395912.6; ENSP00000379248.2; ENSG00000048392.14. [Q7LG56-2] DR Ensembl; ENST00000519317.5; ENSP00000430641.1; ENSG00000048392.14. [Q7LG56-3] DR Ensembl; ENST00000519962.5; ENSP00000429140.1; ENSG00000048392.14. [Q7LG56-4] DR Ensembl; ENST00000522394.1; ENSP00000429578.1; ENSG00000048392.14. [Q7LG56-5] DR GeneID; 50484; -. DR KEGG; hsa:50484; -. DR MANE-Select; ENST00000251810.8; ENSP00000251810.3; NM_015713.5; NP_056528.2. DR UCSC; uc003ykn.4; human. [Q7LG56-1] DR AGR; HGNC:17296; -. DR ClinPGx; PA34866; -. DR CTD; 50484; -. DR DisGeNET; 50484; -. DR GeneCards; RRM2B; -. DR GeneReviews; RRM2B; -. DR HGNC; HGNC:17296; RRM2B. DR HPA; ENSG00000048392; Low tissue specificity. DR MalaCards; RRM2B; -. DR MIM; 268315; phenotype. DR MIM; 604712; gene. DR MIM; 612075; phenotype. DR MIM; 613077; phenotype. DR OpenTargets; ENSG00000048392; -. DR Orphanet; 329336; Adult-onset chronic progressive external ophthalmoplegia with mitochondrial myopathy. DR Orphanet; 254892; Autosomal dominant progressive external ophthalmoplegia. DR Orphanet; 480; Kearns-Sayre syndrome. DR Orphanet; 255235; Mitochondrial DNA depletion syndrome, encephalomyopathic form with renal tubulopathy. DR Orphanet; 298; Mitochondrial neurogastrointestinal encephalomyopathy. DR VEuPathDB; HostDB:ENSG00000048392; -. DR eggNOG; KOG1567; Eukaryota. DR GeneTree; ENSGT00390000013305; -. DR HOGENOM; CLU_035339_2_0_1; -. DR InParanoid; Q7LG56; -. DR OMA; LEPMFLG; -. DR OrthoDB; 10248373at2759; -. DR PAN-GO; Q7LG56; 3 GO annotations based on evolutionary models. DR PhylomeDB; Q7LG56; -. DR BRENDA; 1.17.4.1; 2681. DR PathwayCommons; Q7LG56; -. DR Reactome; R-HSA-499943; Interconversion of nucleotide di- and triphosphates. DR Reactome; R-HSA-5628897; TP53 Regulates Metabolic Genes. DR SignaLink; Q7LG56; -. DR SIGNOR; Q7LG56; -. DR Agora; ENSG00000048392; Agora Nominated Target for Alzheimer's Disease. DR BioGRID-ORCS; 50484; 17 hits in 1170 CRISPR screens. DR ChiTaRS; RRM2B; human. DR EvolutionaryTrace; Q7LG56; -. DR GeneWiki; RRM2B; -. DR GenomeRNAi; 50484; -. DR Pharos; Q7LG56; Tbio. DR PRO; PR:Q7LG56; -. DR Proteomes; UP000005640; Chromosome 8. DR RNAct; Q7LG56; protein. DR Bgee; ENSG00000048392; Expressed in secondary oocyte and 188 other cell types or tissues. DR ExpressionAtlas; Q7LG56; baseline and differential. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0005739; C:mitochondrion; IEA:GOC. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005971; C:ribonucleoside-diphosphate reductase complex; ISS:ComplexPortal. DR GO; GO:0042802; F:identical protein binding; IPI:IntAct. DR GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW. DR GO; GO:0004748; F:ribonucleoside-diphosphate reductase activity, thioredoxin disulfide as acceptor; IBA:GO_Central. DR GO; GO:0009265; P:2'-deoxyribonucleotide biosynthetic process; IDA:ComplexPortal. DR GO; GO:0009200; P:deoxyribonucleoside triphosphate metabolic process; IEA:Ensembl. DR GO; GO:0009263; P:deoxyribonucleotide biosynthetic process; IBA:GO_Central. DR GO; GO:0006281; P:DNA repair; IDA:ComplexPortal. DR GO; GO:0000731; P:DNA synthesis involved in DNA repair; NAS:ComplexPortal. DR GO; GO:0001822; P:kidney development; IEA:Ensembl. DR GO; GO:0006264; P:mitochondrial DNA replication; IMP:ComplexPortal. DR GO; GO:1902254; P:negative regulation of intrinsic apoptotic signaling pathway by p53 class mediator; IEA:Ensembl. DR GO; GO:0070318; P:positive regulation of G0 to G1 transition; IDA:ComplexPortal. DR GO; GO:0010971; P:positive regulation of G2/M transition of mitotic cell cycle; IDA:ComplexPortal. DR GO; GO:0003014; P:renal system process; IEA:Ensembl. DR GO; GO:0014075; P:response to amine; IEA:Ensembl. DR GO; GO:0006979; P:response to oxidative stress; IEA:Ensembl. DR GO; GO:0009185; P:ribonucleoside diphosphate metabolic process; IDA:ComplexPortal. DR CDD; cd01049; RNRR2; 1. DR FunFam; 1.10.620.20:FF:000004; Ribonucleoside-diphosphate reductase subunit M2 B; 1. DR Gene3D; 1.10.620.20; Ribonucleotide Reductase, subunit A; 1. DR InterPro; IPR009078; Ferritin-like_SF. DR InterPro; IPR012348; RNR-like. DR InterPro; IPR033909; RNR_small. DR InterPro; IPR030475; RNR_small_AS. DR InterPro; IPR000358; RNR_small_fam. DR PANTHER; PTHR23409; RIBONUCLEOSIDE-DIPHOSPHATE REDUCTASE SMALL CHAIN; 1. DR PANTHER; PTHR23409:SF19; RIBONUCLEOSIDE-DIPHOSPHATE REDUCTASE SUBUNIT M2 B; 1. DR Pfam; PF00268; Ribonuc_red_sm; 1. DR SUPFAM; SSF47240; Ferritin-like; 1. DR PROSITE; PS00368; RIBORED_SMALL; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; Cytoplasm; Deafness; KW Deoxyribonucleotide synthesis; Disease variant; DNA damage; DNA repair; KW Iron; Metal-binding; Neuropathy; Nucleus; Oxidoreductase; KW Primary mitochondrial disease; Progressive external ophthalmoplegia; KW Proteomics identification; Reference proteome. FT CHAIN 1..351 FT /note="Ribonucleoside-diphosphate reductase subunit M2 B" FT /id="PRO_0000228150" FT REGION 1..32 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 138 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU10014" FT BINDING 100 FT /ligand="Fe cation" FT /ligand_id="ChEBI:CHEBI:24875" FT /ligand_label="1" FT BINDING 131 FT /ligand="Fe cation" FT /ligand_id="ChEBI:CHEBI:24875" FT /ligand_label="1" FT BINDING 131 FT /ligand="Fe cation" FT /ligand_id="ChEBI:CHEBI:24875" FT /ligand_label="2" FT BINDING 134 FT /ligand="Fe cation" FT /ligand_id="ChEBI:CHEBI:24875" FT /ligand_label="1" FT BINDING 194 FT /ligand="Fe cation" FT /ligand_id="ChEBI:CHEBI:24875" FT /ligand_label="2" FT BINDING 228 FT /ligand="Fe cation" FT /ligand_id="ChEBI:CHEBI:24875" FT /ligand_label="2" FT BINDING 231 FT /ligand="Fe cation" FT /ligand_id="ChEBI:CHEBI:24875" FT /ligand_label="2" FT VAR_SEQ 1..16 FT /note="MGDPERPEAAGLDQDE -> MLLLRLPPHRSHASPLDCKLQDRCRKCYSPRS FT GQACPPALAAAWLRRCERRGGRPRGGRRKELTLGLRPARCSAPGPAKDDAWRPQAG FT (in isoform 6)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_053585" FT VAR_SEQ 17..301 FT /note="Missing (in isoform 4)" FT /evidence="ECO:0000303|Ref.2" FT /id="VSP_017668" FT VAR_SEQ 17..228 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|Ref.2" FT /id="VSP_017669" FT VAR_SEQ 17..68 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|Ref.2" FT /id="VSP_017670" FT VAR_SEQ 42..43 FT /note="FV -> SF (in isoform 5)" FT /evidence="ECO:0000303|Ref.2" FT /id="VSP_017671" FT VAR_SEQ 44..351 FT /note="Missing (in isoform 5)" FT /evidence="ECO:0000303|Ref.2" FT /id="VSP_017672" FT VARIANT 33 FT /note="P -> S (found in a patient with combined respiratory FT complex deficiencies, muscle weakness and hearing loss; FT uncertain significance; dbSNP:rs387906892)" FT /evidence="ECO:0000269|PubMed:26741492" FT /id="VAR_076280" FT VARIANT 64 FT /note="W -> R (in MTDPS8A; dbSNP:rs515726182)" FT /evidence="ECO:0000269|PubMed:17486094" FT /id="VAR_046217" FT VARIANT 85 FT /note="Missing (in MTDPS8A; dbSNP:rs515726184)" FT /evidence="ECO:0000269|PubMed:17486094" FT /id="VAR_046218" FT VARIANT 110 FT /note="R -> H (in MTDPS8B; dbSNP:rs267607025)" FT /evidence="ECO:0000269|PubMed:19667227" FT /id="VAR_065122" FT VARIANT 115 FT /note="V -> L (in colorectal adenocarcinomas cell line; FT loss of ribonucleotide reductase activity)" FT /evidence="ECO:0000269|PubMed:11719458" FT /id="VAR_025699" FT VARIANT 121 FT /note="R -> H (in MTDPS8B; dbSNP:rs267607024)" FT /evidence="ECO:0000269|PubMed:19667227" FT /id="VAR_065123" FT VARIANT 194 FT /note="E -> G (in MTDPS8A; dbSNP:rs515726191)" FT /evidence="ECO:0000269|PubMed:17486094" FT /id="VAR_046219" FT VARIANT 194 FT /note="E -> K (in MTDPS8A; dbSNP:rs121918308)" FT /evidence="ECO:0000269|PubMed:17486094" FT /id="VAR_046220" FT VARIANT 224 FT /note="I -> S (in MTDPS8A; without tubulopathy; FT dbSNP:rs515726196)" FT /evidence="ECO:0000269|PubMed:18504129" FT /id="VAR_046221" FT VARIANT 236 FT /note="C -> F (in MTDPS8A; dbSNP:rs121918309)" FT /evidence="ECO:0000269|PubMed:17486094" FT /id="VAR_046222" FT VARIANT 262 FT /note="E -> D (in RCDFRD; dbSNP:rs1810682433)" FT /evidence="ECO:0000269|PubMed:32827185" FT /id="VAR_086956" FT VARIANT 282 FT /note="M -> I (in MTDPS8A; without tubulopathy; FT dbSNP:rs182614164)" FT /evidence="ECO:0000269|PubMed:18504129" FT /id="VAR_046223" FT VARIANT 317 FT /note="L -> V (in MTDPS8A; without tubulopathy; FT dbSNP:rs515726198)" FT /evidence="ECO:0000269|PubMed:18504129" FT /id="VAR_046224" FT CONFLICT 277 FT /note="M -> V (in Ref. 3; BAA92005)" FT /evidence="ECO:0000305" FT HELIX 29..31 FT /evidence="ECO:0007829|PDB:4DJN" FT TURN 33..35 FT /evidence="ECO:0007829|PDB:4DJN" FT HELIX 37..39 FT /evidence="ECO:0007829|PDB:4DJN" FT STRAND 42..44 FT /evidence="ECO:0007829|PDB:4DJN" FT HELIX 50..61 FT /evidence="ECO:0007829|PDB:4DJN" FT HELIX 66..68 FT /evidence="ECO:0007829|PDB:4DJN" FT HELIX 74..78 FT /evidence="ECO:0007829|PDB:4DJN" FT HELIX 83..109 FT /evidence="ECO:0007829|PDB:4DJN" FT HELIX 111..114 FT /evidence="ECO:0007829|PDB:4DJN" FT HELIX 118..145 FT /evidence="ECO:0007829|PDB:4DJN" FT HELIX 149..156 FT /evidence="ECO:0007829|PDB:4DJN" FT HELIX 158..161 FT /evidence="ECO:0007829|PDB:4DJN" FT HELIX 163..177 FT /evidence="ECO:0007829|PDB:4DJN" FT STRAND 179..181 FT /evidence="ECO:0007829|PDB:4DJN" FT HELIX 183..195 FT /evidence="ECO:0007829|PDB:4DJN" FT TURN 196..198 FT /evidence="ECO:0007829|PDB:4DJN" FT HELIX 199..210 FT /evidence="ECO:0007829|PDB:4DJN" FT HELIX 215..240 FT /evidence="ECO:0007829|PDB:4DJN" FT HELIX 248..267 FT /evidence="ECO:0007829|PDB:4DJN" FT HELIX 272..275 FT /evidence="ECO:0007829|PDB:4DJN" FT HELIX 279..296 FT /evidence="ECO:0007829|PDB:4DJN" FT HELIX 310..312 FT /evidence="ECO:0007829|PDB:4DJN" SQ SEQUENCE 351 AA; 40737 MW; 6D008687EEF40994 CRC64; MGDPERPEAA GLDQDERSSS DTNESEIKSN EEPLLRKSSR RFVIFPIQYP DIWKMYKQAQ ASFWTAEEVD LSKDLPHWNK LKADEKYFIS HILAFFAASD GIVNENLVER FSQEVQVPEA RCFYGFQILI ENVHSEMYSL LIDTYIRDPK KREFLFNAIE TMPYVKKKAD WALRWIADRK STFGERVVAF AAVEGVFFSG SFAAIFWLKK RGLMPGLTFS NELISRDEGL HCDFACLMFQ YLVNKPSEER VREIIVDAVK IEQEFLTEAL PVGLIGMNCI LMKQYIEFVA DRLLVELGFS KVFQAENPFD FMENISLEGK TNFFEKRVSE YQRFAVMAET TDNVFTLDAD F // ID ST65G_HUMAN Reviewed; 414 AA. AC O94864; B4E3W3; Q6IB21; Q9H2T6; DT 19-SEP-2002, integrated into UniProtKB/Swiss-Prot. DT 01-MAY-1999, sequence version 1. DT 28-JAN-2026, entry version 175. DE RecName: Full=STAGA complex 65 subunit gamma; DE AltName: Full=Adenocarcinoma antigen ART1; DE AltName: Full=SPTF-associated factor 65 gamma; DE Short=STAF65gamma; DE AltName: Full=Suppressor of Ty 7-like; GN Name=SUPT7L {ECO:0000312|HGNC:HGNC:30632}; Synonyms=KIAA0764; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2). RX PubMed=10987294; RA Nishizaka S., Gomi S., Harada K., Oizumi K., Itoh K., Shichijo S.; RT "A new tumor-rejection antigen recognized by cytotoxic T lymphocytes RT infiltrating into a lung adenocarcinoma."; RL Cancer Res. 60:4830-4837(2000). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Brain; RX PubMed=9872452; DOI=10.1093/dnares/5.5.277; RA Nagase T., Ishikawa K., Suyama M., Kikuno R., Miyajima N., Tanaka A., RA Kotani H., Nomura N., Ohara O.; RT "Prediction of the coding sequences of unidentified human genes. XI. The RT complete sequences of 100 new cDNA clones from brain which code for large RT proteins in vitro."; RL DNA Res. 5:277-286(1998). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3). RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RA Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.; RT "Cloning of human full open reading frames in Gateway(TM) system entry RT vector (pDONR201)."; RL Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15815621; DOI=10.1038/nature03466; RA Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P., RA Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C., RA Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L., RA Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A., RA Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J., RA Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M., RA Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T., RA Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S., RA Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K., RA McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C., RA Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S., RA Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C., RA Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M., RA Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C., RA Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J., RA Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E., RA Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X., RA Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M., RA Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C., RA Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S., RA Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H., RA Wilson R.K.; RT "Generation and annotation of the DNA sequences of human chromosomes 2 and RT 4."; RL Nature 434:724-731(2005). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Uterus; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [7] RP SUBCELLULAR LOCATION, IDENTIFICATION AS PART OF THE STAGA COMPLEX WITH RP SUPT3H; GCN5L2; TRRAP; TAF5L; TAF6L; TADA3L; TAF10; TAF12 AND TAF9, AND RP IDENTIFICATION BY MASS SPECTROMETRY. RX PubMed=11564863; DOI=10.1128/mcb.21.20.6782-6795.2001; RA Martinez E., Palhan V.B., Tjernberg A., Lymar E.S., Gamper A.M., RA Kundu T.K., Chait B.T., Roeder R.G.; RT "Human STAGA complex is a chromatin-acetylating transcription coactivator RT that interacts with pre-mRNA splicing and DNA damage-binding factors in RT vivo."; RL Mol. Cell. Biol. 21:6782-6795(2001). RN [8] RP SUMOYLATION. RX PubMed=15561718; DOI=10.1074/jbc.m411718200; RA Gocke C.B., Yu H., Kang J.; RT "Systematic identification and analysis of mammalian small ubiquitin-like RT modifier substrates."; RL J. Biol. Chem. 280:5004-5012(2005). RN [9] RP IDENTIFICATION IN THE TFTC COMPLEX. RX PubMed=17375202; DOI=10.1371/journal.pone.0000316; RA Demeny M.A., Soutoglou E., Nagy Z., Scheer E., Janoshazi A., Richardot M., RA Argentini M., Kessler P., Tora L.; RT "Identification of a small TAF complex and its role in the assembly of TAF- RT containing complexes."; RL PLoS ONE 2:E316-E316(2007). RN [10] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-334, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [11] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-323 AND SER-334, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [12] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-334, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [13] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-108 AND SER-334, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [14] RP SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-271, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=25218447; DOI=10.1038/nsmb.2890; RA Hendriks I.A., D'Souza R.C., Yang B., Verlaan-de Vries M., Mann M., RA Vertegaal A.C.; RT "Uncovering global SUMOylation signaling networks in a site-specific RT manner."; RL Nat. Struct. Mol. Biol. 21:927-936(2014). RN [15] RP SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-271, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=25755297; DOI=10.1074/mcp.o114.044792; RA Xiao Z., Chang J.G., Hendriks I.A., Sigurdsson J.O., Olsen J.V., RA Vertegaal A.C.; RT "System-wide analysis of SUMOylation dynamics in response to replication RT stress reveals novel small ubiquitin-like modified target proteins and RT acceptor lysines relevant for genome stability."; RL Mol. Cell. Proteomics 14:1419-1434(2015). RN [16] RP SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-271, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=28112733; DOI=10.1038/nsmb.3366; RA Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C., RA Nielsen M.L.; RT "Site-specific mapping of the human SUMO proteome reveals co-modification RT with phosphorylation."; RL Nat. Struct. Mol. Biol. 24:325-336(2017). RN [17] RP INVOLVEMENT IN FZPS. RX PubMed=38592547; DOI=10.1007/s00439-024-02669-y; RA Kopp J., Koch L.A., Lyubenova H., Kuechler O., Holtgrewe M., Ivanov A., RA Dubourg C., Launay E., Brachs S., Mundlos S., Ehmke N., Seelow D., RA Fradin M., Kornak U., Fischer-Zirnsak B.; RT "Loss-of-function variants affecting the STAGA complex component SUPT7L RT cause a developmental disorder with generalized lipodystrophy."; RL Hum. Genet. 143:683-694(2024). CC -!- SUBUNIT: Component of the STAGA transcription coactivator-HAT complex, CC at least composed of SUPT3H, SUPT7L, GCN5L2, TAF5L, TAF6L, TADA3L, CC TAD1L, TAF10, TAF12 and TAF9. {ECO:0000269|PubMed:17375202}. CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:11564863}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=3; CC Name=1; CC IsoId=O94864-1; Sequence=Displayed; CC Name=2; CC IsoId=O94864-2; Sequence=VSP_003974; CC Name=3; CC IsoId=O94864-4; Sequence=VSP_054839; CC -!- TISSUE SPECIFICITY: Expressed at high levels in adenocarcinomas and CC gliomas and low in esophageal cancers and malignant hematological CC disease. Also expressed at high level in the thymus, low in peripheral CC blood mononuclear cells, and lowest in the stomach, small intestine, CC and skeletal muscle. CC -!- PTM: Sumoylated. {ECO:0000269|PubMed:15561718}. CC -!- DISEASE: Fischer-Zirnsak progeroid syndrome (FZPS) [MIM:621130]: An CC autosomal recessive syndrome characterized by intrauterine growth CC retardation, congenital generalized lipodystrophy, and a progeroid CC appearance. Additional features include cataracts and a neonatal tooth. CC {ECO:0000269|PubMed:38592547}. Note=The disease may be caused by CC variants affecting the gene represented in this entry. CC -!- SEQUENCE CAUTION: CC Sequence=BAA34484.2; Type=Erroneous initiation; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF197954; AAG28523.1; -; mRNA. DR EMBL; AF224759; AAG47636.1; -; mRNA. DR EMBL; AB018307; BAA34484.2; ALT_INIT; mRNA. DR EMBL; AK304889; BAG65625.1; -; mRNA. DR EMBL; CR456983; CAG33264.1; -; mRNA. DR EMBL; AC074091; AAX93202.1; -; Genomic_DNA. DR EMBL; BC074000; AAH74000.1; -; mRNA. DR CCDS; CCDS42667.1; -. [O94864-1] DR CCDS; CCDS62885.1; -. [O94864-2] DR CCDS; CCDS62886.1; -. [O94864-4] DR RefSeq; NP_001269658.1; NM_001282729.2. [O94864-1] DR RefSeq; NP_001269659.1; NM_001282730.2. [O94864-2] DR RefSeq; NP_001269660.1; NM_001282731.2. [O94864-2] DR RefSeq; NP_001269661.1; NM_001282732.2. [O94864-4] DR RefSeq; NP_055675.1; NM_014860.3. [O94864-1] DR RefSeq; XP_005264729.1; XM_005264672.5. [O94864-2] DR RefSeq; XP_054200749.1; XM_054344774.1. [O94864-2] DR PDB; 7KTR; EM; 2.93 A; D=51-414. DR PDB; 7KTS; EM; 19.09 A; D=1-414. DR PDB; 8H7G; EM; 3.70 A; I=1-414. DR PDBsum; 7KTR; -. DR PDBsum; 7KTS; -. DR PDBsum; 8H7G; -. DR AlphaFoldDB; O94864; -. DR EMDB; EMD-23027; -. DR EMDB; EMD-23028; -. DR EMDB; EMD-34520; -. DR SMR; O94864; -. DR BioGRID; 115242; 71. DR ComplexPortal; CPX-6802; SAGA complex, KAT2B variant. DR ComplexPortal; CPX-900; SAGA complex, KAT2A variant. DR CORUM; O94864; -. DR FunCoup; O94864; 3672. DR IntAct; O94864; 37. DR MINT; O94864; -. DR STRING; 9606.ENSP00000336750; -. DR GlyGen; O94864; 2 sites, 1 O-linked glycan (2 sites). DR iPTMnet; O94864; -. DR PhosphoSitePlus; O94864; -. DR BioMuta; SUPT7L; -. DR jPOST; O94864; -. DR MassIVE; O94864; -. DR PaxDb; 9606-ENSP00000336750; -. DR PeptideAtlas; O94864; -. DR ProteomicsDB; 50503; -. [O94864-1] DR ProteomicsDB; 50504; -. [O94864-2] DR Pumba; O94864; -. DR Antibodypedia; 50579; 100 antibodies from 20 providers. DR DNASU; 9913; -. DR Ensembl; ENST00000337768.10; ENSP00000336750.5; ENSG00000119760.17. [O94864-1] DR Ensembl; ENST00000404798.6; ENSP00000385218.2; ENSG00000119760.17. [O94864-4] DR Ensembl; ENST00000405491.5; ENSP00000384469.1; ENSG00000119760.17. [O94864-2] DR Ensembl; ENST00000406540.5; ENSP00000385436.1; ENSG00000119760.17. [O94864-2] DR Ensembl; ENST00000464789.2; ENSP00000441110.1; ENSG00000119760.17. [O94864-2] DR GeneID; 9913; -. DR KEGG; hsa:9913; -. DR MANE-Select; ENST00000337768.10; ENSP00000336750.5; NM_014860.3; NP_055675.1. DR UCSC; uc002rli.3; human. [O94864-1] DR AGR; HGNC:30632; -. DR ClinPGx; PA142670854; -. DR CTD; 9913; -. DR DisGeNET; 9913; -. DR GeneCards; SUPT7L; -. DR HGNC; HGNC:30632; SUPT7L. DR HPA; ENSG00000119760; Low tissue specificity. DR MalaCards; SUPT7L; -. DR MIM; 612762; gene. DR MIM; 621130; phenotype. DR OpenTargets; ENSG00000119760; -. DR VEuPathDB; HostDB:ENSG00000119760; -. DR eggNOG; ENOG502QQTJ; Eukaryota. DR GeneTree; ENSGT00390000005572; -. DR HOGENOM; CLU_055453_1_0_1; -. DR InParanoid; O94864; -. DR OMA; ELSWNSC; -. DR OrthoDB; 6021257at2759; -. DR PAN-GO; O94864; 2 GO annotations based on evolutionary models. DR PhylomeDB; O94864; -. DR PathwayCommons; O94864; -. DR Reactome; R-HSA-3214847; HATs acetylate histones. DR SignaLink; O94864; -. DR SIGNOR; O94864; -. DR Agora; ENSG00000119760; -. DR BioGRID-ORCS; 9913; 77 hits in 1171 CRISPR screens. DR ChiTaRS; SUPT7L; human. DR GeneWiki; SUPT7L; -. DR GenomeRNAi; 9913; -. DR Pharos; O94864; Tbio. DR PRO; PR:O94864; -. DR Proteomes; UP000005640; Chromosome 2. DR RNAct; O94864; protein. DR Bgee; ENSG00000119760; Expressed in middle temporal gyrus and 199 other cell types or tissues. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:HGNC-UCL. DR GO; GO:0000124; C:SAGA complex; IDA:UniProtKB. DR GO; GO:0046982; F:protein heterodimerization activity; IEA:InterPro. DR GO; GO:0003713; F:transcription coactivator activity; IDA:UniProtKB. DR GO; GO:0051457; P:maintenance of protein location in nucleus; IDA:HGNC-UCL. DR GO; GO:0045893; P:positive regulation of DNA-templated transcription; NAS:ComplexPortal. DR GO; GO:0006282; P:regulation of DNA repair; NAS:ComplexPortal. DR GO; GO:0043484; P:regulation of RNA splicing; NAS:ComplexPortal. DR CDD; cd06847; HFD_SUPT7L; 1. DR FunFam; 1.10.20.10:FF:000034; STAGA complex 65 subunit gamma; 1. DR Gene3D; 1.10.20.10; Histone, subunit A; 1. DR InterPro; IPR006565; BTP. DR InterPro; IPR009072; Histone-fold. DR InterPro; IPR039460; SUPT7L/Spt7. DR PANTHER; PTHR28598; STAGA COMPLEX 65 SUBUNIT GAMMA; 1. DR PANTHER; PTHR28598:SF1; STAGA COMPLEX 65 SUBUNIT GAMMA; 1. DR Pfam; PF07524; Bromo_TP; 1. DR SMART; SM00576; BTP; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; Congenital generalized lipodystrophy; KW Isopeptide bond; Nucleus; Phosphoprotein; Proteomics identification; KW Reference proteome; Transcription; Transcription regulation; KW Ubl conjugation. FT CHAIN 1..414 FT /note="STAGA complex 65 subunit gamma" FT /id="PRO_0000072233" FT REGION 87..108 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 346..414 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 386..395 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOD_RES 108 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:24275569" FT MOD_RES 323 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:19690332" FT MOD_RES 334 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:20068231, FT ECO:0007744|PubMed:24275569" FT CROSSLNK 271 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:25218447, FT ECO:0007744|PubMed:25755297, ECO:0007744|PubMed:28112733" FT VAR_SEQ 1..4 FT /note="MNLQ -> ML (in isoform 2)" FT /evidence="ECO:0000303|PubMed:10987294" FT /id="VSP_003974" FT VAR_SEQ 5..140 FT /note="RYWGEIPISSSQTNRSSFDLLPREFRLVEVHDPPLHQPSANKPKPPTMLDIP FT SEPCSLTIHTIQLIQHNRRLRNLIATAQAQNQQQTEGVKTEESEPLPSCPGSPPLPDDL FT LPLDCKNPNAPFQIRHSDPESDFYR -> S (in isoform 3)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_054839" FT HELIX 58..86 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 114..117 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 137..140 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 151..169 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 173..175 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 176..207 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 211..214 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 215..222 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 230..238 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 240..261 FT /evidence="ECO:0007829|PDB:7KTR" SQ SEQUENCE 414 AA; 46193 MW; 59724A96353D44D5 CRC64; MNLQRYWGEI PISSSQTNRS SFDLLPREFR LVEVHDPPLH QPSANKPKPP TMLDIPSEPC SLTIHTIQLI QHNRRLRNLI ATAQAQNQQQ TEGVKTEESE PLPSCPGSPP LPDDLLPLDC KNPNAPFQIR HSDPESDFYR GKGEPVTELS WHSCRQLLYQ AVATILAHAG FDCANESVLE TLTDVAHEYC LKFTKLLRFA VDREARLGQT PFPDVMEQVF HEVGIGSVLS LQKFWQHRIK DYHSYMLQIS KQLSEEYERI VNPEKATEDA KPVKIKEEPV SDITFPVSEE LEADLASGDQ SLPMGVLGAQ SERFPSNLEV EASPQASSAE VNASPLWNLA HVKMEPQESE EGNVSGHGVL GSDVFEEPMS GMSEAGIPQS PDDSDSSYGS HSTDSLMGSS PVFNQRCKKR MRKI // ID WRN_HUMAN Reviewed; 1432 AA. AC Q14191; A1KYY9; DT 15-DEC-1998, integrated into UniProtKB/Swiss-Prot. DT 08-FEB-2011, sequence version 2. DT 28-JAN-2026, entry version 251. DE RecName: Full=Bifunctional 3'-5' exonuclease/ATP-dependent helicase WRN {ECO:0000305}; DE AltName: Full=DNA helicase, RecQ-like type 3; DE AltName: Full=RecQ protein-like 2; DE AltName: Full=Werner syndrome protein {ECO:0000303|PubMed:9618508}; DE Includes: DE RecName: Full=3'-5' exonuclease; DE EC=3.1.-.- {ECO:0000269|PubMed:11863428}; DE Includes: DE RecName: Full=ATP-dependent helicase; DE EC=5.6.2.4 {ECO:0000269|PubMed:9611231, ECO:0000305|PubMed:9288107}; DE AltName: Full=DNA 3'-5' helicase WRN {ECO:0000305}; GN Name=WRN; Synonyms=RECQ3, RECQL2; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT PHE-1074. RX PubMed=8602509; DOI=10.1126/science.272.5259.258; RA Yu C.-E., Oshima J., Fu Y.-H., Wijsman E.M., Hisama F., Alisch R., RA Matthews S., Nakura J., Miki T., Ouais S., Martin G.M., Mulligan J., RA Schellenberg G.D.; RT "Positional cloning of the Werner's syndrome gene."; RL Science 272:258-262(1996). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT PHE-1074. RX PubMed=16723399; DOI=10.1073/pnas.0600645103; RA Agrelo R., Cheng W.H., Setien F., Ropero S., Espada J., Fraga M.F., RA Herranz M., Paz M.F., Sanchez-Cespedes M., Artiga M.J., Guerrero D., RA Castells A., von Kobbe C., Bohr V.A., Esteller M.; RT "Epigenetic inactivation of the premature aging Werner syndrome gene in RT human cancer."; RL Proc. Natl. Acad. Sci. U.S.A. 103:8822-8827(2006). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT PHE-1074. RA Paeper B.W., Gayle M., Brady W., Swartz A., Gillett L.A., Alisch R.S., RA Mulligan J., Galas D., Fu Y.-H.; RT "Genomic structure of the human Werner's gene and cloning of the mouse RT homolog."; RL Submitted (AUG-1999) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS ILE-114; LYS-343; ILE-387; RP SER-533; CYS-612; PHE-708; CYS-834; SER-912; LEU-1079; ALA-1133; ILE-1339 RP AND ARG-1367. RG NIEHS SNPs program; RL Submitted (OCT-2003) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16421571; DOI=10.1038/nature04406; RA Nusbaum C., Mikkelsen T.S., Zody M.C., Asakawa S., Taudien S., Garber M., RA Kodira C.D., Schueler M.G., Shimizu A., Whittaker C.A., Chang J.L., RA Cuomo C.A., Dewar K., FitzGerald M.G., Yang X., Allen N.R., Anderson S., RA Asakawa T., Blechschmidt K., Bloom T., Borowsky M.L., Butler J., Cook A., RA Corum B., DeArellano K., DeCaprio D., Dooley K.T., Dorris L. III, RA Engels R., Gloeckner G., Hafez N., Hagopian D.S., Hall J.L., Ishikawa S.K., RA Jaffe D.B., Kamat A., Kudoh J., Lehmann R., Lokitsang T., Macdonald P., RA Major J.E., Matthews C.D., Mauceli E., Menzel U., Mihalev A.H., RA Minoshima S., Murayama Y., Naylor J.W., Nicol R., Nguyen C., O'Leary S.B., RA O'Neill K., Parker S.C.J., Polley A., Raymond C.K., Reichwald K., RA Rodriguez J., Sasaki T., Schilhabel M., Siddiqui R., Smith C.L., RA Sneddon T.P., Talamas J.A., Tenzin P., Topham K., Venkataraman V., Wen G., RA Yamazaki S., Young S.K., Zeng Q., Zimmer A.R., Rosenthal A., Birren B.W., RA Platzer M., Shimizu N., Lander E.S.; RT "DNA sequence and analysis of human chromosome 8."; RL Nature 439:331-335(2006). RN [6] RP FUNCTION AS A HELICASE, CATALYTIC ACTIVITY, AND MUTAGENESIS OF LYS-577. RX PubMed=9288107; DOI=10.1038/ng0997-100; RA Gray M.D., Shen J.C., Kamath-Loeb A.S., Blank A., Sopher B.L., Martin G.M., RA Oshima J., Loeb L.A.; RT "The Werner syndrome protein is a DNA helicase."; RL Nat. Genet. 17:100-103(1997). RN [7] RP FUNCTION AS A HELICASE. RX PubMed=9224595; DOI=10.1093/nar/25.15.2973; RA Suzuki N., Shimamoto A., Imamura O., Kuromitsu J., Kitao S., Goto M., RA Furuichi Y.; RT "DNA helicase activity in Werner's syndrome gene product synthesized in a RT baculovirus system."; RL Nucleic Acids Res. 25:2973-2978(1997). RN [8] RP FUNCTION AS A 3'-5' HELICASE, AND BIOPHYSICOCHEMICAL PROPERTIES. RX PubMed=9611231; DOI=10.1093/nar/26.12.2879; RA Shen J.C., Gray M.D., Oshima J., Loeb L.A.; RT "Characterization of Werner syndrome protein DNA helicase activity: RT directionality, substrate dependence and stimulation by replication protein RT A."; RL Nucleic Acids Res. 26:2879-2885(1998). RN [9] RP SUBCELLULAR LOCATION. RX PubMed=9618508; DOI=10.1073/pnas.95.12.6887; RA Marciniak R.A., Lombard D.B., Johnson F.B., Guarente L.; RT "Nucleolar localization of the Werner syndrome protein in human cells."; RL Proc. Natl. Acad. Sci. U.S.A. 95:6887-6892(1998). RN [10] RP REPEATS. RX PubMed=10049920; DOI=10.1093/genetics/151.3.1027; RA Kusano K., Berres M.E., Engels W.R.; RT "Evolution of the RECQ family of helicases: a Drosophila homolog, Dmblm, is RT similar to the human Bloom syndrome gene."; RL Genetics 151:1027-1039(1999). RN [11] RP FUNCTION, AND COFACTOR. RX PubMed=10212265; DOI=10.1074/jbc.274.18.12797; RA Fry M., Loeb L.A.; RT "Human werner syndrome DNA helicase unwinds tetrahelical structures of the RT fragile X syndrome repeat sequence d(CGG)n."; RL J. Biol. Chem. 274:12797-12802(1999). RN [12] RP POSSIBLE INVOLVEMENT IN CRC. RX PubMed=9989816; DOI=10.1038/sj.onc.1202340; RA Chughtai S.A., Crundwell M.C., Cruickshank N.R., Affie E., Armstrong S., RA Knowles M.A., Takle L.A., Kuo M., Khan N., Phillips S.M., Neoptolemos J.P., RA Morton D.G.; RT "Two novel regions of interstitial deletion on chromosome 8p in colorectal RT cancer."; RL Oncogene 18:657-665(1999). RN [13] RP FUNCTION AS AN EXONUCLEASE, MUTAGENESIS OF GLU-84, DNA-BINDING, INTERACTION RP WITH PCNA, AND SUBUNIT. RX PubMed=11863428; DOI=10.1021/bi0157161; RA Xue Y., Ratcliff G.C., Wang H., Davis-Searles P.R., Gray M.D., Erie D.A., RA Redinbo M.R.; RT "A minimal exonuclease domain of WRN forms a hexamer on DNA and possesses RT both 3'- 5' exonuclease and 5'-protruding strand endonuclease activities."; RL Biochemistry 41:2901-2912(2002). RN [14] RP PHOSPHORYLATION. RX PubMed=11889123; DOI=10.1074/jbc.m111523200; RA Karmakar P., Piotrowski J., Brosh R.M. Jr., Sommers J.A., Miller S.P., RA Cheng W.H., Snowden C.M., Ramsden D.A., Bohr V.A.; RT "Werner protein is a target of DNA-dependent protein kinase in vivo and in RT vitro, and its catalytic activities are regulated by phosphorylation."; RL J. Biol. Chem. 277:18291-18302(2002). RN [15] RP INTERACTION WITH EXO1. RX PubMed=12704184; DOI=10.1074/jbc.m212798200; RA Sharma S., Sommers J.A., Driscoll H.C., Uzdilla L.A., Wilson T.M., RA Brosh R.M. Jr.; RT "The exonucleolytic and endonucleolytic cleavage activities of human RT exonuclease 1 are stimulated by an interaction with the carboxyl-terminal RT region of the Werner syndrome protein."; RL J. Biol. Chem. 278:23487-23496(2003). RN [16] RP INTERACTION WITH SUPV3L1. RX PubMed=17961633; DOI=10.1016/j.mad.2007.09.001; RA Pereira M., Mason P., Szczesny R.J., Maddukuri L., Dziwura S., RA Jedrzejczak R., Paul E., Wojcik A., Dybczynska L., Tudek B., Bartnik E., RA Klysik J., Bohr V.A., Stepien P.P.; RT "Interaction of human SUV3 RNA/DNA helicase with BLM helicase; loss of the RT SUV3 gene results in mouse embryonic lethality."; RL Mech. Ageing Dev. 128:609-617(2007). RN [17] RP FUNCTION, AND SUBCELLULAR LOCATION. RX PubMed=17563354; DOI=10.1073/pnas.0702513104; RA Kamath-Loeb A.S., Lan L., Nakajima S., Yasui A., Loeb L.A.; RT "Werner syndrome protein interacts functionally with translesion DNA RT polymerases."; RL Proc. Natl. Acad. Sci. U.S.A. 104:10394-10399(2007). RN [18] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Embryonic kidney; RX PubMed=17525332; DOI=10.1126/science.1140321; RA Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III, Hurov K.E., RA Luo J., Bakalarski C.E., Zhao Z., Solimini N., Lerenthal Y., Shiloh Y., RA Gygi S.P., Elledge S.J.; RT "ATM and ATR substrate analysis reveals extensive protein networks RT responsive to DNA damage."; RL Science 316:1160-1166(2007). RN [19] RP FUNCTION, SUBUNIT, AND DNA-BINDING. RX PubMed=18596042; DOI=10.1074/jbc.m803370200; RA Compton S.A., Tolun G., Kamath-Loeb A.S., Loeb L.A., Griffith J.D.; RT "The Werner syndrome protein binds replication fork and Holliday junction RT DNAs as an oligomer."; RL J. Biol. Chem. 283:24478-24483(2008). RN [20] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-440 AND SER-467, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [21] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19413330; DOI=10.1021/ac9004309; RA Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.; RT "Lys-N and trypsin cover complementary parts of the phosphoproteome in a RT refined SCX-based approach."; RL Anal. Chem. 81:4493-4501(2009). RN [22] RP FUNCTION, AND SUBCELLULAR LOCATION. RX PubMed=19652551; DOI=10.4161/cc.8.17.9410; RA Zecevic A., Menard H., Gurel V., Hagan E., DeCaro R., Zhitkovich A.; RT "WRN helicase promotes repair of DNA double-strand breaks caused by RT aberrant mismatch repair of chromium-DNA adducts."; RL Cell Cycle 8:2769-2778(2009). RN [23] RP FUNCTION. RX PubMed=19283071; DOI=10.1371/journal.pone.0004825; RA Opresko P.L., Sowd G., Wang H.; RT "The Werner syndrome helicase/exonuclease processes mobile D-loops through RT branch migration and degradation."; RL PLoS ONE 4:E4825-E4825(2009). RN [24] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-426; SER-440; SER-453 AND RP SER-467, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [25] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [26] RP FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH PML. RX PubMed=21639834; DOI=10.1134/s000629791105004x; RA Liu J., Song Y., Qian J., Liu B., Dong Y., Tian B., Sun Z.; RT "Promyelocytic leukemia protein interacts with werner syndrome helicase and RT regulates double-strand break repair in gamma-irradiation-induced DNA RT damage responses."; RL Biochemistry (Mosc.) 76:550-554(2011). RN [27] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1133, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [28] RP ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2, CLEAVAGE OF INITIATOR RP METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RX PubMed=22814378; DOI=10.1073/pnas.1210303109; RA Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A., RA Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E., RA Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.; RT "N-terminal acetylome analyses and functional insights of the N-terminal RT acetyltransferase NatB."; RL Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012). RN [29] RP POSSIBLE INVOLVEMENT IN CRC. RX PubMed=24308539; DOI=10.1186/1755-8794-6-54; RA Lee H., Flaherty P., Ji H.P.; RT "Systematic genomic identification of colorectal cancer genes delineating RT advanced from early clinical stage and metastasis."; RL BMC Med. Genomics 6:54-54(2013). RN [30] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-478; SER-1133 AND SER-1400, RP AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [31] RP FUNCTION, SUBCELLULAR LOCATION, INTERACTION WITH XRCC5 AND XRCC6, DOMAIN, RP XLM MOTIF, KBM MOTIFS, AND MUTAGENESIS OF TRP-18 AND GLU-84. RX PubMed=27063109; DOI=10.1038/ncomms11242; RA Grundy G.J., Rulten S.L., Arribas-Bosacoma R., Davidson K., Kozik Z., RA Oliver A.W., Pearl L.H., Caldecott K.W.; RT "The Ku-binding motif is a conserved module for recruitment and stimulation RT of non-homologous end-joining proteins."; RL Nat. Commun. 7:11242-11242(2016). RN [32] RP SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-154; LYS-241 AND LYS-252, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=28112733; DOI=10.1038/nsmb.3366; RA Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C., RA Nielsen M.L.; RT "Site-specific mapping of the human SUMO proteome reveals co-modification RT with phosphorylation."; RL Nat. Struct. Mol. Biol. 24:325-336(2017). RN [33] {ECO:0007744|PDB:2AXL} RP STRUCTURE BY NMR OF 949-1092. RX PubMed=16339893; DOI=10.1073/pnas.0509380102; RA Hu J.S., Feng H., Zeng W., Lin G.X., Xi X.G.; RT "Solution structure of a multifunctional DNA- and protein-binding motif of RT human Werner syndrome protein."; RL Proc. Natl. Acad. Sci. U.S.A. 102:18379-18384(2005). RN [34] {ECO:0007744|PDB:2FBT, ECO:0007744|PDB:2FBV, ECO:0007744|PDB:2FBX, ECO:0007744|PDB:2FBY, ECO:0007744|PDB:2FC0} RP X-RAY CRYSTALLOGRAPHY (2.00 ANGSTROMS) OF 38-236 IN COMPLEXES WITH RP MAGNESIUM; MANGANESE; EUROPIUM AND GMP, PARTIAL PROTEIN SEQUENCE, RP IDENTIFICATION BY MASS SPECTROMETRY, CATALYTIC ACTIVITY, COFACTOR, RP MUTAGENESIS OF GLU-84; TRP-145 AND TYR-212, AND CHARACTERIZATION OF RP VARIANTS ILE-114 AND PRO-172. RX PubMed=16622405; DOI=10.1038/nsmb1088; RA Perry J.J., Yannone S.M., Holden L.G., Hitomi C., Asaithamby A., Han S., RA Cooper P.K., Chen D.J., Tainer J.A.; RT "WRN exonuclease structure and molecular mechanism imply an editing role in RT DNA end processing."; RL Nat. Struct. Mol. Biol. 13:414-422(2006). RN [35] RP REVIEW ON VARIANTS. RX PubMed=10220139; RX DOI=10.1002/(sici)1098-1004(1999)13:4<271::aid-humu2>3.0.co;2-q; RA Moser M.J., Oshima J., Monnat R.J. Jr.; RT "WRN mutations in Werner syndrome."; RL Hum. Mutat. 13:271-279(1999). RN [36] {ECO:0007744|PDB:2DGZ} RP STRUCTURE BY NMR OF 1140-1239. RG RIKEN structural genomics initiative (RSGI); RA Abe C., Muto Y., Inoue M., Kigawa T., Terada T., Shirouzu M., Yokoyama S.; RT "Solution structure of the helicase and RNase D C-terminal domain in Werner RT syndrome ATP-dependent helicase."; RL Submitted (SEP-2006) to the PDB data bank. RN [37] {ECO:0007744|PDB:2E1E, ECO:0007744|PDB:2E1F} RP X-RAY CRYSTALLOGRAPHY (2.00 ANGSTROMS) OF 1142-1242, PARTIAL PROTEIN RP SEQUENCE, IDENTIFICATION BY MASS SPECTROMETRY, AND CIRCULAR DICHROISM. RX PubMed=17148451; DOI=10.1074/jbc.m610142200; RA Kitano K., Yoshihara N., Hakoshima T.; RT "Crystal structure of the HRDC domain of human Werner syndrome protein, RT WRN."; RL J. Biol. Chem. 282:2717-2728(2007). RN [38] {ECO:0007744|PDB:3AAF} RP X-RAY CRYSTALLOGRAPHY (1.90 ANGSTROMS) OF 949-1079 IN COMPLEX WITH RP DOUBLE-STRANDED DNA, INTERACTION WITH DNA, AND MUTAGENESIS OF ARG-987; RP SER-989; ARG-993; PHE-1037 AND MET-1038. RX PubMed=20159463; DOI=10.1016/j.str.2009.12.011; RA Kitano K., Kim S.Y., Hakoshima T.; RT "Structural basis for DNA strand separation by the unconventional winged- RT helix domain of RecQ helicase WRN."; RL Structure 18:177-187(2010). RN [39] {ECO:0007744|PDB:6TYV} RP X-RAY CRYSTALLOGRAPHY (1.93 ANGSTROMS) OF 8-23 IN COMPLEX WITH X.LAEVIS RP XRCC5. RX PubMed=31733588; DOI=10.1016/j.dnarep.2019.102739; RA Kim K., Min J., Kirby T.W., Gabel S.A., Pedersen L.C., London R.E.; RT "Ligand binding characteristics of the Ku80 von Willebrand domain."; RL DNA Repair 85:102739-102739(2020). RN [40] {ECO:0007744|PDB:6YHR} RP X-RAY CRYSTALLOGRAPHY (2.20 ANGSTROMS) OF 517-1093 IN COMPLEX WITH ADP AND RP ZINC, FUNCTION, DOMAIN, AND MUTAGENESIS OF GLU-84; LYS-577 AND GLU-669. RX PubMed=33199508; DOI=10.26508/lsa.202000795; RA Newman J.A., Gavard A.E., Lieb S., Ravichandran M.C., Hauer K., Werni P., RA Geist L., Boettcher J., Engen J.R., Rumpel K., Samwer M., Petronczki M., RA Gileadi O.; RT "Structure of the helicase core of Werner helicase, a key target in RT microsatellite instability cancers."; RL Life. Sci Alliance 4:0-0(2021). RN [41] RP VARIANT ARG-1367. RX PubMed=9021029; RX DOI=10.1002/(sici)1096-8628(19970211)68:4<494::aid-ajmg30>3.0.co;2-l; RA Ye L., Miki T., Nakura J., Oshima J., Kamino K., Rakugi H., Ikegami H., RA Higaki J., Edland S.D., Martin G.M., Ogihara T.; RT "Association of a polymorphic variant of the Werner helicase gene with RT myocardial infarction in a Japanese population."; RL Am. J. Med. Genet. 68:494-498(1997). RN [42] RP ERRATUM OF PUBMED:9021029. RA Ye L., Miki T., Nakura J., Oshima J., Kamino K., Rakugi H., Ikegami H., RA Higaki J., Edland S.D., Martin G.M., Ogihara T.; RL Am. J. Med. Genet. 70:103-103(1997). RN [43] RP VARIANTS ILE-387 AND PHE-1074. RX PubMed=9450180; RA Meisslitzer C., Ruppitsch W., Weirich-Schwaiger H., Weirich H.G., RA Jabkowsky J., Klein G., Schweiger M., Hirsch-Kauffmann M.; RT "Werner syndrome: characterization of mutations in the WRN gene in an RT affected family."; RL Eur. J. Hum. Genet. 5:364-370(1997). RN [44] RP SUBCELLULAR LOCATION, AND INTERACTION WITH RECQL5. RX PubMed=23180761; DOI=10.1093/nar/gks1134; RA Popuri V., Huang J., Ramamoorthy M., Tadokoro T., Croteau D.L., Bohr V.A.; RT "RECQL5 plays co-operative and complementary roles with WRN syndrome RT helicase."; RL Nucleic Acids Res. 41:881-899(2013). RN [45] RP VARIANT ILE-387. RX PubMed=10206685; RX DOI=10.1002/(sici)1098-1004(1998)11:5<413::aid-humu16>3.0.co;2-i; RA Vidal V., Bay J.-O., Champomier F., Grancho M., Beauville L., RA Glowaczower C., Lemery D., Ferrara M., Bignon Y.-J.; RT "The 1396del A mutation and a missense mutation or a rare polymorphism of RT the WRN gene detected in a French Werner family with a severe phenotype and RT a case of an unusual vulvar cancer."; RL Hum. Mutat. 11:413-414(1998). RN [46] RP VARIANTS ALA-324 AND ARG-1367. RX PubMed=10069711; RX DOI=10.1002/(sici)1096-8628(19990219)82:5<399::aid-ajmg8>3.3.co;2-i; RA Castro E., Ogburn C.E., Hunt K.E., Tilvis R., Louhija J., Penttinen R., RA Erkkola R., Panduro A., Riestra R., Piussan C., Deeb S.S., Wang L., RA Edland S.D., Martin G.M., Oshima J.; RT "Polymorphisms at the Werner locus: I. Newly identified polymorphisms, RT ethnic variability of 1367Cys/Arg, and its stability in a population of RT Finnish centenarians."; RL Am. J. Med. Genet. 82:399-403(1999). RN [47] RP VARIANTS ARG-32; ILE-114; PRO-172; LYS-240; TRP-383; ILE-387; LEU-724; RP PHE-1074; GLU-1269 AND ARG-1367. RX PubMed=11161804; DOI=10.1006/geno.2000.6405; RA Passarino G., Shen P., Van Kirk J.B., Lin A.A., De Benedictis G., RA Cavalli-Sforza L.L., Oefner P.J., Underhill P.A.; RT "The Werner syndrome gene and global sequence variation."; RL Genomics 71:118-122(2001). RN [48] RP VARIANTS WRN ASN-125 AND GLU-135. RX PubMed=16673358; DOI=10.1002/humu.20337; RA Huang S., Lee L., Hanson N.B., Lenaerts C., Hoehn H., Poot M., Rubin C.D., RA Chen D.-F., Yang C.-C., Juch H., Dorn T., Spiegel R., Oral E.A., Abid M., RA Battisti C., Lucci-Cordisco E., Neri G., Steed E.H., Kidd A., Isley W., RA Showalter D., Vittone J.L., Konstantinow A., Ring J., Meyer P., RA Wenger S.L., Herbay A.V., Wollina U., Schuelke M., Huizenga C.R., RA Leistritz D.F., Martin G.M., Mian I.S., Oshima J.; RT "The spectrum of WRN mutations in Werner syndrome patients."; RL Hum. Mutat. 27:558-567(2006). RN [49] RP VARIANT [LARGE SCALE ANALYSIS] VAL-92. RX PubMed=16959974; DOI=10.1126/science.1133427; RA Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., RA Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P., RA Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V., RA Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H., RA Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W., RA Velculescu V.E.; RT "The consensus coding sequences of human breast and colorectal cancers."; RL Science 314:268-274(2006). RN [50] RP VARIANT [LARGE SCALE ANALYSIS] LEU-1141. RX PubMed=18987736; DOI=10.1038/nature07485; RA Ley T.J., Mardis E.R., Ding L., Fulton B., McLellan M.D., Chen K., RA Dooling D., Dunford-Shore B.H., McGrath S., Hickenbotham M., Cook L., RA Abbott R., Larson D.E., Koboldt D.C., Pohl C., Smith S., Hawkins A., RA Abbott S., Locke D., Hillier L.W., Miner T., Fulton L., Magrini V., RA Wylie T., Glasscock J., Conyers J., Sander N., Shi X., Osborne J.R., RA Minx P., Gordon D., Chinwalla A., Zhao Y., Ries R.E., Payton J.E., RA Westervelt P., Tomasson M.H., Watson M., Baty J., Ivanovich J., Heath S., RA Shannon W.D., Nagarajan R., Walter M.J., Link D.C., Graubert T.A., RA DiPersio J.F., Wilson R.K.; RT "DNA sequencing of a cytogenetically normal acute myeloid leukaemia RT genome."; RL Nature 456:66-72(2008). CC -!- FUNCTION: Multifunctional enzyme that has magnesium and ATP-dependent CC 3'-5' DNA-helicase activity on partially duplex substrates CC (PubMed:9224595, PubMed:9288107, PubMed:9611231). Also has 3'->5' CC exonuclease activity towards double-stranded (ds)DNA with a 5'-overhang CC (PubMed:11863428). Has no nuclease activity towards single-stranded CC (ss)DNA or blunt-ended dsDNA (PubMed:11863428). Helicase activity is CC most efficient with (d)ATP, but (d)CTP will substitute with reduced CC efficiency; strand displacement is enhanced by single-strand binding- CC protein (heterotrimeric replication protein A complex, RPA1, RPA2, CC RPA3) (PubMed:9611231). Binds preferentially to DNA substrates CC containing alternate secondary structures, such as replication forks CC and Holliday junctions. May play an important role in the dissociation CC of joint DNA molecules that can arise as products of homologous CC recombination, at stalled replication forks or during DNA repair. CC Alleviates stalling of DNA polymerases at the site of DNA lesions. CC Plays a role in the formation of DNA replication focal centers; stably CC associates with foci elements generating binding sites for RP-A (By CC similarity). Plays a role in double-strand break repair after gamma- CC irradiation (PubMed:9224595, PubMed:9288107, PubMed:9611231). Unwinds CC some G-quadruplex DNA (d(CGG)n tracts); unwinding seems to occur in CC both 5'-3' and 3'-5' direction and requires a short single-stranded CC tail (PubMed:10212265). d(CGG)n tracts have a propensity to assemble CC into tetraplex structures; other G-rich substrates from a telomeric or CC IgG switch sequence are not unwound (PubMed:10212265). Depletion leads CC to chromosomal breaks and genome instability (PubMed:33199508). CC {ECO:0000250|UniProtKB:O09053, ECO:0000269|PubMed:10212265, CC ECO:0000269|PubMed:11863428, ECO:0000269|PubMed:17563354, CC ECO:0000269|PubMed:18596042, ECO:0000269|PubMed:19283071, CC ECO:0000269|PubMed:19652551, ECO:0000269|PubMed:21639834, CC ECO:0000269|PubMed:27063109, ECO:0000269|PubMed:33199508, CC ECO:0000269|PubMed:9224595, ECO:0000269|PubMed:9288107, CC ECO:0000269|PubMed:9611231}. CC -!- CATALYTIC ACTIVITY: CC Reaction=Couples ATP hydrolysis with the unwinding of duplex DNA by CC translocating in the 3'-5' direction.; EC=5.6.2.4; CC Evidence={ECO:0000269|PubMed:9611231, ECO:0000305|PubMed:10212265, CC ECO:0000305|PubMed:9224595, ECO:0000305|PubMed:9288107}; CC -!- CATALYTIC ACTIVITY: CC Reaction=ATP + H2O = ADP + phosphate + H(+); Xref=Rhea:RHEA:13065, CC ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:43474, ChEBI:CHEBI:456216; EC=5.6.2.4; CC Evidence={ECO:0000269|PubMed:16622405, ECO:0000269|PubMed:9224595, CC ECO:0000269|PubMed:9288107, ECO:0000269|PubMed:9611231}; CC -!- COFACTOR: CC Name=a divalent metal cation; Xref=ChEBI:CHEBI:60240; CC Evidence={ECO:0000269|PubMed:16622405}; CC Note=Binds 2 magnesium or manganese ions in the exonuclease domain; has CC high exonuclease activity with both ions in vitro (PubMed:16622405). CC Unwinding of G-quadruplex DNA requires Mg(2+) (PubMed:10212265). CC {ECO:0000269|PubMed:10212265, ECO:0000269|PubMed:16622405}; CC -!- COFACTOR: CC Name=Zn(2+); Xref=ChEBI:CHEBI:29105; CC Evidence={ECO:0000269|PubMed:33199508, ECO:0000312|PDB:6YHR}; CC Note=Binds a Zn(2+) ion in the helicase domain (PubMed:33199508). CC {ECO:0000269|PubMed:33199508, ECO:0000312|PDB:6YHR}; CC -!- BIOPHYSICOCHEMICAL PROPERTIES: CC Kinetic parameters: CC KM=51 uM for ATP in helicase activity {ECO:0000269|PubMed:9611231}; CC KM=119 uM for dATP in helicase activity {ECO:0000269|PubMed:9611231}; CC KM=2.1 uM for CTP in helicase activity {ECO:0000269|PubMed:9611231}; CC KM=3.9 uM for dCTP in helicase activity {ECO:0000269|PubMed:9611231}; CC -!- SUBUNIT: Monomer, and homooligomer (PubMed:11863428, PubMed:18596042, CC PubMed:20159463). May exist as homodimer, homotrimer, homotetramer CC and/or homohexamer (PubMed:11863428, PubMed:18596042, PubMed:20159463). CC Homotetramer, or homohexamer, when bound to DNA (PubMed:11863428, CC PubMed:18596042, PubMed:20159463). Interacts via its N-terminal domain CC with WRNIP1 (By similarity). Interacts with EXO1, PCNA and SUPV3L1 CC (PubMed:12704184, PubMed:17961633). Interacts with PML (isoform PML-4) CC (PubMed:21639834). Interacts (via KBM motif) with XRCC5 and XRCC6; CC promoting recruitment to DNA damage sites (PubMed:27063109). Interacts CC with RECQL5; this interaction stimulates WRN helicase activity on DNA CC fork duplexes (PubMed:23180761). {ECO:0000250|UniProtKB:O09053, CC ECO:0000269|PubMed:11863428, ECO:0000269|PubMed:12704184, CC ECO:0000269|PubMed:17961633, ECO:0000269|PubMed:18596042, CC ECO:0000269|PubMed:20159463, ECO:0000269|PubMed:21639834, CC ECO:0000269|PubMed:23180761, ECO:0000269|PubMed:27063109}. CC -!- INTERACTION: CC Q14191; P54132: BLM; NbExp=9; IntAct=EBI-368417, EBI-621372; CC Q14191; P45973: CBX5; NbExp=3; IntAct=EBI-368417, EBI-78219; CC Q14191; P39748: FEN1; NbExp=9; IntAct=EBI-368417, EBI-707816; CC Q14191; P16104: H2AX; NbExp=6; IntAct=EBI-368417, EBI-494830; CC Q14191; P09874: PARP1; NbExp=8; IntAct=EBI-368417, EBI-355676; CC Q14191; P43351: RAD52; NbExp=9; IntAct=EBI-368417, EBI-706448; CC Q14191; P27694: RPA1; NbExp=9; IntAct=EBI-368417, EBI-621389; CC Q14191; Q96EB6: SIRT1; NbExp=9; IntAct=EBI-368417, EBI-1802965; CC Q14191; Q15554: TERF2; NbExp=8; IntAct=EBI-368417, EBI-706637; CC Q14191; P04637: TP53; NbExp=5; IntAct=EBI-368417, EBI-366083; CC Q14191; P12956: XRCC6; NbExp=11; IntAct=EBI-368417, EBI-353208; CC -!- SUBCELLULAR LOCATION: Nucleus, nucleolus {ECO:0000269|PubMed:23180761, CC ECO:0000269|PubMed:9618508}. Nucleus {ECO:0000269|PubMed:17563354, CC ECO:0000269|PubMed:19652551, ECO:0000269|PubMed:23180761}. Nucleus, CC nucleoplasm {ECO:0000269|PubMed:21639834}. Chromosome CC {ECO:0000269|PubMed:27063109}. Note=Gamma-irradiation leads to its CC translocation from nucleoli to nucleoplasm and PML regulates the CC irradiation-induced WRN relocation (PubMed:21639834). Localizes to DNA CC damage sites (PubMed:27063109). {ECO:0000269|PubMed:21639834, CC ECO:0000269|PubMed:27063109}. CC -!- DOMAIN: The KBM 2 (Ku-binding motif 2) and XLM (XLF-like motif) mediate CC cooperative interaction with XRCC5/Ku80 and XRCC6/Ku70 and recruitment CC to DNA damage sites (PubMed:27063109). The isolated helicase core CC (residues 517-1093) interacts weakly with the HDRC domain in vitro CC (PubMed:33199508). {ECO:0000269|PubMed:27063109, CC ECO:0000269|PubMed:33199508}. CC -!- PTM: Phosphorylated by PRKDC. {ECO:0000269|PubMed:11889123}. CC -!- DISEASE: Werner syndrome (WRN) [MIM:277700]: A rare autosomal recessive CC progeroid syndrome characterized by the premature onset of multiple CC age-related disorders, including atherosclerosis, cancer, non-insulin- CC dependent diabetes mellitus, ocular cataracts and osteoporosis. The CC major cause of death, at a median age of 47, is myocardial infarction. CC {ECO:0000269|PubMed:16673358}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Colorectal cancer (CRC) [MIM:114500]: A complex disease CC characterized by malignant lesions arising from the inner wall of the CC large intestine (the colon) and the rectum. Genetic alterations are CC often associated with progression from premalignant lesion (adenoma) to CC invasive adenocarcinoma. Risk factors for cancer of the colon and CC rectum include colon polyps, long-standing ulcerative colitis, and CC genetic family history. {ECO:0000305|PubMed:24308539, CC ECO:0000305|PubMed:9989816}. Note=The disease may be caused by variants CC affecting the gene represented in this entry. CC -!- SIMILARITY: Belongs to the helicase family. RecQ subfamily. CC {ECO:0000305}. CC -!- WEB RESOURCE: Name=WRN; Note=WRN mutation db (Warner disease); CC URL="http://www.pathology.washington.edu/werner/ws_wrn.html"; CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/284/WRN"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; L76937; AAC41981.1; -; Genomic_DNA. DR EMBL; AY818673; AAX21098.1; -; mRNA. DR EMBL; AF091214; AAC63361.1; -; mRNA. DR EMBL; AF181897; AAF06162.1; -; Genomic_DNA. DR EMBL; AF181896; AAF06162.1; JOINED; Genomic_DNA. DR EMBL; AY442327; AAR05448.1; -; Genomic_DNA. DR EMBL; AC084736; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR CCDS; CCDS6082.1; -. DR RefSeq; NP_000544.2; NM_000553.6. DR PDB; 2AXL; NMR; -; A=949-1092. DR PDB; 2DGZ; NMR; -; A=1140-1239. DR PDB; 2E1E; X-ray; 2.30 A; A=1142-1242. DR PDB; 2E1F; X-ray; 2.00 A; A=1142-1242. DR PDB; 2FBT; X-ray; 2.05 A; A=38-236. DR PDB; 2FBV; X-ray; 2.40 A; A=38-236. DR PDB; 2FBX; X-ray; 2.20 A; A=38-236. DR PDB; 2FBY; X-ray; 2.00 A; A=38-236. DR PDB; 2FC0; X-ray; 2.00 A; A=38-236. DR PDB; 3AAF; X-ray; 1.90 A; A/B=949-1079. DR PDB; 6TYV; X-ray; 1.93 A; B=8-23. DR PDB; 6YHR; X-ray; 2.20 A; A=517-1093. DR PDB; 7GQS; X-ray; 1.57 A; A=517-945. DR PDB; 7GQT; X-ray; 2.21 A; A=517-945. DR PDB; 7GQU; X-ray; 1.54 A; A=517-945. DR PDB; 7XUT; X-ray; 1.60 A; A/B=435-451. DR PDB; 8PFL; X-ray; 1.80 A; A=517-945. DR PDB; 8PFO; X-ray; 1.90 A; A=517-945. DR PDB; 8PFP; X-ray; 1.60 A; A=517-945. DR PDB; 8YLE; X-ray; 1.86 A; A=517-945. DR PDB; 9OG3; X-ray; 2.06 A; A=526-946. DR PDB; 9OG8; X-ray; 1.66 A; A=526-946. DR PDB; 9OW9; X-ray; 2.34 A; A=500-942. DR PDB; 9OWA; X-ray; 1.98 A; A=500-942. DR PDB; 9OWB; X-ray; 1.56 A; A/B/C/D=500-942. DR PDB; 9OWC; X-ray; 1.67 A; A=500-942. DR PDB; 9OWD; X-ray; 1.96 A; A=500-942. DR PDBsum; 2AXL; -. DR PDBsum; 2DGZ; -. DR PDBsum; 2E1E; -. DR PDBsum; 2E1F; -. DR PDBsum; 2FBT; -. DR PDBsum; 2FBV; -. DR PDBsum; 2FBX; -. DR PDBsum; 2FBY; -. DR PDBsum; 2FC0; -. DR PDBsum; 3AAF; -. DR PDBsum; 6TYV; -. DR PDBsum; 6YHR; -. DR PDBsum; 7GQS; -. DR PDBsum; 7GQT; -. DR PDBsum; 7GQU; -. DR PDBsum; 7XUT; -. DR PDBsum; 8PFL; -. DR PDBsum; 8PFO; -. DR PDBsum; 8PFP; -. DR PDBsum; 8YLE; -. DR PDBsum; 9OG3; -. DR PDBsum; 9OG8; -. DR PDBsum; 9OW9; -. DR PDBsum; 9OWA; -. DR PDBsum; 9OWB; -. DR PDBsum; 9OWC; -. DR PDBsum; 9OWD; -. DR AlphaFoldDB; Q14191; -. DR BMRB; Q14191; -. DR SMR; Q14191; -. DR BioGRID; 113323; 124. DR CORUM; Q14191; -. DR DIP; DIP-31380N; -. DR ELM; Q14191; -. DR FunCoup; Q14191; 2264. DR IntAct; Q14191; 67. DR MINT; Q14191; -. DR STRING; 9606.ENSP00000298139; -. DR BindingDB; Q14191; -. DR ChEMBL; CHEMBL2146312; -. DR GuidetoPHARMACOLOGY; 3259; -. DR GlyGen; Q14191; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; Q14191; -. DR PhosphoSitePlus; Q14191; -. DR SwissPalm; Q14191; -. DR BioMuta; WRN; -. DR DMDM; 322510082; -. DR jPOST; Q14191; -. DR MassIVE; Q14191; -. DR PaxDb; 9606-ENSP00000298139; -. DR PeptideAtlas; Q14191; -. DR ProteomicsDB; 59913; -. DR Pumba; Q14191; -. DR ABCD; Q14191; 1 sequenced antibody. DR Antibodypedia; 10619; 313 antibodies from 41 providers. DR DNASU; 7486; -. DR Ensembl; ENST00000298139.7; ENSP00000298139.5; ENSG00000165392.12. DR GeneID; 7486; -. DR KEGG; hsa:7486; -. DR MANE-Select; ENST00000298139.7; ENSP00000298139.5; NM_000553.6; NP_000544.2. DR UCSC; uc003xio.5; human. DR AGR; HGNC:12791; -. DR ClinPGx; PA367; -. DR CTD; 7486; -. DR DisGeNET; 7486; -. DR GeneCards; WRN; -. DR GeneReviews; WRN; -. DR HGNC; HGNC:12791; WRN. DR HPA; ENSG00000165392; Low tissue specificity. DR MalaCards; WRN; -. DR MIM; 114500; phenotype. DR MIM; 277700; phenotype. DR MIM; 604611; gene. DR OpenTargets; ENSG00000165392; -. DR Orphanet; 902; Werner syndrome. DR VEuPathDB; HostDB:ENSG00000165392; -. DR eggNOG; KOG0351; Eukaryota. DR eggNOG; KOG4373; Eukaryota. DR GeneTree; ENSGT00940000159168; -. DR HOGENOM; CLU_001103_11_1_1; -. DR InParanoid; Q14191; -. DR OMA; TYLIHMV; -. DR OrthoDB; 10261556at2759; -. DR PAN-GO; Q14191; 11 GO annotations based on evolutionary models. DR PhylomeDB; Q14191; -. DR BRENDA; 3.6.4.12; 2681. DR PathwayCommons; Q14191; -. DR Reactome; R-HSA-174414; Processive synthesis on the C-strand of the telomere. DR Reactome; R-HSA-174437; Removal of the Flap Intermediate from the C-strand. DR Reactome; R-HSA-3108214; SUMOylation of DNA damage response and repair proteins. DR Reactome; R-HSA-5685938; HDR through Single Strand Annealing (SSA). DR Reactome; R-HSA-5685942; HDR through Homologous Recombination (HRR). DR Reactome; R-HSA-5693554; Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA). DR Reactome; R-HSA-5693568; Resolution of D-loop Structures through Holliday Junction Intermediates. DR Reactome; R-HSA-5693579; Homologous DNA Pairing and Strand Exchange. DR Reactome; R-HSA-5693607; Processing of DNA double-strand break ends. DR Reactome; R-HSA-5693616; Presynaptic phase of homologous DNA pairing and strand exchange. DR Reactome; R-HSA-6804756; Regulation of TP53 Activity through Phosphorylation. DR Reactome; R-HSA-69473; G2/M DNA damage checkpoint. DR Reactome; R-HSA-9701192; Defective homologous recombination repair (HRR) due to BRCA1 loss of function. DR Reactome; R-HSA-9704331; Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function. DR Reactome; R-HSA-9704646; Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function. DR Reactome; R-HSA-9709570; Impaired BRCA2 binding to RAD51. DR Reactome; R-HSA-9709603; Impaired BRCA2 binding to PALB2. DR SignaLink; Q14191; -. DR SIGNOR; Q14191; -. DR Agora; ENSG00000165392; -. DR BioGRID-ORCS; 7486; 55 hits in 1158 CRISPR screens. DR CD-CODE; 8C2F96ED; Centrosome. DR CD-CODE; 91857CE7; Nucleolus. DR CD-CODE; B5B9A610; PML body. DR ChiTaRS; WRN; human. DR EvolutionaryTrace; Q14191; -. DR GeneWiki; Werner_syndrome_ATP-dependent_helicase; -. DR GenomeRNAi; 7486; -. DR Pharos; Q14191; Tbio. DR PRO; PR:Q14191; -. DR Proteomes; UP000005640; Chromosome 8. DR RNAct; Q14191; protein. DR Bgee; ENSG00000165392; Expressed in calcaneal tendon and 165 other cell types or tissues. DR ExpressionAtlas; Q14191; baseline and differential. DR GO; GO:0005813; C:centrosome; IDA:UniProtKB. DR GO; GO:0005694; C:chromosome; IBA:GO_Central. DR GO; GO:0000781; C:chromosome, telomeric region; IDA:BHF-UCL. DR GO; GO:0005737; C:cytoplasm; IBA:GO_Central. DR GO; GO:0016607; C:nuclear speck; IDA:HPA. DR GO; GO:0005730; C:nucleolus; IDA:UniProtKB. DR GO; GO:0005654; C:nucleoplasm; IDA:UniProtKB. DR GO; GO:0005634; C:nucleus; IBA:GO_Central. DR GO; GO:0005657; C:replication fork; ISS:BHF-UCL. DR GO; GO:0043138; F:3'-5' DNA helicase activity; IDA:UniProtKB. DR GO; GO:0008408; F:3'-5' exonuclease activity; IDA:UniProtKB. DR GO; GO:0070337; F:3'-flap-structured DNA binding; IDA:BHF-UCL. DR GO; GO:1905773; F:8-hydroxy-2'-deoxyguanosine DNA binding; IDA:BHF-UCL. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0016887; F:ATP hydrolysis activity; IDA:UniProtKB. DR GO; GO:0000405; F:bubble DNA binding; IDA:UniProtKB. DR GO; GO:0003677; F:DNA binding; IDA:UniProtKB. DR GO; GO:0003678; F:DNA helicase activity; IDA:UniProtKB. DR GO; GO:0004527; F:exonuclease activity; IDA:MGI. DR GO; GO:0061749; F:forked DNA-dependent helicase activity; IDA:BHF-UCL. DR GO; GO:0000400; F:four-way junction DNA binding; IDA:BHF-UCL. DR GO; GO:0009378; F:four-way junction helicase activity; IDA:UniProtKB. DR GO; GO:0051880; F:G-quadruplex DNA binding; IDA:UniProtKB. DR GO; GO:0000287; F:magnesium ion binding; IDA:UniProtKB. DR GO; GO:0030145; F:manganese ion binding; IDA:UniProtKB. DR GO; GO:0032405; F:MutLalpha complex binding; IDA:UniProtKB. DR GO; GO:0042803; F:protein homodimerization activity; IDA:UniProtKB. DR GO; GO:0044877; F:protein-containing complex binding; IDA:UniProtKB. DR GO; GO:0061821; F:telomeric D-loop binding; IDA:BHF-UCL. DR GO; GO:0061849; F:telomeric G-quadruplex DNA binding; IDA:BHF-UCL. DR GO; GO:0000403; F:Y-form DNA binding; IDA:UniProtKB. DR GO; GO:0006284; P:base-excision repair; IDA:UniProtKB. DR GO; GO:0071480; P:cellular response to gamma radiation; IDA:UniProtKB. DR GO; GO:0009267; P:cellular response to starvation; IDA:MGI. DR GO; GO:0090398; P:cellular senescence; IMP:GO_Central. DR GO; GO:0008340; P:determination of adult lifespan; IEA:Ensembl. DR GO; GO:0006974; P:DNA damage response; IDA:UniProtKB. DR GO; GO:0032392; P:DNA geometric change; IDA:BHF-UCL. DR GO; GO:0006259; P:DNA metabolic process; IDA:UniProtKB. DR GO; GO:0006260; P:DNA replication; IMP:UniProtKB. DR GO; GO:0000731; P:DNA synthesis involved in DNA repair; IDA:UniProtKB. DR GO; GO:0006302; P:double-strand break repair; IMP:UniProtKB. DR GO; GO:0000724; P:double-strand break repair via homologous recombination; IBA:GO_Central. DR GO; GO:0006298; P:mismatch repair; IDA:BHF-UCL. DR GO; GO:0051345; P:positive regulation of hydrolase activity; IDA:UniProtKB. DR GO; GO:0098530; P:positive regulation of strand invasion; IDA:BHF-UCL. DR GO; GO:1902570; P:protein localization to nucleolus; IDA:MGI. DR GO; GO:0040009; P:regulation of growth rate; IEA:Ensembl. DR GO; GO:0031297; P:replication fork processing; IDA:UniProtKB. DR GO; GO:0090399; P:replicative senescence; IEA:Ensembl. DR GO; GO:0006979; P:response to oxidative stress; IDA:UniProtKB. DR GO; GO:0010225; P:response to UV-C; IDA:UniProtKB. DR GO; GO:0090656; P:t-circle formation; TAS:BHF-UCL. DR GO; GO:0000723; P:telomere maintenance; IDA:BHF-UCL. DR GO; GO:0032201; P:telomere maintenance via semi-conservative replication; TAS:Reactome. DR GO; GO:0061820; P:telomeric D-loop disassembly; IDA:BHF-UCL. DR CDD; cd18017; DEXHc_RecQ3; 1. DR CDD; cd06129; RNaseD_like; 1. DR CDD; cd18794; SF2_C_RecQ; 1. DR DisProt; DP00443; -. DR FunFam; 1.10.10.10:FF:000369; Werner syndrome ATP-dependent helicase; 1. DR FunFam; 1.10.150.80:FF:000005; Werner syndrome ATP-dependent helicase homolog; 1. DR FunFam; 3.30.420.10:FF:000053; Werner syndrome ATP-dependent helicase homolog; 1. DR FunFam; 3.40.50.300:FF:000941; Werner syndrome RecQ like helicase; 1. DR FunFam; 3.40.50.300:FF:001023; Werner syndrome RecQ like helicase; 1. DR Gene3D; 1.10.150.80; HRDC domain; 1. DR Gene3D; 3.40.50.300; P-loop containing nucleotide triphosphate hydrolases; 2. DR Gene3D; 3.30.420.10; Ribonuclease H-like superfamily/Ribonuclease H; 1. DR Gene3D; 1.10.10.10; Winged helix-like DNA-binding domain superfamily/Winged helix DNA-binding domain; 1. DR IDEAL; IID00246; -. DR InterPro; IPR002562; 3'-5'_exonuclease_dom. DR InterPro; IPR011545; DEAD/DEAH_box_helicase_dom. DR InterPro; IPR004589; DNA_helicase_ATP-dep_RecQ. DR InterPro; IPR014001; Helicase_ATP-bd. DR InterPro; IPR001650; Helicase_C-like. DR InterPro; IPR029491; Helicase_HTH. DR InterPro; IPR010997; HRDC-like_sf. DR InterPro; IPR002121; HRDC_dom. DR InterPro; IPR044876; HRDC_dom_sf. DR InterPro; IPR027417; P-loop_NTPase. DR InterPro; IPR032284; RecQ_Zn-bd. DR InterPro; IPR012337; RNaseH-like_sf. DR InterPro; IPR036397; RNaseH_sf. DR InterPro; IPR018982; RQC_domain. DR InterPro; IPR036388; WH-like_DNA-bd_sf. DR InterPro; IPR036390; WH_DNA-bd_sf. DR NCBIfam; TIGR00614; recQ_fam; 1. DR PANTHER; PTHR13710:SF120; BIFUNCTIONAL 3'-5' EXONUCLEASE_ATP-DEPENDENT HELICASE WRN; 1. DR PANTHER; PTHR13710; DNA HELICASE RECQ FAMILY MEMBER; 1. DR Pfam; PF00270; DEAD; 1. DR Pfam; PF01612; DNA_pol_A_exo1; 1. DR Pfam; PF00271; Helicase_C; 1. DR Pfam; PF00570; HRDC; 1. DR Pfam; PF14493; HTH_40; 1. DR Pfam; PF16124; RecQ_Zn_bind; 1. DR Pfam; PF09382; RQC; 1. DR SMART; SM00474; 35EXOc; 1. DR SMART; SM00487; DEXDc; 1. DR SMART; SM00490; HELICc; 1. DR SMART; SM00341; HRDC; 1. DR SMART; SM00956; RQC; 1. DR SUPFAM; SSF47819; HRDC-like; 1. DR SUPFAM; SSF52540; P-loop containing nucleoside triphosphate hydrolases; 1. DR SUPFAM; SSF53098; Ribonuclease H-like; 1. DR SUPFAM; SSF46785; Winged helix' DNA-binding domain; 1. DR PROSITE; PS51192; HELICASE_ATP_BIND_1; 1. DR PROSITE; PS51194; HELICASE_CTER; 1. DR PROSITE; PS50967; HRDC; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; ATP-binding; Chromosome; KW Direct protein sequencing; Disease variant; DNA damage; DNA repair; KW DNA-binding; Exonuclease; Helicase; Hydrolase; Isomerase; Isopeptide bond; KW Magnesium; Metal-binding; Multifunctional enzyme; Nuclease; KW Nucleotide-binding; Nucleus; Phosphoprotein; Proteomics identification; KW Reference proteome; Repeat; Ubl conjugation; Zinc. FT INIT_MET 1 FT /note="Removed" FT /evidence="ECO:0007744|PubMed:22814378" FT CHAIN 2..1432 FT /note="Bifunctional 3'-5' exonuclease/ATP-dependent FT helicase WRN" FT /id="PRO_0000205045" FT DOMAIN 60..228 FT /note="3'-5' exonuclease" FT /evidence="ECO:0000255, ECO:0000269|PubMed:11863428" FT REPEAT 424..450 FT /note="1" FT /evidence="ECO:0000269|PubMed:10049920" FT REPEAT 451..477 FT /note="2" FT /evidence="ECO:0000269|PubMed:10049920" FT DOMAIN 558..724 FT /note="Helicase ATP-binding" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00541" FT DOMAIN 749..899 FT /note="Helicase C-terminal" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00542" FT DOMAIN 1150..1229 FT /note="HRDC" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00328" FT REGION 2..277 FT /note="Interaction with WRNIP1" FT /evidence="ECO:0000250|UniProtKB:O09053" FT REGION 424..477 FT /note="2 X 27 AA tandem repeats of H-L-S-P-N-D-N-E-N-D-T-S- FT Y-V-I-E-S-D-E-D-L-E-M-E-M-L-K" FT REGION 498..529 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 987..993 FT /note="Interaction with DNA" FT /evidence="ECO:0000269|PubMed:20159463" FT MOTIF 11..23 FT /note="KBM 1" FT /evidence="ECO:0000305|PubMed:27063109" FT MOTIF 668..671 FT /note="DEAH box" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00541" FT MOTIF 1403..1412 FT /note="KBM 2" FT /evidence="ECO:0000305|PubMed:27063109" FT MOTIF 1419..1432 FT /note="XLM" FT /evidence="ECO:0000305|PubMed:27063109" FT COMPBIAS 507..525 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT BINDING 82 FT /ligand="Mn(2+)" FT /ligand_id="ChEBI:CHEBI:29035" FT /ligand_label="1" FT /ligand_note="catalytic" FT /evidence="ECO:0000269|PubMed:16622405, FT ECO:0007744|PDB:2FBV, ECO:0007744|PDB:2FBX, FT ECO:0007744|PDB:2FC0" FT BINDING 82 FT /ligand="Mn(2+)" FT /ligand_id="ChEBI:CHEBI:29035" FT /ligand_label="2" FT /ligand_note="catalytic" FT /evidence="ECO:0000269|PubMed:16622405, FT ECO:0007744|PDB:2FBV, ECO:0007744|PDB:2FBX, FT ECO:0007744|PDB:2FC0" FT BINDING 84 FT /ligand="Mn(2+)" FT /ligand_id="ChEBI:CHEBI:29035" FT /ligand_label="1" FT /ligand_note="catalytic" FT /evidence="ECO:0000269|PubMed:16622405, FT ECO:0007744|PDB:2FBV, ECO:0007744|PDB:2FBX, FT ECO:0007744|PDB:2FC0" FT BINDING 216 FT /ligand="Mn(2+)" FT /ligand_id="ChEBI:CHEBI:29035" FT /ligand_label="1" FT /ligand_note="catalytic" FT /evidence="ECO:0000269|PubMed:16622405, FT ECO:0007744|PDB:2FBV, ECO:0007744|PDB:2FBX, FT ECO:0007744|PDB:2FC0" FT BINDING 546 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000305|PubMed:33199508, FT ECO:0000312|PDB:6YHR" FT BINDING 548 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000312|PDB:6YHR" FT BINDING 550 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000305|PubMed:33199508" FT BINDING 553 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000305|PubMed:33199508, FT ECO:0000312|PDB:6YHR" FT BINDING 574 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000312|PDB:6YHR" FT BINDING 908 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000269|PubMed:33199508, FT ECO:0000312|PDB:6YHR" FT BINDING 935 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000269|PubMed:33199508, FT ECO:0000312|PDB:6YHR" FT BINDING 936 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000269|PubMed:33199508, FT ECO:0000312|PDB:6YHR" FT BINDING 939 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000269|PubMed:33199508, FT ECO:0000312|PDB:6YHR" FT SITE 145 FT /note="Interaction with DNA" FT /evidence="ECO:0000305|PubMed:20159463" FT SITE 1037 FT /note="Interaction with DNA" FT /evidence="ECO:0000305|PubMed:20159463" FT MOD_RES 2 FT /note="N-acetylserine" FT /evidence="ECO:0007744|PubMed:22814378" FT MOD_RES 426 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:19690332" FT MOD_RES 440 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:19690332" FT MOD_RES 453 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:19690332" FT MOD_RES 467 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:19690332" FT MOD_RES 478 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 1133 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:21406692, FT ECO:0007744|PubMed:23186163" FT MOD_RES 1400 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT CROSSLNK 154 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:28112733" FT CROSSLNK 241 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:28112733" FT CROSSLNK 252 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:28112733" FT VARIANT 32 FT /note="K -> R (in dbSNP:rs34477820)" FT /evidence="ECO:0000269|PubMed:11161804" FT /id="VAR_017453" FT VARIANT 92 FT /note="G -> V (in a colorectal cancer sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_036318" FT VARIANT 114 FT /note="V -> I (no effect on exonuclease activity; FT dbSNP:rs2230009)" FT /evidence="ECO:0000269|PubMed:11161804, FT ECO:0000269|PubMed:16622405, ECO:0000269|Ref.4" FT /id="VAR_017454" FT VARIANT 125 FT /note="K -> N (in WRN; dbSNP:rs387906337)" FT /evidence="ECO:0000269|PubMed:16673358" FT /id="VAR_026588" FT VARIANT 135 FT /note="K -> E (in WRN; dbSNP:rs267607008)" FT /evidence="ECO:0000269|PubMed:16673358" FT /id="VAR_026589" FT VARIANT 172 FT /note="T -> P (no effect on exonuclease activity; FT dbSNP:rs367991517)" FT /evidence="ECO:0000269|PubMed:11161804, FT ECO:0000269|PubMed:16622405" FT /id="VAR_017455" FT VARIANT 240 FT /note="N -> K (in dbSNP:rs148229804)" FT /evidence="ECO:0000269|PubMed:11161804" FT /id="VAR_017456" FT VARIANT 324 FT /note="T -> A (in dbSNP:rs1800390)" FT /evidence="ECO:0000269|PubMed:10069711" FT /id="VAR_006904" FT VARIANT 329 FT /note="Q -> R (in dbSNP:rs4987237)" FT /id="VAR_020450" FT VARIANT 343 FT /note="E -> K (in dbSNP:rs11574222)" FT /evidence="ECO:0000269|Ref.4" FT /id="VAR_018941" FT VARIANT 383 FT /note="L -> F (in dbSNP:rs4987238)" FT /id="VAR_020451" FT VARIANT 383 FT /note="L -> W" FT /evidence="ECO:0000269|PubMed:11161804" FT /id="VAR_017457" FT VARIANT 387 FT /note="M -> I (in dbSNP:rs1800391)" FT /evidence="ECO:0000269|PubMed:10206685, FT ECO:0000269|PubMed:11161804, ECO:0000269|PubMed:9450180, FT ECO:0000269|Ref.4" FT /id="VAR_006905" FT VARIANT 533 FT /note="N -> S (in dbSNP:rs11574240)" FT /evidence="ECO:0000269|Ref.4" FT /id="VAR_018942" FT VARIANT 612 FT /note="S -> C (in dbSNP:rs11574250)" FT /evidence="ECO:0000269|Ref.4" FT /id="VAR_018943" FT VARIANT 708 FT /note="S -> F (in dbSNP:rs11574289)" FT /evidence="ECO:0000269|Ref.4" FT /id="VAR_018944" FT VARIANT 711 FT /note="R -> W (in dbSNP:rs34560788)" FT /id="VAR_057124" FT VARIANT 724 FT /note="Q -> L" FT /evidence="ECO:0000269|PubMed:11161804" FT /id="VAR_017458" FT VARIANT 834 FT /note="R -> C (in dbSNP:rs3087425)" FT /evidence="ECO:0000269|Ref.4" FT /id="VAR_014913" FT VARIANT 912 FT /note="I -> S (in dbSNP:rs11574323)" FT /evidence="ECO:0000269|Ref.4" FT /id="VAR_018945" FT VARIANT 1074 FT /note="L -> F (in dbSNP:rs1801195)" FT /evidence="ECO:0000269|PubMed:11161804, FT ECO:0000269|PubMed:16723399, ECO:0000269|PubMed:8602509, FT ECO:0000269|PubMed:9450180, ECO:0000269|Ref.3" FT /id="VAR_007903" FT VARIANT 1079 FT /note="S -> L (in dbSNP:rs3087414)" FT /evidence="ECO:0000269|Ref.4" FT /id="VAR_014914" FT VARIANT 1133 FT /note="S -> A (in dbSNP:rs11574358)" FT /evidence="ECO:0000269|Ref.4" FT /id="VAR_018946" FT VARIANT 1141 FT /note="S -> L (in dbSNP:rs139323683)" FT /evidence="ECO:0000269|PubMed:18987736" FT /id="VAR_054162" FT VARIANT 1269 FT /note="K -> E (in dbSNP:rs746648510)" FT /evidence="ECO:0000269|PubMed:11161804" FT /id="VAR_017459" FT VARIANT 1339 FT /note="V -> I (in dbSNP:rs11574395)" FT /evidence="ECO:0000269|Ref.4" FT /id="VAR_018947" FT VARIANT 1367 FT /note="C -> R (associated with a higher risk of myocardial FT infarction; dbSNP:rs1346044)" FT /evidence="ECO:0000269|PubMed:10069711, FT ECO:0000269|PubMed:11161804, ECO:0000269|PubMed:9021029, FT ECO:0000269|Ref.4" FT /id="VAR_006906" FT MUTAGEN 18 FT /note="W->G: Abolished interaction with XRCC5 and XRCC6." FT /evidence="ECO:0000269|PubMed:27063109" FT MUTAGEN 84 FT /note="E->A: Abolishes exonuclease activity. Restores FT chromosome stability in depletion experiments." FT /evidence="ECO:0000269|PubMed:11863428, FT ECO:0000269|PubMed:16622405, ECO:0000269|PubMed:27063109, FT ECO:0000269|PubMed:33199508" FT MUTAGEN 88 FT /note="L->A: No effect on exonuclease activity." FT MUTAGEN 145 FT /note="W->A: Reduces exonuclease activity." FT /evidence="ECO:0000269|PubMed:16622405" FT MUTAGEN 212 FT /note="Y->F: Strongly reduces exonuclease activity." FT /evidence="ECO:0000269|PubMed:16622405" FT MUTAGEN 577 FT /note="K->M: Loss of helicase activity, loss of DNA- FT dependent ATPase activity. Does not restore chromosome FT stability in depletion experiments." FT /evidence="ECO:0000269|PubMed:33199508, FT ECO:0000269|PubMed:9288107" FT MUTAGEN 669 FT /note="E->A: Does not restore chromosome stability in FT depletion experiments." FT /evidence="ECO:0000269|PubMed:33199508" FT MUTAGEN 987 FT /note="R->A: Reduces affinity for DNA about 8-fold. Loss of FT DNA binding; when associated with A-993." FT /evidence="ECO:0000269|PubMed:20159463" FT MUTAGEN 989 FT /note="S->A: Reduces affinity for DNA about 4-fold." FT /evidence="ECO:0000269|PubMed:20159463" FT MUTAGEN 993 FT /note="R->A: Reduces affinity for DNA about 20-fold. Loss FT of DNA binding; when associated with A-987." FT /evidence="ECO:0000269|PubMed:20159463" FT MUTAGEN 993 FT /note="R->E: Loss of DNA binding." FT /evidence="ECO:0000269|PubMed:20159463" FT MUTAGEN 1037 FT /note="F->A: Reduces affinity for DNA about 8-fold." FT /evidence="ECO:0000269|PubMed:20159463" FT MUTAGEN 1038 FT /note="M->A: Reduces affinity for DNA about 4-fold." FT /evidence="ECO:0000269|PubMed:20159463" FT HELIX 17..19 FT /evidence="ECO:0007829|PDB:6TYV" FT HELIX 39..41 FT /evidence="ECO:0007829|PDB:2FBY" FT STRAND 51..56 FT /evidence="ECO:0007829|PDB:2FBY" FT HELIX 59..72 FT /evidence="ECO:0007829|PDB:2FBY" FT STRAND 78..84 FT /evidence="ECO:0007829|PDB:2FBY" FT STRAND 99..105 FT /evidence="ECO:0007829|PDB:2FBY" FT STRAND 108..112 FT /evidence="ECO:0007829|PDB:2FBY" FT HELIX 114..116 FT /evidence="ECO:0007829|PDB:2FBY" FT STRAND 117..119 FT /evidence="ECO:0007829|PDB:2FBY" FT HELIX 122..128 FT /evidence="ECO:0007829|PDB:2FBY" FT STRAND 133..139 FT /evidence="ECO:0007829|PDB:2FBY" FT HELIX 140..151 FT /evidence="ECO:0007829|PDB:2FBY" FT STRAND 157..160 FT /evidence="ECO:0007829|PDB:2FBY" FT HELIX 161..169 FT /evidence="ECO:0007829|PDB:2FBY" FT HELIX 177..185 FT /evidence="ECO:0007829|PDB:2FBY" FT HELIX 193..196 FT /evidence="ECO:0007829|PDB:2FBY" FT STRAND 202..204 FT /evidence="ECO:0007829|PDB:2FBY" FT HELIX 207..228 FT /evidence="ECO:0007829|PDB:2FBY" FT HELIX 435..447 FT /evidence="ECO:0007829|PDB:7XUT" FT HELIX 524..527 FT /evidence="ECO:0007829|PDB:8PFL" FT HELIX 534..544 FT /evidence="ECO:0007829|PDB:7GQU" FT HELIX 551..563 FT /evidence="ECO:0007829|PDB:7GQU" FT STRAND 567..570 FT /evidence="ECO:0007829|PDB:7GQU" FT TURN 575..577 FT /evidence="ECO:0007829|PDB:8PFL" FT HELIX 579..588 FT /evidence="ECO:0007829|PDB:7GQU" FT STRAND 590..595 FT /evidence="ECO:0007829|PDB:7GQU" FT HELIX 599..611 FT /evidence="ECO:0007829|PDB:7GQU" FT STRAND 616..618 FT /evidence="ECO:0007829|PDB:7GQU" FT HELIX 625..632 FT /evidence="ECO:0007829|PDB:7GQU" FT STRAND 637..641 FT /evidence="ECO:0007829|PDB:7GQU" FT HELIX 643..648 FT /evidence="ECO:0007829|PDB:7GQU" FT HELIX 650..659 FT /evidence="ECO:0007829|PDB:7GQU" FT STRAND 662..667 FT /evidence="ECO:0007829|PDB:7GQU" FT HELIX 670..673 FT /evidence="ECO:0007829|PDB:7GQU" FT STRAND 677..679 FT /evidence="ECO:0007829|PDB:8PFL" FT HELIX 682..688 FT /evidence="ECO:0007829|PDB:7GQU" FT HELIX 689..693 FT /evidence="ECO:0007829|PDB:7GQU" FT STRAND 699..704 FT /evidence="ECO:0007829|PDB:7GQU" FT HELIX 708..718 FT /evidence="ECO:0007829|PDB:7GQU" FT STRAND 724..727 FT /evidence="ECO:0007829|PDB:7GQU" FT STRAND 735..741 FT /evidence="ECO:0007829|PDB:7GQU" FT HELIX 746..750 FT /evidence="ECO:0007829|PDB:7GQU" FT HELIX 751..753 FT /evidence="ECO:0007829|PDB:7GQU" FT STRAND 754..756 FT /evidence="ECO:0007829|PDB:7GQU" FT STRAND 761..765 FT /evidence="ECO:0007829|PDB:7GQU" FT STRAND 767..770 FT /evidence="ECO:0007829|PDB:7GQU" FT HELIX 774..786 FT /evidence="ECO:0007829|PDB:7GQU" FT STRAND 791..795 FT /evidence="ECO:0007829|PDB:7GQU" FT HELIX 800..811 FT /evidence="ECO:0007829|PDB:7GQU" FT STRAND 816..821 FT /evidence="ECO:0007829|PDB:7GQU" FT HELIX 826..828 FT /evidence="ECO:0007829|PDB:7GQS" FT STRAND 835..840 FT /evidence="ECO:0007829|PDB:7GQU" FT HELIX 845..853 FT /evidence="ECO:0007829|PDB:7GQU" FT STRAND 862..868 FT /evidence="ECO:0007829|PDB:7GQU" FT HELIX 873..875 FT /evidence="ECO:0007829|PDB:7GQU" FT HELIX 877..879 FT /evidence="ECO:0007829|PDB:7GQS" FT HELIX 886..904 FT /evidence="ECO:0007829|PDB:7GQU" FT HELIX 909..915 FT /evidence="ECO:0007829|PDB:7GQU" FT STRAND 917..919 FT /evidence="ECO:0007829|PDB:7GQU" FT HELIX 924..929 FT /evidence="ECO:0007829|PDB:7GQU" FT TURN 933..935 FT /evidence="ECO:0007829|PDB:7GQU" FT HELIX 937..944 FT /evidence="ECO:0007829|PDB:7GQU" FT STRAND 956..958 FT /evidence="ECO:0007829|PDB:6YHR" FT HELIX 960..972 FT /evidence="ECO:0007829|PDB:3AAF" FT TURN 973..975 FT /evidence="ECO:0007829|PDB:3AAF" FT HELIX 980..986 FT /evidence="ECO:0007829|PDB:3AAF" FT HELIX 996..1000 FT /evidence="ECO:0007829|PDB:3AAF" FT TURN 1002..1009 FT /evidence="ECO:0007829|PDB:3AAF" FT HELIX 1012..1024 FT /evidence="ECO:0007829|PDB:3AAF" FT STRAND 1027..1032 FT /evidence="ECO:0007829|PDB:3AAF" FT TURN 1036..1038 FT /evidence="ECO:0007829|PDB:2AXL" FT STRAND 1039..1043 FT /evidence="ECO:0007829|PDB:3AAF" FT HELIX 1045..1054 FT /evidence="ECO:0007829|PDB:3AAF" FT STRAND 1062..1064 FT /evidence="ECO:0007829|PDB:6YHR" FT TURN 1067..1069 FT /evidence="ECO:0007829|PDB:6YHR" FT HELIX 1147..1171 FT /evidence="ECO:0007829|PDB:2E1F" FT HELIX 1175..1178 FT /evidence="ECO:0007829|PDB:2E1F" FT HELIX 1181..1190 FT /evidence="ECO:0007829|PDB:2E1F" FT HELIX 1195..1198 FT /evidence="ECO:0007829|PDB:2E1F" FT STRAND 1201..1203 FT /evidence="ECO:0007829|PDB:2DGZ" FT HELIX 1206..1211 FT /evidence="ECO:0007829|PDB:2E1F" FT HELIX 1213..1225 FT /evidence="ECO:0007829|PDB:2E1F" SQ SEQUENCE 1432 AA; 162461 MW; 63F10D19E90AA461 CRC64; MSEKKLETTA QQRKCPEWMN VQNKRCAVEE RKACVRKSVF EDDLPFLEFT GSIVYSYDAS DCSFLSEDIS MSLSDGDVVG FDMEWPPLYN RGKLGKVALI QLCVSESKCY LFHVSSMSVF PQGLKMLLEN KAVKKAGVGI EGDQWKLLRD FDIKLKNFVE LTDVANKKLK CTETWSLNSL VKHLLGKQLL KDKSIRCSNW SKFPLTEDQK LYAATDAYAG FIIYRNLEIL DDTVQRFAIN KEEEILLSDM NKQLTSISEE VMDLAKHLPH AFSKLENPRR VSILLKDISE NLYSLRRMII GSTNIETELR PSNNLNLLSF EDSTTGGVQQ KQIREHEVLI HVEDETWDPT LDHLAKHDGE DVLGNKVERK EDGFEDGVED NKLKENMERA CLMSLDITEH ELQILEQQSQ EEYLSDIAYK STEHLSPNDN ENDTSYVIES DEDLEMEMLK HLSPNDNEND TSYVIESDED LEMEMLKSLE NLNSGTVEPT HSKCLKMERN LGLPTKEEEE DDENEANEGE EDDDKDFLWP APNEEQVTCL KMYFGHSSFK PVQWKVIHSV LEERRDNVAV MATGYGKSLC FQYPPVYVGK IGLVISPLIS LMEDQVLQLK MSNIPACFLG SAQSENVLTD IKLGKYRIVY VTPEYCSGNM GLLQQLEADI GITLIAVDEA HCISEWGHDF RDSFRKLGSL KTALPMVPIV ALTATASSSI REDIVRCLNL RNPQITCTGF DRPNLYLEVR RKTGNILQDL QPFLVKTSSH WEFEGPTIIY CPSRKMTQQV TGELRKLNLS CGTYHAGMSF STRKDIHHRF VRDEIQCVIA TIAFGMGINK ADIRQVIHYG APKDMESYYQ EIGRAGRDGL QSSCHVLWAP ADINLNRHLL TEIRNEKFRL YKLKMMAKME KYLHSSRCRR QIILSHFEDK QVQKASLGIM GTEKCCDNCR SRLDHCYSMD DSEDTSWDFG PQAFKLLSAV DILGEKFGIG LPILFLRGSN SQRLADQYRR HSLFGTGKDQ TESWWKAFSR QLITEGFLVE VSRYNKFMKI CALTKKGRNW LHKANTESQS LILQANEELC PKKLLLPSSK TVSSGTKEHC YNQVPVELST EKKSNLEKLY SYKPCDKISS GSNISKKSIM VQSPEKAYSS SQPVISAQEQ ETQIVLYGKL VEARQKHANK MDVPPAILAT NKILVDMAKM RPTTVENVKR IDGVSEGKAA MLAPLLEVIK HFCQTNSVQT DLFSSTKPQE EQKTSLVAKN KICTLSQSMA ITYSLFQEKK MPLKSIAESR ILPLMTIGMH LSQAVKAGCP LDLERAGLTP EVQKIIADVI RNPPVNSDMS KISLIRMLVP ENIDTYLIHM AIEILKHGPD SGLQPSCDVN KRRCFPGSEE ICSSSKRSKE EVGINTETSS AERKRRLPVW FAKGSDTSKK LMDKTKRGGL FS //